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Summary 
The biochemical activities and resultant metabolic by-products of the vaginal microbial 
community during gestation can provide useful insight into the pathophysiology of preterm birth 
(PTB), as well as help in identifying women at risk. These metabolic changes leave specific 
signature fingerprints that can be investigated by Magnetic resonance spectroscopy (MRS). 
Therefore, we hypothesised that women who ultimately deliver prematurely will have 
significantly different vaginal microbiota metabolite signatures compared to their term 
counterparts even in the absence of clinical infection. 
In order to characterise and validate the cervicovaginal fluid (CVF) metabolite profiles and 
determine their predictive capacities for PTB, high-vaginal swabs were obtained from 
asymptomatic and symptomatic pregnant women sub-classified depending on a previous history 
of PTB and/or short cervix (< 25 mm) into: asymptomatic low risk (ALR) women with no prior 
PTB nor short cervix, 20-22 gestational weeks (w), n = 183; and asymptomatic high risk (AHR) 
women with prior history of PTB and/or short cervix, 20-22 w, n = 186. A subset of these 
women were assessed again at 26-28 w (due to their high-risk status), n = 129. The fourth 
cohort comprised women presenting with symptoms of threatened preterm labour (PTL) 24-36 
w, n = 89 (SYM).  
CVF dissolved in phosphate buffered saline was analysed with a 9.4T MR spectrometer. 
Metabolites were identified, integrated for peak area and normalised to the total spectrum 
integral (excluding water signal). Acetate concentrations (AceConc) were also determined from 
a randomly selected subset of SYM women (n = 57), by a spectrophotometric technique. 
Additionally, clinical parameters such as cervical length (CL), fetal fibronectin (FFN), and vaginal 
pH were recorded and correlated to the metabolites. Furthermore, the 16S rDNA of vaginal 
bacterial species were PCR-amplified and the vaginal cytology was also determined by Gram, 
Hematoxylin and eosin, and Papanicolaou staining methods. 
We observed that acetate normalised integral (N.I.) (P = 0.002), and acetate/lactate ratio (P = 
0.002) were higher in the SYM women who delivered preterm.  These were also predictive of 
PTB < 37 w (AUROC: acetate N.I. = 0.75; acetate/lactate ratio = 0.76), < 32 w (AUROC: 
acetate N.I. = 0.73; acetate/lactate ratio = 0.79), and within 2 weeks of the index assessment 
xvii 
 
(AUROC: acetate N.I. = 0.77; acetate/lactate ratio = 0.78), whilst glutamine/glutamate N.I.s was 
predictive of PTB < 32 w (AUROC = 0.71), and within 2 weeks of the index assessment 
(AUROC = 0.68) only.  
Also, in the AHR20-22w and ALR women, acetate (AUROC = 0.61) and branched chain amino 
acids N.I.s (AUROC = 0.75) were predictive of PTB < 37 w respectively. Normalised integrals 
of succinate, formate, lactate, and glucose did not differ in relation to PTB in any of the groups. 
Like the acetate N.I.s, AceConc in the SYM women was higher (P = 0.006) in the preterm-
delivered women and was predictive of PTB < 37 w (AUROC = 0.74), and within 2 weeks of 
the index assessment (AUROC = 0.68), with an optimal cut-off of > 0.53 g/l. AceConc also 
correlated with acetate N.I. (r = 0.69; P < 0.0001).  
PCR revealed a higher prevalence of potentially pathogenic anaerobic bacteria species in the 
preterm-delivered women across the groups except the ALR women. 
Apart from correlating with clinical parameters, the prediction of PTB was improved especially 
in the SYM women when metabolite N.I.s, CL and FFN were combined. 
In conclusion, elevated CVF acetate showed clinically useful discriminative propensity for 
preterm delivery and delivery within 2 weeks of presentation in symptomatic women. A ratio of 
acetate to lactate showed similar discriminatory capacity in symptomatic women, whilst 
branched chain amino acids appeared predictive of preterm delivery in asymptomatic women at 
low risk of PTB. These metabolite differences were supported with the association of higher 
prevalence of mixed anaerobes in the vaginal melieu and preterm birth. 
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Preterm birth (PTB), defined as birth before 37 weeks of gestation, is the world’s commonest 
cause of perinatal morbidity and mortality.1 Approximately 15 million PTBs (~12% of all births) 
occur annually,2, 3 costing in excess of $26 billion.4 Preterm babies that survive commonly have 
greater risk of developing respiratory, gastrointestinal and neurodevelopmental complications.1, 
5 Accordingly, the prediction and possible prevention of PTB has become a major health care 
priority.6  
Approximately two-thirds of PTBs occur without an identifiable cause and follow spontaneous 
onset of preterm labour (PTL), and preterm premature rupture of membranes (PPROM).5 
About 40-50% of spontaneous PTBs are associated with ascending intrauterine infection,1 which 
could be related to changes in the vaginal microflora,7, 8 that  often eludes detection by 
conventional culture-dependent techniques.9  
The human vaginal microflora is a community of microorganisms (mainly bacteria) that 
represents a balanced mutualistic relationship which critically influences the reproductive 
physiology and immunity of the host.10 The magnitude of the bacterial population of healthy 
vaginal fluid is 106-8 per gram. Although, opportunistic pathogens are present, this diverse 
microbial community constitutes a first line of defence against infection by competitive 
exclusion of foreign pathogenic organisms.10 The composition of the vaginal microbial 
community is dependent on host-environmental interactions varying between and within 
individuals over time.11 
The human vagina, apart from being a passage for sperm, menstruum, or neonates, is a highly 
versatile organ with profound capacity to influence the health of women and their newborns. 
The vaginal ecosystem can influence conception, the timing of delivery, and risk of acquiring 
sexually transmitted infections (STIs).12 The cervicovaginal epithelium contributes to maintaining 
an ecosystem that is supportive of commensal organisms but hostile to invading pathogens. The 
epithelium is laden with glycogen which allows commensal Lactobacillus sp. to thrive, whilst the 
resulting lactic acid produced by anaerobic glycolysis, renders the vaginal milieu unfavourable to 
invading pathogens, many of which require a relatively alkaline medium to thrive.13-15 In addition, 
the vaginal microbiota provides protection against bacterial vaginosis (BV), candidiasis, STIs (e.g., 
chlamydia, gonorrhoea, human papillomavirus (HPV), urinary tract infections (UTIs),16-18 human 
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immunodeficiency virus (HIV) infection etc. 19, 20 This protective function is mostly due to lactic 
acid/hydrogen peroxide (H2O2)–producing bacteria species, predominantly Lactobacillus that 
inhabit the vagina.21 The microbiota also plays a crucial role in determining the metabolic and 
inflammatory profile of the vaginal ecosystem.12   
1.1. Normal Vaginal Microflora 
 
The normal physiological vaginal microflora was initially described as homogenous, consisting of 
only Gram-positive bacilli (Doderlein’s bacilli),22 now known to be a part of the genus 
Lactobacillus.23 Presently, the healthy vaginal microbiota is described as a diverse ecosystem 
comprising of anaerobic and aerobic microorganisms, with Lactobacilli as the predominant 
species.21, 24-26 The most often identified species of Lactobacillus are L. crispatus, L. jensenii, L. 
gasseri and L. iners.25, 27-29 The female lower genital tract ordinarily becomes predominantly 
inhabited by Lactobacilli with the onset of puberty. This corresponds with an increase in 
circulating oestrogen which stimulates the maturation of vaginal epithelium and deposition of 
glycogen.30, 31 Glycogen is metabolised to lactic acid by vaginal bacteria22 and/or epithelial cells,32, 
33 thereby enhancing the proliferation of Lactobacilli-dominated vaginal microbiota.1, 30, 34 Lactic 
acid is the preponderant acid metabolite in the cervicovaginal fluid (CVF) of healthy 
asymptomatic women (Table 1.1). The normal pH of the vagina in reproductive-age women 
ranges between 3.5-4.5,35-38 driven by oestrogen, glycogen, and Lactobacilli.36 Lactobacilli play a 
critical role in inhibiting the proliferation of opportunistic pathogens such as Gardnerella 
vaginalis, Chlamydia trachomatis, Trichomonas vaginalis, Neisseria gonorrhoeae, anaerobes, and HIV, 
by maintaining the vaginal pH at ≤ 4.5 through lactic acid permeabilisation of bacterial lipid 
membrane, by production of bacteriostatic and bacteriocidal substances including H2O2,
39-41 
bacteriocins, bactriocin-like substances42-44 and biosurfactants, stimulation of local immune 
responses,23, 45, 46 and by adherence and competitive exclusion.28, 40, 47-52 Lactic acid enhances the 
protective activities of H2O2 and bacteriocins.
53, 54 At physiological concentrations (55-111 mM), 
lactic acid is markedly more lethal to bacterial vaginosis-associated bacteria (BVAB) compared 
to HCl or acetic acid acidified media (pH 4.5). Glycogen and lactic acid are diminished in BV 
infected women (Table 1).38  Accordingly, a Lactobacillus-dominated vaginal microflora is 
indicative of vaginal health.25, 55 Interestingly, in the absence of Lactobacillus dominance, some 
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women ostensibly maintain healthy vaginal ecosystems. These women have been found to 
harbour other lactic acid producers such as Atopobium vaginae, Megasphaera, Leptotrichia, 
Streptococcus and Staphylococcus.56, 57 
Racial/ethnic variations in the composition of the “normal” vaginal microflora have been 
reported. Vaginal bacterial communities devoid of Lactobacillus dominance have been observed 
to be normal in black and Hispanic women.21, 58, 59 H2O2-producing Lactobacilli sp. are lower in 
black women,55 who show higher vaginal pH compared to white women with/without 
infection.60-62 Black and Hispanic women also showed higher vaginal pH compared to white and 
Asian women, and this correlated with bacterial communities dominated by species other than 
Lactobacillus. For these women, this diverse microbiota appears normal and healthy.21, 25 Host 
differences in innate and adaptive immunity, volume and composition of vaginal fluid, expression 
of epithelia cells surface ligands,21 as well as other human behaviours and practices (such as 
smoking, sexual intercourse, douching, contraceptive and antibiotics use etc.) have been 
implicated.63 
The composition of the vaginal microbiota could be highly dynamic,21, 64-66 changing over time in 
response to changes in sex hormone levels, sexual activity, antibiotic therapy, vaginal douching, 
oral contraceptives, stage of menstrual cycle, menopause status, pregnancy, lactation, diabetes 
mellitus and stress.25, 35, 65, 67-69 For instance, the vaginal microbiota prior to puberty is dominated 
by anaerobes.70 At puberty, the rising levels of oestrogen leads to the accumulation of glycogen 
in the vaginal epithelial cells whose metabolic substrates enhance vaginal colonisation with 
Lactobacilli sp.70, 71 Lactobacilli dominance decreases as oestrogen levels decline following 
menopause.72, 73 The vaginal microbiota in normal pregnancy is predominated by Lactobacilli sp. 
and is more stable than that in non-pregnant state.74, 75 This can be explained by the rising level 
of oestrogen during pregnancy resulting in increased vaginal glycogen deposition which 
enhances the proliferation of Lactobacilli-dominated vaginal microbiota.1, 74 Also, replacement of 
Lactobacillus by G. vaginalis microflora has been associated with unprotected vaginal 
intercourse.76 The number of G. vaginalis and L. iners is elevated remarkably during menses and 
decrease thereafter without intervention, whereas L. crispatus-dominated flora remains fairly 
stable during menses.64 Other studies have shown that menses significantly alters the vaginal 
microbial diversity with about a 100-fold decrease in L. crispatus and significant increase in L. 
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iners, G. vaginalis, Prevotella bivia and A. vaginae.77  Gajer et al. have also reported that in some 
women, there is a high species turnover and low constancy of vaginal microbial communities, 
which is widely variable among women including those that exist in the same bacterial 
community class. Despite these fluctuations, bacterial community function is still preserved in 
some cases. 65 In summary, there is a crucial inter-individual inconstancy in the vaginal 
microbiota, and replacement of L. crispatus (associated with increased vaginal community 
stability) with L. iners and/or G. vaginalis during menstruation.25 However, lack of substantial 
change in the vaginal microbiota during menses has been reported.78 
1.2. Bacterial Vaginosis 
Bacterial vaginosis is defined as a dysbiosis or shift from the normal (Döderlein’s) vaginal 
microflora. It is a polymicrobial, superficial vaginal infection characterised by a decreased in 
Lactobacillus sp., a rise in vaginal pH79, 80 and overgrowth of a variety of anaerobic and facultative 
bacteria.76, 80-82 The magnitude of the vaginal bacterial population increases from 106-8 cells/gram  
in normal conditions to 108-9 cells/gram in BV and 1010-11 cells/gram in BV biofilms.36 BV was 
originally called nonspecific vaginitis, Gardnerella vaginitis or Haemophilus vaginitis.83 However, 
this is only one point of view as it is now described to be a rather poorly characterised disease 
both symptomatically and microbiologically.38, 84, 85 BV is the most common vaginal infection 
affecting reproductive-age women globally,86 with a prevalence rate of 5-70%.87 The ratio of 
anaerobes to aerobes in the normal vaginal ecosystem is 2:1 – 5:1, but this is increased to about 
100:1 – 1000:1 in BV.69, 88 This is due to a decrease in the amount of H2O2-producing Lactobacilli 
and increase vaginal pH. H2O2 inhibits the growth of catalase-negative anaerobic organisms by 
production of hydroxyl free radicals and by combining with chloride ions in the vaginal fluid to 
form chloridinium ions. 89, 90 Lactobacilli lose the H2O2-producing capacity at pH >4.5.
83, 90 Vaginal 
microbiota dominated by H2O2-producing Lactobacillus species is inversely correlated to the 
presence of BV-related anaerobes.26 Hence, BV is usually associated with a decrease in 
Lactobacilli, influencing the normal vaginal microbiota signature, as opposed to an increase in 
other endogenous pathogens.91 The BVAB are also part of the normal vaginal microflora, but 
become virulent when they proliferate and increase in quantity above the lactic acid/H2O2-
producing Lactobacilli. These organisms are Gram-negative and/or Gram-variable anaerobic 
bacteria species such as Gardnerella vaginalis, Mycoplasma hominis, Ureaplasma urealyticum, 
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Bacteroides fragilis, Prevotella sp. Mobiluncus sp., Fusobacterium, Atopobium vaginalis, Megasphaera 
sp., Eggerthella, Leptotrichia, Dialister, Sneathia, Peptostreptococcus, Porphyromonas and the newly 
identified but poorly resolved Bacterial vaginosis-associated bacterium (BVAB-1), BVAB-2, and 
BVAB-3 in the Clostridiales Order.88, 92-97 These organisms increase vaginal pH by producing short 
chain fatty acids (SCFAs: acetate, propionate, butyrate, isobutyrate, succinate, formate, valerate 
etc.) and amines (putrescine, cadaverine, trimethylamine), and sometimes utilise lactic acid as 
energy source.38, 98, 99 Overall, in contrast to healthy women, the CVF metabolite profile of BV-
infected women is characterised by increased concentration and variety of SCFAs and amines, 
and a low lactic acid concentration (Table 1.1).38 SCFAs produced by BVAB act as virulence 
factors that inhibit the migration of immunocompetent cells capable of initiating an 
inflammatory response against the invading pathogens, thereby permitting the establishment of 
dysbiosis and contributing to the pathogenesis of BV.38, 100 BVAB also act synergistically to 
promote a woman’s risk of BV and PTB. For instance the presence of G. vaginalis and M. hominis 
in the vagina are enhanced in the presence of other anaerobic BVAB.101, 102  Also Prevotella sp. via 
a commensal symbiotic relationship encourages the growth and survival of G. vaginalis and 
Peptostreptococus anaerobius through the provision of nutrients such as ammonia and amino 
acids.21, 83, 103-105 G. vaginalis and other anaerobes such as Atopobium, Prevotella, Mobiluncus have 
been reported to form biofilms that contribute to the pathogenesis of BV.106-109 Though G. 
vaginalis is often noticed in healthy women especially during menstruation, its proportion in BV 
infected women is higher.64 Of the four major Lactobacillus species found in the vaginal 
microflora (i.e. L. crispatus, L. gasseri, L. iners, and L. jensenii), L. iners is more often associated 
with BV.110-112 This has been attributed to its inability to produce H2O2
55, 113 and D-lactate.1, 114 It 
has also been reported to be a predominant component of the intermediate transitional stage 
from normal to abnormal microflora.95, 97, 115-117 Its presence may be correlated with the 
colonisation of the vagina by BV-associated organisms.110,115, 118 
BV was previously described as a sexually enhanced rather than sexually transmitted infection.119 
This was because no evidence of direct heterosexual transmission of BVAB was recorded, but 
BV is positively associated with frequent sexual intercourse119 with new and multiple sexual 
partners.120-122 Also, treatment of male sexual partners with antibiotics was not beneficial to the 
women.123 However, direct transmission may occur in female to female sexual act.119, 124 
Presently, epidemiological evidence supports the hypothesis that BV is sexually transmitted.36, 106, 
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107 This is as a result of the detection of BVAB including Gardnerella and Atopobium in the male 
genital microniche,36, 106, 125, 126 decreased BV infection with consistent use of condom,63, 127 and 
recurrence after treatment when the patient remained with the same sex partner.128 Other 
factors associated with prevalence of BV include, black race,86, 88, 121, 122, 129 smoking,122, 129-131 
contraceptive practice,88, 129, 130vaginal douching,121, 129, 132 menstruation,133, 134 pregnancy,122, 135 low 
educational and socioeconomic status.121, 122, 130 Most women with BV (about 85%) are usually 
asymptomatic.122, 136 However, symptoms could appear in the form of a non-itchy but irritating,35 
creamy vaginal discharge with a fishy odour, that may be more prominent after sexual 
intercourse and during menses.94 137 Symptomatic BV is a syndrome characterised by the 
appearance of clinical features in the absence of identifiable aetiologic factors.12 The 
asymptomatic women usually have a lower risk of adverse pregnancy outcomes compared to 
symptomatic women.138 There is usually no obvious local inflammation due to the absence of 
leucocytes in the vaginal fluid, hence the term vaginosis rather than vaginitis.83, 88, 139 The absence 
of inflammation may be due to co-evolution determined immune tolerance between the distal 
gut microbiota (source of vaginal microbiota) and the immune system.36, 140-143 Also, the 
immunomodulatory functions of certain SCFA produced by BVAB have been implicated.100, 144 
Bacterial vaginosis is a common syndrome among reproductive-age women associated with 
increased risk of acquisition of STI such as N. gonorrhoea, C. trachomatis, T. vaginalis, Herpes 
simplex virus (HSV), HPV, and HIV,38, 87, 145-148 pelvic inflammatory disease,149-151 endometritis,152 
chorioamnionitis,83, 153 amniotic fluid infection,154-156 PROM and PTB.81, 94, 157-161 Increased 
prevalence of PTB in women diagnosed with BV by Nugent criteria has being reported.162-164 Six 
– 35% of asymptomatic pregnant women have BV.88  About 10-15% of women with BV deliver 
preterm, and the risk is increased notwithstanding the presence or absence of symptoms.163 
The rate of PTB is increased by 7-fold if BV is diagnosed <16 weeks of gestation and > 4-fold if 
detected by 20 weeks.88 However, most pregnant women with BV do not deliver preterm.163, 
165A gene-environment interaction between BV and PTB has been observed.165,166 Interaction 
between genetic susceptibility [e.g. presence of TNF-α allele 2 and single nucleotide 
polymorphism (SNP) alleles of protein kinase C-α (PRKCA)] and environmental factors (BV) is 
associated with increased risk of spontaneous PTL and PTB.166, 167 
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Several probable factors may operate independently or contribute to the increased risk of PTB 
in women with BV. BVAB may ascend from the vagina to the upper genital tract, resulting in 
chorioamnionitis, preterm rupture of membranes (PROM), and subsequent PTB.168 Host 
immune response triggered by BVAB within the vagina and cervix e.g. release of cytokines and 
chemokines.165, 168 169The differences in the risk of PTB associated with BV can be attributed to 
immune hypo- or hyperresponse.165, 170 Individuals vary in their ability to initiate an immune 
response against BV-associated organisms.165 Intense immune response may stimulate the 
inflammatory pathways to PTB, while low response may allow more ascending genital 
infection.171 An “appropriate/optimal” immune response (especially during pregnancy) to BV 
capable of regulating the changes in the vaginal milieu without leading to an adverse pregnancy 
outcome is required.88 Also, BV-associated organisms produce hydrolytic and proteolytic 
enzymes including sialidase, mucinase and proteases, capable of altering the permeability of the 
vaginal mucosal epithelium leading to ascending intrauterine infection,168 transudation and 
discharge.83 
BV is commonly diagnosed by two methods in clinical research: 1) clinically (Amsel criteria) and 
2) microscopically (Gram staining of vaginal fluid and Nugent criteria). The Amsel criteria 
involves the diagnosis of BV based on the presence of 3 of the 4 following criteria:172 1) the 
presence of a thin, homogenous, milky and adherent vaginal discharge; 2) a vaginal fluid pH > 
4.5; 3) presence of “clue cells” (desquamated vaginal epithelial cells studded with BVAB) on 
saline wet mount; 4) positive “whiff test” i.e. an amine (trimethylamine), fishy odour after 
application of 10% potassium hydroxide (KOH) solution to the vaginal discharge. 
The Nugent criteria (Table 1.2), which is more objective, reliable and reproducible,88, 171 with 
considerable inter-observer concordance in the examination of vaginal specimens,88 is the 
method widely used in research.93 The Nugent scoring is based on microscopically identifying 
the morphotypes of 3 different bacterial species following Gram stain, and evaluated broadly on 
the prevalence of Lactobacilli.173 A score of 7 – 10 is diagnostic of BV, while 0 – 3 is considered 
normal. A score of 4 – 6 is referred to as intermediate because it is a transition between 
normal flora and BV.  There is a good correlation between clinical features of BV and Gram 
stain scores.88  
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Other less commonly used methods in the diagnosis of BV include BVBlue test (detection of 
sialidase, a microbial enzyme that cleaves the glycosidic linkages of neuraminic acid),83, 174, 175 
detection of amines (putrescine, cadaverine and trimethylamine),83, 175 proline aminopeptidase 
assay,175, 176 detection of volatile (acetate, butyrate, isobutyrate, propionate), and non-volatile 
(lactate and succinate) short chain organic acids,35, 100, 144, 177-179 e.g. a vaginal fluid succinate/lactate 
ratio ≥ 0.4 is suggestive of BV.83, 100, 139, 179-183 Treatment of BV is by oral or intravaginal 
metronidazole (500 mg) twice daily for 7 days, metronidazole gel (0.75%) once daily for 5 days 
or clindamycin cream (2%) for 7 days,83 and probiotics.184-188 Although antibiotic therapy is 
usually efficacious, recurrence is very common.38, 64 Antibiotic resistance, biofilm formation, 
recruitment from extravaginal reservoirs and distortion of the microbiota have been implicated 
in recurrence by studies reviewed by Aldunate et al.38 However, rifaximin appears to overcome 
these limitations by reinstating the vaginal microbiota as well as metabolome in non-pregnant 
women affected by BV.189 
Although BV is the most common and widely reported, other forms of abnormal vaginal flora 
related to poor reproductive outcomes have been identified. An example of such is aerobic 
vaginitis (AV), an equally disruptive infection of the normal vaginal Lactobacillus-dominated 
microflora but is characterised by overt inflammation, leukocyte and parabasal cells infiltration 
and proliferation of enteric aerobic bacterial organisms including Escherichia coli, Enteroccoci, S. 
aureus, and group B Streptococcus.190-192 It has been described as the aerobic equivalent of BV.190 
Like BV, there is decreased lactate concentration due to loss or depressed Lactobacillus 
dominance. However, owing to the absence of anaerobes, succinate concentration is low.190  It 
has also been associated with STIs such as C. trachomatis, N. gonorrhoeae and T. vaginalis.193 The 
clinical features of AV include: red vaginal mucosal inflammation, increased IL-1β and IL-6, 
vaginal pH > 6, pruritus, dyspareunia and yellowish sticky discharge devoid of fishy 
(trimethylamine) odour.160, 190, 191 AV is present in 2-25% of women and has been associated with 
severe adverse gynaecological outcomes including ascending genital infection/inflammation, 
preterm rupture of membranes (PROM), PTL and PTB.1, 160, 191, 192, 194 There is no universally 
agreed optimal treatment regimen for AV currently, but treatment of AV-infected women with 
antibiotics (e.g. oral moxifloxacin),195 and probiotics (e.g. oral/vaginal L. acidophilus), have shown 
significant effectiveness.191, 194 
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Another genital infection with significant adverse gynaecological and obstetric implication is 
vulvovaginal candidiasis (VVC). This is often caused by an overgrowth of Candida albicans.196 It is 
the second most common vaginal infection after BV in reproductive-aged women. There are 
usually no changes in the vaginal microflora and pH, though it can co-exist with BV and AV.195 
The frequency of vaginal colonisation by Candida is increased in pregnancy as a result of 
increased circulating oestrogen and deposition of glycogen in vaginal epithelium.197 C. albicans 
induces the production of extracellular matrix metalloproteinase inducer (EMMPRIN) by vaginal 
epithelial cells, which is a potent inducer of matrix metalloproteinase-8 (MMP-8). Elevated 
MMP-8 and leukocytes could trigger a pro-inflammatory immune response, enhance tissue 
destruction, ascending genital infection196 and provoke clinical symptoms. Despite its high 
prevalence in pregnant women and the tendency of treatment to reduce the incidence of 
PTB,197 the association between candidiasis, PROM and PTB is still being debated.198 
Data on the role of viruses in the pathogenesis of PTL and PTB are relatively limited, though 
viral DNA of adenovirus, cytomegalovirus, and enterovirus have been detected in amniotic fluid 
of pregnant women irrespective of their risk of preterm delivery. The presence of hepatitis B 
virus antigens is a risk factor for spontaneous PTB.199 
It is plausible that BV and other female genital tract infections during gestation may predispose a 
woman to ascending intrauterine infection or microbial invasion of the amniotic cavity (MIAC) 
and consequently initiate the onset of PTL and PTB. Isolation and characterisation of BVAB in 
gestational tissues and amniotic fluid of pregnant women with adverse delivery outcomes has 
certainly enhanced our understanding of the association between genital infection and PTB, but 
the individual organisms involved, and the metabolites they produce as well as the aetiology and 
pathogenesis of this putatively proinflammatory process is still undergoing scrutiny by various 
investigators. 
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Table 1.1: CVF metabolite concentrations in healthy and Bacterial vaginosis- 
infected non-pregnant women 
Metabolite 
Concentration, mM 
Healthy women BV-infected women 
Lactate ~120 <20 
Acetate 0-4 <120 
Propionate <1 2-4 
Butyrate <1 2-4 
Succinate <1 ≥20 
CVF, cervicovaginal fluid; BV, Bacterial vaginosis. 
Adapted from: Aldunate et al., 2015.38 
 
 
Table 1.2: Nugent scoring system for Gram stained vaginal smears 
                                                                   Morphotypes 
Lactobacilli sp. Gardnerella vaginalis, 
Bacteroides sp. 
Mobiluncus sp. 
(curved gram variable rods) 
Count Score Count Score Count Score 
≥ 30 0 0 0 0 0 
5-30 1 <1 1 1 1 
1-4 2 1-4 2 1-4 1 
<1 3 5-30 3 5-30 2 
0 4 ≥ 30 4 ≥ 30 2 
Nugent Score = sum of 3 scores (0-10) i.e. Lactobailli + Gardnerella and Bacteroides + Mobiluncus. 
Nugent score of ≥ 7 = Bacterial vaginosis; 4 – 6 (intermediate), and 0 – 3 (normal). 
Adapted from: Hoffmann et al., 2014.200 
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1.3. Infection and Preterm Birth  
 
PTB may be iatrogenic (e.g. due to fetal growth restriction or preeclampsia) or spontaneous. 
About 70-80% of premature births are spontaneous (Fig. 1.1).201 Spontaneous PTL and PTB are 
associated with heterogeneous conditions with multiple risk factors e.g. previous PTB, cervical 
dysfunction, idiopathic uterine contractions, antepartum vaginal haemorrhage, intrauterine 
infection, multiple gestation, malnutrition, maternal BMI, black race, psychological or social 
stress, depression, smoking, low socioeconomic and educational statuses, and spontaneous 
preterm premature rupture of membranes (PPROM).161, 201-203 Studies have suggested four 
distinct pathways for the pathogenesis of PTL and PTB: a) premature activation of the fetal 
hypothalamic-pituitary axis, b) infection/inflammation and matrix remodeling, c) uterine over 
distension, and d) placenta abruption/decidual haemorrhage.204, 205 Approximately 40-50% of 
spontaneous PTBs are associated with ascending upper genital tract infection (Fig. 1.1).1,161, 206 
Changes in the vaginal microbiota have been implicated in the pathogenesis of ascending 
intrauterine infection and microbial invasion of the amniotic cavity (MIAC),7,8, 207 which may be 
undetectable using conventional culture-dependent techniques.9 Vaginal bacterial invasion and 
infection, and consequently choriodecidual colonisation triggers the release of 
lipopolysaccharides (LPS), peptidoglycans (PGN), lipoproteins and SCFAs, that elicit deciduitis 
and chorioamnionitis. Subsequently proinflammatory chemokines (e.g. IL-8, C-C motif ligands 5), 
and cytokines [e.g. TNF-α and β, IL1-α and β, IL-2, IL-6, and granulocyte colony stimulating 
factor (G-CSF)], are synthesised and released.144, 208-212 These act in a positive feed-forward 
fashion to activate a cascade of inflammatory responses including the synthesis and release of 
matrix metalloproteinases (MMP) e.g. MMP-8 and 9,114, 207, 212, 213 and prostaglandins (e.g. PGE2 and 
PGF2α,).
7, 214 MMPs (collagenases) degrade the extracellular matrix proteins of the cervix, 
cervical plug and gestational tissues causing cervical remodeling, permitting more ascending 
bacterial infection,213 and rupture of the fetal membranes. PGs apart from stimulating 
myometrial contraction are capable of triggering cervical ripening and release of MMPs, leading 
to PPROM and PTB (Fig. 1.2).1, 7, 114, 211 
During pregnancy, microorganisms invade the uterus and fetus most frequently by ascending 
through the vagina and cervix.5, 8  Other routes include: haematogenous circulation across the 
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placenta (e.g. from periodontitis),215 by descending from the peritoneal cavity via the fallopian 
tubes,208 inadvertently during invasive prenatal diagnostic procedures (e.g. amniocentesis or 
cordocentesis) (Fig. 1.1).216 The frequency of intrauterine infection is greater with earlier 
presentations of PTL.217 Most spontaneous PTBs at mid-second trimester (21-24 weeks 
gestation) or less than 30 weeks are associated with infection and inflammation of the 
gestational tissues compared with about 10% at 35-36 weeks.5, 211, 218 The most commonly 
identified microorganisms in the amniotic cavity and placenta are genital Mycoplasma sp. 
especially U. urealyticum. Others include G. vaginalis, M. hominis, Bacteroides sp, group B 
Streptococcus, Fusobacterium, Peptostreptococci and E. coli.5, 219, 220 These infections are usually 
subclinical as the organisms are typically of low virulence. 
Chamydia trachomatis is another STI associated with short cervix and BV, both of which are 
known risk factors of PTB.221 Mid–second trimester C. trachomatis infection predisposes 
pregnant women to a 2-3 fold risk of spontaneous PTB.222 Their risk of having PROM, PTB and 
low birth weight infants is also increased,223 and are significantly more susceptible to harbouring 
vaginal Mycoplasmas differing from U. urealyticum (noted for its lack of cell wall and present in 
70% of sexually active humans).224 As a result, potential subjects for PTB prediction studies are 
usually screened for these organisms prior to recruitment as they have been identified as 
possible risk factors.225-227  However, the link between Chlamydia infection and PPROM, PTB, 
low birth weight and infant death is not without controversy.  Andrew et al. 228  studied 2,470 
pregnant women recruited in an antibiotic treatment trial for BV and T. vaginalis infections and 
reported that there was no link between mid-trimester Chlamydia infection and increased risk 
of PTB, neither did the frequency of PTB decline after treatment of Chlamydia infection. A 
similar study demonstrated that early treatment may be the reason for lack of association.229 
Also, Chlamydia infection was not associated with low birth weight and infant mortality.230 
Therefore, first trimester screening and treatment may alter the possible determination of an 
association between Chlamydia infection and adverse pregnancy outcomes.231 
U. urealyticum and Mycoplasma isolated from the lower genital tract and amniotic fluid at mid-
trimester trigger the synthesis of prostaglandins resulting in PPROM, PTL and PTB.216,187, 188 This 
may have a significant influence on pregnancy outcomes among unmarried pregnant women.232 
However, it has been argued that U. parvum, but not U. urealyticum, is linked to late pregnancy 
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loss or PTB regardless of a previous history of PTB.224 This contradicts previous observation 
that U. urealyticum poses more danger to pregnancy outcome.233 Another study demonstrated 
that vaginal and amniotic fluid contained about 80% of U. parvum and U. urealyticum.224 This 
indicates that these organisms may invade the amniotic cavity at approximately equal rates, 
albeit, U. parvum was detected in significantly higher amounts compared to the other 
mycoplasmas in women with PPROM and PTB.  
The amniotic cavity was previously considered to be ‘sterile’.6, 7 Consequently, isolation of 
bacteria from the amniotic fluid was regarded as a pathological finding and termed microbial 
invasion of the amniotic cavity (MIAC).220 However, recent studies have reported that the 
amniotic cavity234 and fetal membranes235, 236 are not always sterile, as bacteria can cross intact 
maternal-fetal membrane barriers and may not always cause PTL.220, 237 Most MIAC result from 
ascending bacterial infection from the vagina and cervix and are present in 25% of preterm 
deliveries.6, 7 MIAC is promoted by inflammatory products such as MMPs that degrade the 
collagen of the extracellular matrix of the cervix, thereby allowing potential pathogenic 
organisms into the putatively ‘sterile’ amniotic cavity with subsequent activation of PTL, PPROM 
and PTB.114, 207 
There is a strong causal relationship between infection/inflammation and PTB.238-241 Inflammation 
could be a defence mechanism through which the mother (host) expels infected fetal 
membranes and/or fetus, thereby preventing further fetal and maternal complications. This 
could also be a survival mechanism with which a fetus is emancipated from the unpleasant 
intrauterine environment.7 The inflammatory process is initiated by the ability of the innate 
immune system to recognise microorganisms and their products. This is accomplished by 
specific pattern recognition receptors (PRRs) including Toll-like receptors (TLRs) 1-10.38, 45 The 
TLRs expressed by the epithelium of the female reproductive tract are capable of recognising 
microbial products such as lipopolysaccharide (LPS), peptidoglycan (PGN), lipoprotein, dsRNA, 
and flagellin,45, 220 and induce the production of cytokines, chemokines, prostaglandins, and 
proteases leading to parturition.212 The fetus also has the capacity to recognise and mount an 
immune response to pathogenic organisms through TLR-initiated pathways, production of 
antimicrobial peptides, and LPS-binding protein.240 This has been termed fetal inflammatory 
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response syndrome (FIRS).242 Therefore, an inadequate signalling mechanism will reduce 
infection-induced PTL. Inflammation is vital to reproductive success.238 
A gene-environment interaction has also been implicated in the pathogenesis of PTB. A specific 
polymorphism in the promoter region of TNF-α at position -308 referred to as TNF-α allele 2 
is associated with an increased production of TNF-α in response to microbial stimulation during 
genital tract infection.243, 244 245TNF-α promotes the production of collagen-digesting MMP-3, -8, 
and -9 (from maternal plasma and amniotic fluid),246-248 which results in an inadequate and 
exaggerated inflammatory response leading to cervical ripening, MIAC, PPROM and PTB.243 246-
248TNF-α allele 2 carriers are about three times more likely to deliver preterm than non-
carriers.166, 249, 250 This association is enhanced by co-occurrence with BV,166 and a synergistic 
effect has been suggested between these two risk factors for PTB.243 A similar synergistic effect 
exists between BV and SNPs in 3 other genes that regulate the inflammatory pathway i.e. IL-6, 
fms-like tyrosine kinase 1, and PRKCA.167 Also, individuals belonging to the black race have 
higher ratio of amniotic fluid TNF-α and soluble TNF receptor (sTNFR) concentrations 
indicative of a TNF-α mediated immunological response of PTB.251 Genetic polymorphisms of 
MMP-9 (-14CA),252 MMP-1 (-1607),253 IL-4 (-590)254 and Fas gene (TNFRSF6, -670)255 promoters 
in relation to PPROM and PTB have also been documented. Conversely, polymorphisms that 
promote reduced inflammatory response are associated with reduced risk of PTB.243, 250 
There are indications that the host response rather than mere colonisation or overgrowth of 
the bacteria themselves, may be the determining factor for an increased risk of PTB.82, 256 More 
so, assessment of the degree of the association between infection and PTB is daunting as there 
are racial/ethnic, gestational ages and geographical variations in genital bacterial colonisation 
rates during pregnancy.214, 257, 258 In addition, the mode or pattern of bacterial invasion of the 
uterine cavity and the possible involvement of viral, protozoan or other bacterial infections in 
PTB is rather unclear.214 
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Figure 1.1. Major routes for intrauterine infection leading to spontaneous preterm birth (sPTB) and 
role of Magnetic Resonance Spectroscopy (MRS).  Changes in vaginal microbiota implicated in the 
pathogenesis of intrauterine infection which accounts for about half of spontaneous PTB, leave metabolic 
fingerprints detectable by MRS. 
Adapted from: Goldenberg et al 20085 
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Figure 1.2. Pathogenesis of infection in PPROM and PTB.  
BV, bacterial vaginosis; CRH, Corticotropin-releasing hormone; GCSF, Granulocyte colony stimulating factor; IL, 
Interleukin; LPS, Lipopolysaccharide; PGE2, Prostaglandin E2; PGF2α, Prostaglandin F2α; PGN, Peptidoglycan; PPROM, 
Preterm premature rupture of membranes; PTB, Preterm birth; SCFA, Short chain fatty acids; TNF, Tumour 
necrosis factor.  
Adapted from: Goldenberg et al. 2002,211  and Pararas et al. 2006.89  
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It is highly probable that the epithelium plays a role in preventing cervical inflammation and 
remodelling during pregnancy, and in causing inflammation and remodelling leading up to 
parturition at the end of pregnancy. Ascending genital infection may perturb this equilibrium 
during pregnancy by triggering inflammatory changes within cervical tissue, a process that 
appears to include changes in cell permeability, tissue hydration, and leukocyte infiltration of 
cervical stroma, triggered by key cytokines and chemokines. Although these inflammatory 
changes occur in the cervix and uterus prior to term labour, they characterise PTB more 
dramatically, even in the absence of positive microbial cultures from vaginal swabs and amniotic 
fluid.259 
Increasing vaginal pH, as a consequence of reduced activity of protective commensal 
Lactobacillus species, has been observed in women who deliver prematurely,21, 260 and the lower 
the gestational age at birth, the more the likelihood of an infection in the fetal compartment.261, 
262 
1.3.1. Other risk factors of preterm birth 
 
Although intrauterine infection accounts for about 50% of spontaneous PTB,1 several other 
interacting factors can influence the initiation of PTL and PTB. Hence, PTB has been described 
as a syndrome. These risk factors can be classified into: maternal background, pregnancy history 
and pregnancy characteristics.5 
There is a potential genetic component in the pathways involved in the pathogenesis of PTB. 
Sisters of women who delivered premature babies have about 80% greater risk of PTB. The 
history of PTBs in some women has been traced to their grandparents.5 Mothers born preterm 
are also at a greater risk of having preterm babies (OR = 1.4).263 Single nucleotide 
polymorphisms (SNP) of several genes associated with PTB have been identified through 
candidate gene-based association studies.264, 265 
Women of the black, African-American, and Afro-Caribbean decent have been reported to be 
at higher risk of PTB with an incidence of 16-18% compared with <12% in Caucasians.5, 266 The 
likelihood of a very early PTB is about 4 times greater in black women than women from other 
racial/ethnic population.5 This disparity could be attributed to differences in the composition of 
19 
 
the normal vaginal microflora, susceptibility to genital infection (e.g. BV), and immune response 
to genital infection. For instance, the normal vaginal pH of black women is higher than that of 
their white counterparts and related to higher prevalence of vaginal bacterial community state 
types (CST) devoid of Lactobacillus dominance.21, 45 This also corresponds to a higher Nugent 
score and may account for an increased incidence of BV infection and consequently PTB in 
black women.59, 88, 266, 267 
The expression and function of inflammatory cytokines in relation to infection and PTB appear 
to be different across racial/ethnic groups. African-American women exhibit elevated TNF-α 
and IL-β, while Caucasians show elevated IL-6 and IL-8 in association with PTB. These 
observations may be due to genetic variation as demonstrated by SNP analyses of genes 
encoding these inflammatory mediators.268 Black women have an imbalance of amniotic fluid 
TNF-α and soluble TNF receptor (sTNFR) concentrations indicative of a heightened TNF-α- 
mediated immunological response of PTB compared to white women.251, 269, 270 A gene-
environment interaction whereby a SNP of TNF-α at position -308 resulting in TNF-α risk allele 
2 common among blacks, and the presence of BV or periodontitis further enhances the risk of 
spontaneous PTB.166, 269 In addition, black women with the IL-6 allele and BV infection showed a 
2-fold higher risk of PTB. This was not seen in white women.5 Polymorphisms in genes coding 
for MMP-1, MMP-8, MMP-9, IL-1RN, IL-1R2, IL-2, TNF-R1, IFN-γ etc. in association with 
race/ethnicity and PTB have also been reported.265 
Other maternal demographic factors associated with PTB include maternal age (<18 or >35 
years), type of work and level of physical activity (e.g. standing for long hours), low 
socioeconomic and educational status, single marital status, inter-pregnancy interval less than 6 
months, poor nutrition, body mass index (BMI, underweight or obese), alcohol and drug abuse, 
smoking and stress.2, 5, 271, 272 
Women with a previous PTB have about 2.5-fold greater risk of recurrent PTB. The gestational 
age of a previous PTB is inversely related to the risk of subsequent PTB.5 Many recurrent PTB 
can be attributed to persistent or recurrent genital tract infection. Diabetes, hypertension, 
preeclampsia, obesity, thyroid disease, asthma, anaemia, periodontal disease and mental 
disorders (depression), are common comorbidities that increase a woman’s risk of PTB.2, 5, 271 
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Multiple gestations, short cervix at mid-trimester, history of cervical cone biopsy, fetal 
abnormalities, intrauterine growth restriction, vaginal bleeding, placenta previa or abruption, 
polyhydramnios or oligohydamnios, maternal abdominal surgery, pregnancy resulting from in 
vitro fertilisation are all risk factors associated with PTB.2, 271, 272 The mechanistic pathways of 
how these factors stimulate PTL and PTB is poorly defined. However, they interact to provoke 
a transition from uterine quiescence to an active contraction state resulting in PTL or PPROM.2, 
5 
Although, it has been hypothesised that the incidence of PTB in women at risk could be 
reduced by routine evaluation for, and eventual treatment of common vaginal infections,273 the 
microbial link between infection/inflammation and PTB remains unclarified by conventional 
microbiological assay techniques. Hence the need for more study of the changes in vaginal 
microflora in PTB using advanced molecular techniques such as 16S rRNA pyrosequencing and 
targeted species specific PCR. This technique has the advantage of detecting fastidious or 
culture-insensitive organisms and has provided a great insight into the hitherto “unculturable” 
or “uncharacterised” pathogenic and non-pathogenic microorganisms present in natural 
microbial communities such as the vagina and gut.21, 27 Some of these organisms include 
Atopobium vaginae, Megasphaera sp., Actinobacteridae, Bifidobacterium biavatii, Dialister sp, 
Finegoldia, Gemella, Parvimonas, Peptoniphilus, Prevotella sp., Leptotrichia sp., Sneathia sanguinagens, 
Eggerthella honkongensis, Veillonella sp. etc.21, 27 This has enabled researchers to compare the 
composition of the normal and BV inflicted vaginal microbiota signatures with tremendous 
success.274 
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1.4. 16S ribosomal RNA Pyrosequencing 
The use of this high throughput technique, which involves pyrosequencing of barcoded 16S 
rRNA genes, has provided a clearer understanding of the vaginal microbiota signature in health 
and during an infection or disease.21 It involves the use of specific and highly sensitive universal 
primers for amplification of the variable and/or hypervariable regions of the 16S rRNA genes,27, 
275 producing lengthy unidirectional amplicon reads required to characterise microbial 
community diversity and functionality devoid of cloning bias. The primers must include 454 
specific sequencing adaptors, amplicon (DNA target) specific primer sequences and a multiplex 
identifier (MID) to barcode each amplicon and sample. After the PCR, the purified amplicon 
mixture can then be sequenced by the GS FLX or GS Junior sequencing systems. This will 
eventually produce a data set of high quality sequences that can be classified using the 
Ribosomal Database Project (RDP) Naive Bayesian Classifier, SILVA or “BLASTed” against a 
GenBank. 276, 277 This culture independent molecular technique is currently frequently applied to 
study human and animal microbial flora (including those of the mouth and gut segments), in 
health and various pathological conditions. 56, 278-282 
The 16S rRNA gene (1.542 kb long) is a constituent of the 30S small subunit of prokaryotic 
ribosomes encoded for by the 16S rDNA gene. It has highly conserved primer-binding sites, 
hence used for phylogenetic studies. Its gene sequences also contain species-specific signature 
sequences (5 – 10 bases long, in hypervariable regions) necessary for identification of bacteria. 
It has found great use in the identification and reclassification of novel species and genera of 
bacteria including other uncultured organisms.283-287 The data obtained from pyrosequencing of 
barcoded 16S rRNA genes clearly differentiates strains of organisms and provides accurate 
microbiota signature. This is useful for determining the diversity and functional characteristics 
of the vaginal microbial community in healthy and disease conditions. 
The 16S rRNA genes of bacteria broadly consist of alternating hypervariable (V1-V9) and more 
conserved regions (Fig. 1.3). The hypervariable regions possess appreciable sequence 
heterogeneity between diverse bacterial species that can be amplified and sequenced to detect 
and distinguish these bacterial species,288 while the conserved regions which are parts of the 
genes that have experienced little degree of changes or mutations in their nucleotide sequence, 
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are perfect positions for universal primer hybridisation during PCRs.289-292  The variable regions 
are more correctly characterised than the conserved regions.276 Of all the hypervariable 
regions, V2 (137-242 bp), V3 (433-497 bp) and V6 (986-1043 bp) were shown to have the 
highest sequence heterogeneity and the highest discriminatory capacity in over 100 bacterial 
species studied.293 V6 has the highest density of sequence heterogeneity although it is the 
shortest. Primer sets designed to amplify the V3-V6 regions produced reliable results in PCR 
assays.293 Increased accuracy for and broadened peaks have been observed around the V2 and 
V4 variable regions. Thus, the semiconserved regions flanking these hypervariable regions may 
provide good binding sites for PCR as the read length of sequencing techniques increases.276  
No single hypervariable region has the ability to determine the distinction among all bacterial 
species. Therefore, sequencing as many hypervariable regions as possible is more beneficial as 
this further enhances the high sensitivity, specificity and reliability of microbiome assays.293 
Specie identification with 16S rRNA genes is best when almost the whole gene is sequenced. 
For this reason, the regions with the highest amount of taxonomic information in the shortest 
nucleotide sequence within the target gene must be identified. The most useful hypervariable 
regions with less intra-species diversity are V1 – V6.290, 293  
Pyrosequencing technique has been useful in the assessment of the number of OTUs (richness) 
and relative abundance (evenness) in microbial ecosystems.294 Shorter amplicons (e.g. < 400 bp), 
produce higher richness and primer choice influenced the relative abundance of OTUs. 
Sequence variability of the actual hypervariable region amplified accounts for the difference in 
specie richness. The sequence variability of the V1 – V2 region was higher than that of V8. 
Differences in species evenness occur when mismatches in DNA templates are not resolved by 
degeneracies in the primer sequence.294  
Also pyrosequencing has been employed in the identification and determination of genus/specie 
level composition and diversity. Ravel et al.21 using barcoded broad spectrum primers in 
amplifying the V1 – V2 regions of 16S rRNA genes, identified the dominant genera and species 
in the vaginal microbiome of about 400 non-pregnant asymptomatic women and classified them 
into 5 different communities designated as Community State Types (CSTs). Four of the 5 
communities identified were dominated by Lactobacillus sp., while the fifth (CST IV) had higher 
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proportions of mixed anaerobes such as Atopobium, Leptotrichia, Prevotella, Megasphaera etc. CST 
I was dominated by L. crispatus, while CSTs II, III and V had predominantly L. gasseri, L. iners, and 
L. jensenii. Women who harboured higher amounts of L. crispatus and L. iners (i.e. CST I and III), 
had lower vaginal pH values, whilst those with greater proportion of CST IV (mixed anaerobes), 
indicated the greatest pH values. Both high vaginal pH and Nugent score were directly 
associated with predominance of non-Lactobacillus sp.  
Again, amplifying the V1 – V2 regions of 16S rRNA genes of 32 healthy reproductive-age 
women, Gajer et al. identified similar CSTs except CST V due to low prevalence of CST V in 
their relatively small study population. However, they reported that temporal changes in the 
vaginal microbiome e.g. from one CST to another produces detectable changes in the 
metabolite profile. For instance a change from an L. iners (CST III) to Atopobium sp. (CST IV)-
dominated microbiota produced considerable changes in the metabolome characterised by high 
amounts of acetate and succinate with a corresponding decrease in lactate. Also, women with L. 
crispatus (CST I) and L. gasseri (CST II)-dominated microbiota experienced fewer transitions 
with low Nugent scores, indicating that these CSTs confers some degree of stability to the 
vaginal bacterial community.65  
Similarly, Bai et al. analysing 23 vaginal fluid samples from 8 women, explored the same region 
of the 16S rRNA genes and reported higher lactate production by L. crispatus-dominated CST I 
compared with other Lactobacillus sp.-dominated CSTs. Interestingly, vaginal samples from CST 
IV dominated by other lactate producing bacteria including Atopobium and Megasphaera also 
exhibited varying quantities of lactate although not as high as that of CSTs I, II, III and V 
dominated by Lactobacillus sp.295  
Furthermore, Drell et al.277 obtained a total of 828, 551 16S gene sequences (average read 
length = 300 bp) from 494 non-pregnant asymptomatic women. Again 5 groups were identified 
based on their OTU composition with Lactobacillus sp. dominating 4, whilst the last group had 
predominantly Gardnerella sp. Increased vaginal microbial diversity was associated with 
abnormal discharge and high pH.  
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More recently, it has been reported that the prevalence of a Lactobacillus-deficient vaginal 
microbial CST IV is inversely associated with gestational age at birth. Women in this group had 
greater amounts of Gardnerella or Ureaplasma and were at a significantly greater risk of 
delivering preterm. The researchers amplified the V3 – V5 variable regions of the 16S gene of 
bacterial species from 4 body sites (vaginal, distal intestine, saliva, and tooth/gum) of 40 
pregnant women.75  
Collectively, these reports demonstrate that vaginal bacterial communities dominated by 
commensal Lactobacillus sp. (CST I, II, III, and V), are more stable, resistant to infection, 
associated with low pH, and thus indicative of a ‘healthy’ vaginal environment and good 
reproductive outcome. While CST IV predominated by mixed anaerobes with pathogenic 
propensity is relatively unstable, less resistant to infection, associated with high pH and Nugent 
score, and indicative of poor vaginal and reproductive health. However, vaginal microbiome 
dominated by L. iners (CST III), has been found to be associated with the presence of BVAB 
seen in CST IV, predisposing such women to BV infection.110 
Apart from its application to the characterisation of the vaginal microbiota, 16S rRNA 
pyrosequencing has proved useful in the study of the bacterial composition of other sites of the 
human body e.g. the mouth and gut. 56, 278-282 Hutter et al. 296 using 27F/519R and 515F/1525R 
primer sets established a satisfying degree of diversity in the microbiota of periodontal lesions. 
The 27F/519R primer showed a greater proportion of diversity and this was attributed to the 
discriminatory properties of the hypervariable regions of the 16S gene. The effectiveness of this 
primer set can be exploited if the data available in the database are sufficient.  
16S rRNA genes have found considerable suitability in the study of bacterial phylogeny and 
taxonomy because it is ubiquitous among bacteria, has evolutionary conserved activities, and 
the relatively short  (1.5 kb)  nucleotide sequence is easily sequenced and sufficient for 
extracting substantial amount of data.286  
Overall, a multidisciplinary approach combining fetal and maternal clinical parameters, 16S 
rRNA pyrosequencing and other molecular techniques to characterise the complex vaginal 
microbiota and metabolite signatures should be more advantageous in the quest to identify 
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potential markers of PTB. Biochemical makers which are either intermediates or end products 
of several metabolic pathways determined originally by the genetic composition of the host and 
microbial population are a promising source of information capable of resolving the 
multifaceted PTB syndrome. 
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Figure 1.3. Bacterial 16S rRNA gene demonstrating the conserved and variable regions. Universal 
(broad-range) primers bind to the conserved regions to unselectively amplify the unique signature DNA sequences 
of the variable regions. 
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1.5. Biochemical markers of preterm birth 
 
Underpinning the clinical process of cervical remodelling prior to labour is a complex series of 
molecular events that include increasing vascularisation and infiltration of the cervix by 
inflammatory cells, release of hydrolytic and proteolytic enzymes that degrade cervical matrix, 
and chemicals that modulate these processes (e.g. prostaglandins and nitric oxide). These 
molecular events are not fully understood but necessarily involve altered metabolism within 
cervical and vaginal cells. Whether the aerobic or anaerobic form of glucose metabolism 
predominates has never been described. It is plausible that the process of cervical remodelling 
involves a dramatic shift in the energy balance and aerobic glucose breakdown.  
The pathophysiology of PTB still remains unclear; hence the need for a search for more 
accurate predictors. Chorioamnionitis due to female genital tract colonisation by anaerobic 
bacteria (that produce metabolic by-products in relation to the host), can lead to cervical 
remodelling, disruption of fetal membranes and leakage of FFN. Recently, biological fluids such 
as amniotic fluid, CVF, urine, serum, plasma, whole blood, placenta, cord blood and saliva, have 
been analysed to assess the predictive value of biomarkers for PTB.297-299 Analyses of 
biomarkers has enhanced the understanding of the pathogenesis of conditions leading to 
spontaneous PTB, but only a handful of such markers have attained clinical relevance.298 Table 3 
shows the diagnostic utility of various biochemical markers for spontaneous PTL, PPROM and 
PTB, obtained at different points in the mid-trimester. The 2 most widely used biochemical 
predictors of PTB are fetal fibronectin (FFN),300-302 and phosphorylated insulin-like growth factor 
binding protein-1 (phIGFBP-1).201, 303 These are proteins indicative of choriodecidual disruption 
when present in CVF. 
1.5.1. Fetal Fibronectin  
 
Fetal fibronectin (FFN) is an extracellular matrix glycoprotein (450 kDa) produced by cells of 
the amnion and cytotrophoblast localised at the feto-maternal interface between the chorion 
and decidua, where it serves as an adhesive binding the fetal membranes to the decidua.201, 304 In 
normal pregnancies, FFN is present at undetectable amounts in CVF between 16–22 weeks 
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gestation. However, levels ≥50 ng/ml between 22-34 weeks gestation is associated with an 
increased risk of spontaneous PTB.201, 304 In fact, detection of FFN in the CVF is currently the 
most effective marker of PTB especially in women with threatened PTL, and is one of the best 
risk assessment markers for PTB in all populations.303, 305 Detection of FFN at levels >50 ng/ml 
at mid to late second trimester is suggestive of membrane activation and premature separation 
of the fetal membranes from the uterine lining and spontaneous PTB.306-309 In symptomatic 
women, the initial study to determine the predictive capacity of FFN reported sensitivity, 
specificity, positive predictive value (PPV), and negative predictive value (NPV) of 81.7%, 82.5%, 
83.1%, and 81.0% respectively, based on a cut-off value of ≥50 ng/ml. More recently, FFN 
predicted PTB within 7 days (sensitivity: 50%; specificity: 80.2%; PPV: 9.1%; NPV: 97.6%), at < 34 
weeks (sensitivity: 62.5%; specificity: 82.5%; PPV: 22.7%; NPV: 96.4%), and <37 weeks 
(sensitivity: 50%; specificity: 85.9%; PPV: 45.5%; NPV: 88.0%), in women studied at 24-34 weeks’ 
gestation.310 
In asymptomatic women, Goldenberg et al. reported a high sensitivity of FFN at 22-24 weeks 
for predicting >60% of spontaneous PTB (<28 weeks) (sensitivity = 63%, and RR = 59.2). 
However, the sensitivity and PPV were low in predicting PTB at <34 weeks (i.e. 20–29% and 
17–25% respectively); but a high NPV (96-97%) was maintained.311 A similar specificity (97%) 
and sensitivity (22%),312 likelihood ratio, LR of 4.0,313 and RR = 3.8314 predictive of delivery 
within 7 days as well as <34 weeks of gestation were observed in other studies of 
asymptomatic women. Also, high NPVs and specificities have been recorded for vaginal FFN as 
a predictor of PTB in similar cohorts within 14 and 21 days of index assessment.309 
FFN is putatively the most clinically useful test for predicting PTB within 7–14 days of 
assessment due to its high NPV.313, 315, 316 However, its predictive accuracy is limited by poor 
sensitivity and false positive results due to recent unprotected vaginal intercourse, vaginal digital 
examination, uterine contractions, vaginal bleeding or amniotic fluid contamination from 
ruptured fetal membranes.317-319 The more recent approach of combining cervical length and 
FFN screening in asymptomatic320, 321 and symptomatic women302, 322-324 compared to FFN alone, 
results in a higher sensitivity and PPV to predict PTB risk, while maintaining high NPV.  This 
guides acute management and reduces unnecessary interventions particularly in low risk 
women.302 
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1.5.2. Phosphorylated insulin-like growth factor binding protein-1 (phIGFBP-1) 
 
phIGFBP-1 is necessary for growth and development of gestational tissues, such as the decidua, 
placenta, chorion and amnion.325 It is a 25 kDa protein secreted by maternal decidual cells 
regardless of the isoform of IGFBP-1 in amniotic fluid, fetal plasma and maternal plasma.303, 325 At 
the onset of second trimester when the amnion and choriodecidua become fused, the level of 
IGFBP-1 and extent of phosphorylation in amniotic fluid and decidua rises up to late 
gestation.303 phIGFBP-1 concentrations have been used to evaluate cervical maturation.201 Non-
phosphorylated IGFBP-1 (npIGFBP-1) concentration is about 1000-fold higher in amniotic fluid 
than serum, and elevated levels of npIGFBP-1 in CVF can be diagnostic of PPROM and PTB 
(LR+ 3.1).326, 327 Small quantities of phIGFBP-1 can be detected in cervical secretions at the 
beginning of labour when fetal membranes begin to detach from the parietal decidua. Detection 
of phIGFBP-1 in CVF, like FFN, at the onset of labour indicates detachment of fetal membranes 
from the parietal decidua and is a valuable predictor of PTB in asymptomatic and symptomatic 
women.325, 328-330 
A positive test has been employed in the diagnosis of PPROM and PTB with a high sensitivity 
(71-94%), specificity (82-94%) and NPV (70-99%); but unsatisfactory PPV (0-83%).329, 331-334 In 
symptomatic women, cervical phIGFBP-1level ≥10 µg/l is associated with a 10-fold greater 
risk335 and was predictive of spontaneous PTB with high sensitivity, specificity, NPV, and 
considerably high PPV (48-50%).328, 336, 337 Again, positive phIGFBP-1 in women with threatened 
PTL was a useful predictor of PTB at <32 weeks (LR = 2.2), and <34 weeks (LR =1.8).325 In 
asymptomatic women, a pooled sensitivity (33%), specificity (79%), LR+ =1.6 and LR- = 0.8 have 
been demonstrated.338 
Like FFN, phIGFBP-1 is a dependable negative predictor of PTB.201, 303 However, in 
asymptomatic women, the PPV of phIGFBP-1 is significantly lower than that of FFN, while their 
NPVs are similar for predicting PTB.331 But in symptomatic women the NPVs of both tests are 
comparable in predicting PTB within 7 days,310, 339 at <34 and <37 weeks.310 Fortunately, the 
level of phIGFBP-1 is not altered by the presence of semen or vaginal bleeding,303 and perhaps a 
better test than FFN in predicting births before 34 weeks’ gestation.310 
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1.5.3. Other biomarkers 
 
Due to the relatively low sensitivity and PPV of the FFN and phIGFBP-1 tests in predicting 
spontaneous PTL, PPROM and PTB especially in asymptomatic pregnant women, alternative 
biomarkers have been investigated for their predictive accuracy.303, 338 However, none of these 
biomarkers have been consistent in predicting spontaneous PTB in clinical settings.338 They 
include activin–A, albumin/vitamin D-binding protein (VDBP),340 alkaline phosphatase (AP), 
alpha-fetoprotein (AFP), angiogenin,338 β-human chorionic gonadotrophin (hCG), Cluster of 
Differentiation 163 antigen,327 Corticotropin releasing hormone (CRH), C-reactive protein 
(CRP), creatinine, defensins, elastase, endoglin,338 ferritin, G-CSF, glucose,341 IGFBP-4,342 IL-1, 2, 
6, 8, 10, 18,327, 343, 344 IL-1 receptor antagonist (IL1RN),345 interferon-gamma (IFN-γ), interstitial 
cell adhesion molecule-1, lactate, lactoferrin, lipocalin-type prostaglandin D2 synthase (L-
PGDS),346 MMPs,338, 347 nitric oxide,348, 349 placental alpha macroglobulin-1 (PAMG-1), placental 
protein 13,338 pregnancy associated plasma protein-A (PAPPP-A),338, 350 pregnancy-specific β-1-
glycoprotein,338 prolactin, relaxin, salivary estriol351 and progesterone,352-354 sex hormone-binding 
globulin (SHBG),342 sialidase, thioredoxin,345 TNF-α, thrombin-antithrombin III complex,338 urea, 
vascular endothelial growth factor347 and proteomic profile: stratifin, desmoplakin isoform-1, 
and thrombospondin-1 precursor.202, 297, 298, 326, 327, 338, 344, 349, 355 Table 1.3 summarises the sources 
of these biomarkers investigated and their predictive performance for prognosticating PTB. The 
heterogeneity of the pathogenesis of PTL and PTB, experimental design (e.g. sample sizes, 
inclusion/exclusion criteria, gestation age at sampling etc.), and reproducibility are the common 
challenges in identifying accurate biomarkers for prediction of PTL and PTB.303 Hence, 
improvement in study design and methodology, combining multiple biochemical diagnostic tests 
that incorporate environmental and behavioural risk factors, cervical length assessment, uterine 
activity check, fetal DNA and genetic polymorphism, and microbiome test may improve the 
prediction of spontaneous PTB across diverse populations.201, 303, 307, 356 However, increasing the 
range of predictive biomarkers may improve accuracy but may become cost-ineffective.  
Analyses of the genome (genomics), transcriptome (transcriptomics) and protein composition 
(proteomics) have aided the discovery of biomarkers of PTL and PTB.298, 357 Nonetheless, 
metabolomics i.e. the study of metabolites <1 kDa and characterisation of the metabolic 
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network (profile) of cells, is more advantageous as the metabolites are downstream products of 
gene expression and protein synthesis.299, 357 This provides a closer insight into the functional 
activity of the cells.299, 357 Also, it provides information on the relationship between the host, the 
microbiome, and the environment to give a comprehensive understanding of physiological and 
pathological states.358 Metabolomics appears to be a promising novel tool in obstetrics and 
gynaecology that may be employed to seek to improve health care during pregnancy.299 The 
metabolomics techniques currently employed include liquid chromatography-mass 
spectrometry (LC-MS), ultra-performance liquid chromatography-mass spectrometry (UPLC-
MS), gas chromatography-mass spectrometry (GC-MS) and magnetic resonance spectroscopy 
(MRS).65, 98, 295, 299, 357-360 
Evaluation and comparison of biological ecosystems by characterisation of their metabolome 
and finger printing using high throughput techniques, such as MRS, in pregnant women at risk of 
PTB compared to their term counterparts may improve the accuracy of predicting PTB.359 
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Table 1.3: Diagnostic utility of biochemical markers obtained at midtrimester for 
spontaneous PTL, PPROM and PTB (< 37 weeks) 
Biomarker 
Source of 
marker 
Cut-
off 
value 
Sensitivity 
(%) 
Specificity 
(%) 
PPV 
(%) 
NPV 
(%) 
Reference 
Albumin/VDBP CVF 
≥1900
0/≥90 
77.8 100 100 98 340 
Alkaline 
phosphatase 
serum 90th* 14 3   
298, 326 
Alpha-
fetoprotein 
serum >30 
µg/l 
90-94 95-100 94-100 91-94 202, 297, 327 
β-human 
chorionic 
gonadotrophin 
CVF/serum >40-65 
µIU/ml 
68-95 70-95 73-91 78-97 202, 338, 350 
CRH serum 90th* 39 13   
298, 326 
C-reactive 
protein 
plasma 8 mg/l 26 15   
298, 326, 361 
Estriol saliva 
≥2.1 
ng/ml 
44 92 19 98 326, 351 
Ferritin serum 
>30 
mg/dl 
62 45   298, 362 
Fetal 
fibronectin 
CVF ≥50 
ng/ml 
97-98 70-97 36-93 98-100 298, 327, 340 
G-CSF** serum 90th* 49 15   298, 326 
Glucose ** amniotic 
fluid 
<25 
mg/dl 
59.3 91.0 85.4 71.8 341 
phIGFBP-1 CVF >10 
µg/l 
52.9 89.2 48.7 90.8 310, 338 
IGFBP-4/SHBG serum  75 74   
342 
IL-6 amniotic 
fluid 
≥99.3 
pg/ml 
89.6 80.2 40.0 98.1 326, 347, 363 
IL-8** amniotic 
fluid 
≥13.3 
ng/ml 
67.8 95.5 93 77.1 341, 344 
IL1RN** CVF 0.4 
µg/mg 
57.1 97.8 72.7 95.7 345 
Lactate*** CVF 
≥4.5m
mol/l 
86 92 92 87 364 
MMP-8 amniotic 
fluid 
5.14 
pg/ml 
69.4 68.3   338, 347 
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† Centile 
* Percentile  
** Endpoint was PTB < 32-35 weeks’ gestation. 
*** PPROM > 34 weeks’ gestation. 
CRH, corticotropin-releasing hormone; CVF, cervicovaginal fluid; G-CSF, granulocyte colony stimulating factor; 
IGFBP-4, insulin-like growth factor binding protein-4; IL1RN, interleukin 1 receptor antagonist; PAPP-A, pregnancy 
associated plasma protein-A; phIGFBP-1, phosphorylated insulin-like growth factor binding protein-1; SHBG, sex 
hormone-binding globulin; VEGF, vascular endothelial growth factor; VDBP, vitamin D-binding protein. 
 
 
 
 
 
 
 
 
 
Nitric oxide cervix 
87.6 
µmol/l 
88.2 86.5 53.6 97.6 349 
PAPP-A blood 5th† 11 93   
338, 350 
Progesterone saliva 3950 
pg/ml 
82 69 66 83 352 
Prolactin CVF >30-50  
µIU/ml 
83 74   202, 365 
Relaxin serum 90th* 38 58   
298, 327, 338 
Thioredoxin** CVF 0.4 
µg/mg 
64.3 97.8 75.0 96.4 345 
TNF-α amniotic 
fluid 
6.3 
pg/ml 
81.3 79.2 36.2 96.7 327, 363 
VEGF amniotic 
fluid 
25 
pg/ml 
91.7 75.0   347 
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1.6. Cervical length assessment in preterm birth 
In many women who deliver preterm, the cervix begins to shorten weeks prior to the 
occurrence of PTL and PPROM. These changes can be detected by cervical ultrasonography.366, 
367 Transvaginal ultrasonography (TVUS) has been employed since the 1980s and is currently 
the gold standard for measuring cervical length (CL) and estimation of internal cervical os 
dilation.303, 366 TVUS has the advantage of direct and clear visualisation of the cervix without the 
interference of bowel gas in comparison to transabdominal ultrasound.366, 368 The average CL (at 
24 weeks’ gestation) i.e. the distance between the internal cervical os and external cervical os is 
about 35 mm and cervix <25 mm and funnelling, is considered a short cervix by several authors 
although there is no consensus regarding the threshold CL below which the risk of PTB 
increases significantly.369 There is an association between delivery outcomes and both CL and 
gestational age at diagnosis of short cervix.370 Mid-trimester CL is the single most predictive risk 
factor of PTB.371-376 CL screening, an estimate of cervical competence, has some predictive 
clinical utility in low and high-risk women for PTB: a shortened CL <25 mm (at any gestation < 
34 weeks) is associated with increased risk of spontaneous PTB.372, 377-379 About half of the 
women with a CL ≤15 mm experience early spontaneous PTB.376 Women with progressively 
shorter cervices seen on a mid-trimester sonogram experience increased rates of PTB (≤35 
weeks)380-382 and a reasonable proportion of these women have intra-amniotic inflammation, 
with a 40% risk of PTB within 7 days.383, 384 In another study, 9% of patients with short cervix 
measured between 14-24 weeks had MIAC, of which 40% delivered preterm (<32 weeks).385 In 
addition, mid-trimester CL is inversely related to vaginal pH, Nugent score and BV, but not 
after adjustment for relevant confounders.386 In a study of women with spontaneous PTL, CL 
and plasma nitric oxide (which activates MMPs) measured between 24-33 weeks’ gestations 
were negatively correlated.349 Also, obstetric risk factors such as vaginal bleeding387 and multiple 
pregnancies could influence the optimal CLs and their predictive value for PTB.388 However, in 
high risk women a <25 mm CL at 16-19 weeks’ gestation appears highly predictive (75%) of 
recurrent spontaneous PTB,372, 378, 382as neither the number of cases nor the gestational ages of 
previous PTBs impact its predictive value.373 Its predictive value improved when CL is assessed 
sequentially.382 A combination of the patients’ obstetric history and CL provides a more 
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accurate predictive tool for spontaneous PTB than either factors alone, with improvement in 
the sensitivity and specificity of the screening as the degree of prematurity increases.389   
In asymptomatic high risk women, CL <25 mm predicted spontaneous PTB (<35 weeks) with 
LRs+ of 4.3 (<20 weeks’ gestation), 2.8 (20-24 weeks), and 4.0 (>24 weeks).377 Among 
asymptomatic women with twin pregnancies, mid second trimester CL ≤20 mm was predictive 
of PTB (<32 and <34 weeks) with sensitivities, specificities, LR+ and LR- of 39% and 29%, 96% 
and 97%, 10.1 and 9.0 and 0.64 and 0.74, respectively. A CL ≤25 mm at same gestation 
predicted PTB (<28 weeks) with LR+ of 9.6.390 
In women with threatened PTL and intact membranes, CL (≤20.5 mm) had a sensitivity of 88% 
and specificity of 54% for prediction of delivery at <34 weeks, <32 weeks, and within 48 hours 
and 7 days of assessment.325 An earlier study using a cut-off of <25 mm had reported sensitivity 
of 80%, specificity of 97%, PPV of 80% and NPV of 97%, for prediction of delivery <35 weeks 
and within 7 days.391 Using a criteria of <15 mm, Sotiriadis et al. reported that CL measurement 
can identify symptomatic women at risk of delivering within 7days (sensitivity = 59.9%, 
specificity = 90.5%, LR+ = 5.7, and LR- = 0.5).392  The LR+ for PTB within 7days in another 
study was higher (8.7) at a cut-off of <15 mm compared to 0.4 when the cut-off is ≥15 mm.393 
At a higher cut-off of 30 mm (26-34 weeks), the predictive accuracy of CL for PTB was 83.0 
with sensitivity, specificity, PPV and NPV of 68-100%.354 In cases of CL between 15-30 mm, a 
combination with FFN test enhances the detection of women at low risk of spontaneous 
delivery within 7 days.394 There is inadequate indication to suggest routine CL screening for 
both symptomatic and asymptomatic women. Further investigation is necessary as a non-
significant association between knowledge of CL result and lower prevalence of PTB (<37 
weeks) in symptomatic women has been observed.395 
Ultrasonographic CL assessment is a safe and clinically useful technique to determine increased 
risk of PTB in selected women.396 However, there is currently no consensus regarding the 
threshold CL below which the risk of PTB is considerably increased. Also, as a result of its low 
PPV and sensitivities, routine CL screening is not recommended in low risk women with about 
4.3% incidence of PTB.397 Consequently, some investigators have argued that universal screening 
in the general obstetrical population is unwarranted.396 Its effectiveness has also been challenged 
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due to the absence of a proven intervention once a short cervix is diagnosed.398 Hence, there is 
a need for a more accurate biomarker of PTB with potential universal applicability regardless of 
risk and/or symptom statuses of the patients. 
1.7. Preventive interventions to reduce the incidence and complications of preterm 
birth 
 
Over the years, evidence based insight into the pathophysiology of PTB has led to the 
development of several therapeutic interventions to prevent its occurrence and/or reduce the 
effects of its deleterious complications. The primary objective of these treatments is to defer 
delivery until the fetal organs are fully developed to sustain the survival of the newborn outside 
the uterine compartment or to when adequate perinatal care is available. There are also 
treatments administered to protect the vital organs of the conceptus from the devastating 
complications that accompany uncontrolled intrauterine infection and inflammation leading to 
PTL. Lifestyle modifications before and during pregnancy such as smoking cessation, nutritional 
adjustment, reduced BMI as well calcium, folic acid and vitamins supplementation have been 
advocated.399, 400 Generally, these interventions are directed to all women of reproductive age 
(i.e. lifestyle modification, dietary supplementation, prenatal care and screening of low risk 
women), targeted at minimising or eradicating identified risk factors (e.g. antibiotic, 
progesterone, cervical cerclage and tocolytics), or intended to prevent complications and 
improve survival of preterm infants (e.g. corticosteroids).399 
Antibiotics 
Antibiotics treat BV and other bacterial genital infections by reducing the overgrowth of 
pathogenic aerobic and anaerobic species and reinstate the stability of the protective 
Lactobacilliary microflora thereby preventing the development of inflammation-induced PTL and 
PTB.188, 195  Routine prescription of antibiotics for women at risk of PTB has been controversial. 
Antibiotic treatment eradicates BV during pregnancy but does not reduce the risk of PTB 
significantly.188, 401 In women with PPROM, antibiotics delay delivery and improve neonatal 
morbidities in the short term but does not significantly reduce perinatal mortality.402 Although 
maternal infection may be reduced, prophylactic antibiotics did not show great improvement in 
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important neonatal outcomes for women in PTL with intact membranes.403 Despite these 
limitations, reduction in the incidence of PTB has been reported with treatment before 20 
weeks gestation.399 
Progesterone 
Progesterone (often administered as17-hydroxyprogesterone caproate) reduces the risk of PTB 
by preventing uterine contraction and cervical remodelling, decreasing the production of 
prostaglandins and inflammatory mediators (e.g. IL-6).199, 404 In a recent randomised, placebo-
controlled study with singleton pregnancies, prophylactic vaginal progesterone reduced the rate 
of PTB, the risk of a low birth weight, the rates of respiratory distress syndrome (RDS) and 
admission to neonatal intensive care unit (NICU) in women at risk of PTB. Also, with a 
shortened second trimester CL (≤ 25 mm), vaginal progesterone reduced the risk of PTB and 
neonatal morbidity and mortality without any neurodevelopmental adverse effect. Hence, 
regardless of the history of spontaneous PTB, vaginal progesterone has been recommended for 
ultrasound-indicated short cervix at 18-24 weeks gestation.404, 405 However other reports did 
not indicate any benefit of progesterone in relation to PTB and poor neonatal outcome.406  
Cervical cerclage 
The length of the cervix at mid-trimester is inversely related to risk of PTB. Reduction in CL 
and effacement (widening) can arise from biochemical, infection and inflammation-related 
factors.399, 407 Cervical cerclage is a surgical procedure that involves sticking a suture (stitch) 
around the uterine cervix aimed at preventing cervical shortening and effacement, thereby 
reducing the risk of PTB.408 It appears to be most adequate in women with structurally 
(anatomical) defective or incompetent cervix,399 and history of PTB.409 It reduces the rate of 
PTB in women with singleton pregnancies at risk of recurrent PTB but has not shown significant 
effectiveness against perinatal morbidity and mortality.410 Its effectiveness in women with 
multiple gestations has not been established,408 and poor delivery outcomes have been reported 
when inflammation is present.399 However, in combination with prolonged antibiotic therapy 
(e.g. azithromycin), its prophylactic and therapeutic efficacy for PTB, fetal mortality, low birth 
weight and rate of abortion is significantly improved.411 
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Corticosteroids 
Infants born prematurely may have underdeveloped lungs and other vital organs inevitable for 
survival ex-utero. Corticosteroids have proven effect on fetal lung development and 
maturation. They also stimulate the development of other important organs that sustain 
postnatal adaptation including brain, heart, kidneys, thyroid etc.412  Corticosteroids improve 
fetal lung function by inducing the production of surfactant, stimulating the development of 
alveolar structure, increased vascularisation and alveolar fluid clearance. As a result, antenatal 
corticosteroids reduce the incidence of neonatal mortality, respiratory distress syndrome 
(RDS), and other neonatal complications such as intraventricular haemorrhage, necrotising 
enterocolitis, and patent ductus arteriosus.412, 413 Oral or intramuscular dexamethasone and 
bethamethasone are currently the widely used corticosteroids clinically and have been effective 
in improving short- and long-term sequelae in premature infants.413 
Tocolytics 
Tocolytics are anti-contraction drugs also known as labour represents. They are medications 
used to delay PTL and PTB, providing enough time (usually 24-48 hours) for intrauterine 
transfer to a specialist centre, permit overall fetal maturation and antenatal corticosteroids to 
have clinical effect i.e. production of adequate amount of surfactant in the lungs.414 There is no 
evidence that tocolytics reduce the rate of PTB.399 
A wide variety of tocolytic agents have been employed to inhibit uterine contraction and 
postpone delivery by affecting the interaction of contractile proteins in the myometrium or 
inhibiting the synthesis/ blocking the activity of myometrial stimulants.414 They include: β-
adrenergic agonists (Salbutamol, terbutaline, fenoterol), Calcium channel blockers (nifedipine), 
oxytocin receptor antagonists (atosiban), cyclo-oxygenase inhibitors (indomethacin), and 
myosin light chain inhibitors (Magnesium sulphate).414-418 Amongs these agents, the β-adrenergic 
agonists are the most widely used but with a high frequency of severe maternal side effects.417 
Interestingly, calcium channel blockers and oxytocin receptor antagonists have lesser side 
effects417 and are capable of delaying delivery for up to 7 days.399 
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1.8. Magnetic Resonance Spectroscopy  
 
An approach to demonstrating the vaginal host-microbial changes associated with PTB is to 
determine the metabolite fingerprints resulting from these interactions. These metabolic 
changes which are direct reflections of vaginal bacterial community function can be detected by 
Magnetic Resonance Spectroscopy (MRS) also known as Nuclear magnetic resonance (NMR).65, 
295 MRS is a research technique that utilises the magnetic characteristics of certain atomic nuclei 
to ascertain the physical and chemical properties of atoms or molecules in which they exist. It 
differs from magnetic resonance imaging (MRI), in that it detects the resonance frequency of 
chemical compounds other than water allowing for depiction of internal chemistry, whilst MRI 
which is achieved through the application of linear magnetic field gradient on an existing 
magnetic field, detects the resonance of hydrogen nuclei in water and fat to produce high-
resolution images of the gross internal anatomy of body tissues and organs.419, 420 Nuclear 
magnetic resonance occurs when an MR-active nucleus (i.e. 1H, 13C, 19F, 23Na, 29Si, 31P etc.),419, 421-
423 changes its spin state driven by the absorption of electromagnetic radiation at a specific 
resonance frequency (Larmor precession), that is dependent on the strength of the magnetic 
field and the magnetic properties of the atomic isotope.424, 425 MRS signals arise from the 
interaction between MR-active nuclei and a strong magnetic field.423, 424 This can provide useful 
insight into the molecular structure, dynamics, reaction state, and chemical environment of 
molecules.424, 426 It has the capacity to determine the relationships between specific nuclei within 
or between molecules. Though MRS can be applied to any sample containing MR-detectable 
nuclei (nuclei possessing spin), it is often used to study the molecular properties of organic 
molecules. One-dimensional (1H or 13C), 2-dimensional (1H-1H or 1H-13C) (for small 
compounds) and 3, 4, or 5-dimensional experiments (for macromolecules e.g. proteins, nucleic 
acids and polysaccharides)422 can be performed. At least one MR-active isotope exists in almost 
every element. 
1.8.1. Nuclear spin, resonance and magnetisation 
 
The charged and spinning nuclei of atoms have a nuclear spin quantum number, I, which is in 
multiples of ½ e.g. ½, 1, 3/2 etc. Atomic nuclei with I = 0 possess no nuclear spin and are ‘MR-
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inactive’ e.g. 12C and all nuclei with even atomic mass and atomic numbers. The spin > 0 nuclei 
possess angular momentum and are capable of forming magnetic dipoles.427 These magnetic 
dipoles, like those of bar magnets (north and south poles), are normally randomly oriented. MR 
signal is not generated at this state as there is no net magnetic field emanating from them. 
However, when placed in a strong external and static magnetic field, B0, 2I+1 spin energy states 
are created, e.g. for a spin-½ nucleus, 2 spin states are formed; one energetically favourable 
spin (α state) parallel to the external magnetic field and a higher energy spin (β state) 
antiparallel to the external magnetic field (Fig. 1.4). At equilibrium a small excess of nuclei exist 
in the α spin state. The parallel spin which is of lower energy aligns with B0, while the other 
opposes it resulting in a net magnetic moment, M, from the sample.419 Although MR is a 
quantum mechanical phenomenon it can be more intuitively understood from a classical 
interpretation (Fig. 1.4). 
 
Figure 1.4. At equilibrium, the excess α spin state places the net magnetic moment, M, parallel to B0  
on the +z axis. 
 
The application of a second magnetic field, B1, perpendicular to B0, displaces the net magnetic 
moment, M, from alignment with the B0 i.e. away from equilibrium towards the x-y plane. 
Removal of B1 allows the magnetic moment to precess about B0 along the x-y plane, thereby 
generating radio frequency (rf) signals in the detection coil (Fig. 1.5).419 A pulse is applied when 
an rf irradiation is turned on and then off after a specific time interval e.g. 90° pulse. In MR 
experiments, pulse sequences (series of timed rf pulse magnetic field gradients) are used to 
exploit the magnetic properties of nuclear spins in order to obtain the required data.427 
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Figure 1.5. Signal is generated when the net magnetic moment is “flipped” out of equilibrium (z 
axis), towards the x-y plane by the applied rf pulse. 
 
The circular motion of the magnetic moment around B0 is called Larmor precession. The rate 
of precession (Larmor frequency) is defined as:  
                                                
where γ = magnetogyric ratio (a measure of the magnetic properties of a particular nuclide), v is 
expressed in Hertz (Hz), and B0 in Tesla (T). The direction of the motion though constant for 
any given nuclide, can be either clockwise on anticlockwise depending on the sign of γ.  
NMR is achieved when an MR-active nucleus changes its spin state stimulated by the absorption 
of electromagnetic radiation, which is at a specific resonance frequency (Larmor precession), 
that depends on the strength of the magnetic field, B0, and the magnetic properties of the 
isotope of the atom. The energy difference (∆E) between the 2 spin states is proportional to B0. 
This is expressed as:   
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where h is the Plank’s constant. For the resonance condition to be met, the excitation field 
must be at the same frequency as the Larmor precession i.e. the resonance frequency of the 
spin nuclei, hence the name nuclear magnetic resonance.  
Through a process called Fourier transformation (FT), nuclear spins can be stimulated 
simultaneously using a single pulse radio frequency (rf), acquiring time-domain response and 
converting it to frequency-domain spectrum. This allows averaging of the signal to increase the 
signal-to-noise ratio and an MR spectrum from which metabolites can be identified is 
generated.419, 427 
The signals detected as the resonating nuclei realigns along B0, possess a distinctive frequency 
which is dependent on the magnetic properties of the isotopes of the atoms (e.g. 1H, 13C, 23Na, 
31P), and the strength of the magnetic field. In other words, MR signals are isotope specific with 
each signal strongly linked to an element or nuclide.419, 428 The size of the signal is proportional 
to the number of nuclei present provided the signal is acquired with adequate relaxation decay. 
All signals are detected simultaneously. These signals decay via the transfer of energy from the 
excited nuclei into its surroundings (i.e. relaxation). The relaxation varies from one sample to 
another depending on the molecular environment. Signals relax to equilibrium via 2 energy 
transfer processes; T1 and T2.
419, 427  
T1 - longitudinal relaxation, is the loss of excess energy into the surrounding molecular lattice 
(spin-lattice relaxation), as net magnetisation is returned to the z-axis (Fig. 1.6). The lattice is 
the sample in which the nuclei are contained. Usually T1 ranges between 0.5-5s for medium-
sized organic compounds, and a minimum period of 5T1 is required for nuclei to relax 
completely after a 90° pulse.  This is because T1 decays exponentially. At 5T1 about 99.3%  
magnetisation recovery has taken place.427 
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Figure 1.6. Longitudinal relaxation. Recovery of the magnetisation along the z axis establishing equilibrium 
after pulse excitation.  
T2 - transverse relaxation (Fig. 1.7), is the loss of net magnetisation in the x-y plane as seen in 
the free induction decay (FID). It is due to differences in the magnetic field within the sample 
which arises from 2 sources: heterogeneity of the static magnetic field (reduced by “shimming”), 
and mainly from the sample intra- and intermolecular interactions-stimulated local magnetic 
fields. It is also referred to as spin-spin relaxation because it defines the exchange of energy 
between adjacent nuclei that precess at the same frequencies but different local magnetic fields. 
In other words, magnetisation decays away due to each spin experiencing different local 
magnetic fields i.e. loss of phase coherence on the x-y plane.427  
 
Figure 1.7. Transverse relaxation. No net magnetisation as a result of differences in local magnetic fields 
within the sample. 
Therefore, by placing a sample containing nuclei possessing spin in a magnetic field and exciting 
it with a second magnetic field (quantum of energy), the structure, dynamics, reaction state and 
chemical environment of its molecules can be studied noninvasively and non-destructively.419 
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Chemical shift 
The practicality of MRS is based on the evidence that atomic nuclei that differ in chemical 
structure resonate at different frequencies in the same magnetic field. This is due to differences 
in the electronic environment of the protons. With the aid of their electrons, different chemical 
compounds shield their nuclei from the applied B0 by different degrees. For resonance to occur, 
the applied magnetic field must be greater than the local magnetic field generated by the 
electrons “shielding effect”. This is called chemical shift,419, 423, 428 and described by:   
                                         
where σ is the shielding constant and usually reported in parts per million (ppm). The chemical 
shift provide information about the structure of compounds as the different chemical groups 
contained in the sample generate correspondingly varying signals at different frequencies.419 In 
1H-MR, most molecules have a chemical shift range of 0-20 ppm and defined relative to a 
reference compound, e.g. 3-(trimethylsilyl)-propionic-2,2,3,3-d4 acid sodium salt (TSP). An 
example as shown in Fig. 1.8, is the 1H-MR spectrum of ethanol (CH3-CH2-OH), in which 3 
signals (CH3 – 1.17 ppm, CH2 – 3.65 ppm, and OH – 5.19 ppm), corresponding to the 3 
hydrogen groups, with the peak intensities proportional to the number of 1H nuclei in each 
chemical group (Fig. 1.8).427  In addition, adjacent MR-active nuclei influence the resonance 
frequencies in a manner dependent on the chemical bonds within the molecule (J or scalar or 
spin-spin coupling). J-coupling indicates how nuclei can sense the presence and number of 
neighbouring nuclei and importantly provides additional structural information via chemical 
bonds present in the molecule.421, 429 By analysing the shape, area and signal intensities of MR 
spectral peaks (integration), the unique molecular structure and concentration of a particular 
compound (metabolites) in a biological sample can be determined.  
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Figure 1.8. 1H-MR chemical shift of ethanol indicating the frequencies and peak intensity ratio. Time-
domain signals are converted to frequency domain spectra via Fourier transformation. 
MRS can qualitatively and quantitatively elucidate the metabolic profiles of tissues and biofluids, 
thereby providing biomarkers that indicate physiological and pathological states. It is an efficient 
non-invasive and non-destructive technique that can be used to distinguish a large variety of 
metabolites in body fluids including serum, urine, faeces, spinal fluid, vaginal fluid, follicular 
fluid,65, 295, 430-433 and provide insight into the metabolic activities of organs such as the heart, 
breast, cervix, prostate, liver, stomach, pancreas, colon, skeletal and vascular smooth muscle, 
kidneys and brain.423, 432, 433 It has also been applied to identify the chemotypes of 
microoganisms,434 as well as in food,435 drug and plant biochemistry.421, 436 
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1.9. Aim of Study 
 
The interaction between genital tract bacterial colonisation and PTB remains unsatisfactorily 
determined by conventional assay techniques.  There may be an association between the vaginal 
microbial community composition and the metabolite signature of cervicovaginal fluid. An 
altered vaginal ecosystem have been indicated in the progression of ascending intrauterine 
infection or MIAC leading to PTL,8 and could influence the initiation of PTB.1 The biochemical 
activities and resultant metabolic by-products of the vaginal microbial population during 
gestation can provide useful insight into the pathophysiology of PTB as well as help in identifying 
women at risk.358 These metabolic changes, which are reflective of vaginal bacterial community 
function, leave fingerprints that can be investigated by MRS.65   
Accurate identification of women at risk of PTB remains challenging. Given that two-thirds of 
spontaneous PTBs are associated with infection/inflammation in reproductive and gestational 
tissue, investigation of the microbiome and metabolic patterns associated with PTB is topical. 
Hypothesis: It was hypothesised that PTB is associated with detectable early linked 
“signature” microbial and metabolite patterns. In other words, women who go on to deliver 
prematurely will have significantly different vaginal bacterial specie composition and 1H-MR 
metabolite signatures compared to their term counterparts even in the absence of clinical 
infection.  
Therefore, in order to characterise the functional identity of the vaginal microbiome during 
pregnancy and elucidate an integrated picture of microbiome composition and activity in 
relation to delivery outcome, we performed an MRS metabolite study and PCR assessment on 
CVF of different cohorts of asymptomatic pregnant women and women presenting with 
symptoms of threatened preterm labour across the second trimester. 
This study focussed on metabolic changes in the vaginal microenvironment early in pregnancy in 
(2nd trimester), i.e. where an early diagnostic tool aligned with standard pregnancy checkpoints 
would be advantageous. In parallel, we assessed the prevalence of specific vaginal commensal 
and potentially pathogenic bacterial species in these patients while assessing other factors 
indicative of the state of the vaginal environment (e.g. pH).   
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On the whole, we studied three broad cohorts of pregnant women: 
 A group of asymptomatic pregnant women at a lower risk of PTB presenting at 20-22 
weeks gestation with a normal cervical length (>25 mm), and/or without prior PTB. 
 A group of asymptomatic high-risk pregnant women with a previous history of PTB at 
20-22 weeks, and at 26-28 weeks. Primary study end point was delivery before 37 
weeks and the secondary endpoints was delivery before 32 weeks. 
 A group of symptomatic pregnant women presenting on labour ward with symptoms 
reminiscent of preterm labour (regular uterine contractions but cervix <3 cm dilated). 
Predictive endpoint was delivery within two weeks of index assessment while secondary 
endpoints were delivery before 32 and 37 weeks of gestation. 
 
1.9.1. Specific study objectives 
 
- To determine if the 1H-MR spectrum of CVF can identify women who ultimately deliver 
prematurely from cohorts of women at high or low risk of PTB, and pregnant women 
presenting with symptoms of threatened preterm labour. 
- To characterise and validate the metabolite profile of CVF of a cohort of pregnant women by 
1H-MRS and spectrophotometry, and determine their predictive capacity for PTB. 
- To investigate the relationship between CVF fetal fibronectin, ultrasound cervical length, and 
vaginal microbiota metabolites of pregnant women in relation to gestational age at delivery. 
- To identify the cellular composition of the CVF sample and determine the vaginal bacterial 
specie composition by PCR during pregnancy. 
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Chapter 2 
 
Determination of cervicovaginal fluid metabolite profile during 
pregnancy by Magnetic Resonance Spectroscopy 
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2.1. Recruitment of study participants at different gestations and sample collection 
 
2.1.1. Ethical approval 
These studies were reviewed and approved by the Yorkshire & Humber (Sheffield) Committee 
of the UK National Research Ethics Service (REC Number 13/YH/0167). 
2.1.2. Recruitment of study participants 
The study participants (N = 458), mainly Caucasians (>80%), comprised of two clinical 
categories of pregnant women: those that had no symptoms of PTL (asymptomatic group) and 
those presenting to the delivery suite with symptoms of, but not established, PTL. The 
asymptomatic pregnant women were further classified into 2 gestationally-matched groups 
based on a prior history of PTB: a low-risk group (ALR, n = 183), who had no history of PTB 
(assessed at 20-22 gestational weeks, w), and a high-risk group (AHR, n =186), who had a 
previous history of PTB and/or short cervix (< 25 mm) on transvaginal ultrasonography 
(assessed at 20-22w and repeated at 26-28w). The third study group (SYM, n = 89) comprised 
women presenting with uterine contractions, cervix < 3cm dilated, and intact fetal membranes 
(24-36w). All participants were recruited via the antenatal clinics and Triage Delivery Suites of 
the Jessop Wing Hospital, Sheffield, UK. The asymptomatic women were sampled at 20-22w 
and 26-28w as part of their normal routine visits for antenatal care. Also, these are early critical 
gestational time points in which an accurate diagnostic marker for PTB can promptly inform 
therapeutic decisions and interventions before the onset of PTL and adverse pregnancy 
outcome. On the other hand, the symptomatic women presented at random and were studied 
between 24-36w in other to exclude pregnant women with miscarriages (i.e. loss of pregnancy 
before the first 23w). These women were recruited via the Triage Delivery Suites as they 
presented with symptoms suggestive of PTL. 
2.1.3. Sample collection 
At presentation, a pair of high vaginal samples was obtained with dry polystyrene Dacron swabs 
(Deltalab Eurotubo 300263, Fisher Scientific, UK) from each woman by a single clinical research 
staff following written informed consent. This was to ensure consistency in the sample 
collection protocol. With a subset of the AHR women assessed at 2 gestational time points i.e. 
at 20-22w and 26-28w, the total number of CVF samples obtained rose to 587 (i.e. ALR20-22w 
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= 183; AHR20-22w = 186; AHR26-28w = 129; SYM = 89).The collected samples were 
immediately processed or stored in a refrigerator at -20°C, for up to 3 days, pending analysis. 
The clinical course and delivery outcomes of participants were subsequently ascertained. 
Women with multiple gestation, bacteriologically proven infection, history of abnormal cervical 
cytology within 3 years, ruptured fetal membranes, and prior vaginal examination at 
presentation were excluded from the study. Parity was not considered because it is not a 
known risk factor of PTB independently.437, 438 
Also at presentation, commonly employed clinical diagnostic methods of PTL and PTB including 
CVF FFN level, vaginal pH and ultrasound cervical length (CL) were examined. Quantitative 
CVF FFN levels were analysed using the 10Q Rapid FFN analyser (Hologic, MA), according to 
manufacturer’s instruction, and cervical length (CL) by transvaginal ultrasonography. Vaginal pH 
was determined by obtaining a sample of vaginal fluid from the lateral vaginal wall with the aid of 
a dry swab and smeared on a high quality narrow range pH paper (pH-Fix 3.6-6.1, #92130, 
Macherey-Nagel, Düren, Germany). All measurements were performed by the same clinical 
research staff at the Jessop Wing Maternity Hospital. 
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2.1.4. Subject details and Pregnancy outcomes 
 
Table 2.1 summarises the clinical details of the study cohorts. At present (30/10/2015) only 408 
out of the 458 (89%) pregnant women recruited in this study have their delivery outcomes 
ascertained. About 4% (n = 5) of the ALR women delivered preterm and this was the lowest 
prevalence of PTB observed compared to women in the other groups:  AHR 20-22w (33%, n = 
35), and AHR 26-28w (28.6%, n = 26). Of women presenting with symptoms suggestive of PTL 
(SYM), 81.7% (n = 67) went on to deliver at term, while 18.3% (n =15) delivered preterm, with 
mean gestation between presentation and delivery of 15.7±3.5 and 60.3±3.2 days for preterm- 
and term-delivered SYM women respectively. All the preterm-delivered women in the SYM 
group delivered approximately within 2 weeks (15.7±3.5 days) of presentation at the Triage 
Delivery Suites of the Jessop Wing Hospital, Sheffield, UK. 
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Table 2.1: Clinical characteristics of the study participants 
Data are presented as mean ± SE (range, n); w, gestational weeks; BMI, body mass index; PTB, preterm birth; NA, 
not applicable. N, total number of term- or preterm-delivered women in each cohort; n, actual number of women 
for each clinical parameter obtained. 
* Differences between preterm and term-delivered women within the group, P < 0.05 (shaded yellow). 
a Reduced study population (n) due to absence of participants’ consent/data. 
 
 
 
 
 
 
 
 
Characteristics 
Asymptomatic 
Low risk women, 
20-22w 
Asymptomatic 
High risk women, 
20-22w 
Asymptomatic 
20-22w 
(Combined) 
Asymptomatic 
High risk women, 
26-28w 
Symptomatic 
women 
24-36w 
Preterm 
(N=5) 
Term 
(N=124) 
Preterm 
(N=35) 
Term 
(N=71) 
Preterm 
(N=40) 
Term 
(N=195) 
Preterm 
(N=26) 
Term 
(N=65) 
Preterm 
(N=15) 
Term 
(N=67) 
Age 
(years) 
29.8±2.6 
(22-36) 
5 
29.4±0.4 
(19-39) 
123 
31.9±0.9 
(19-45) 
34 
30.9±0.6 
(19-39) 
70 
31.6±0.8 
(19-45) 
39 
29.9±0.4 
(19-39) 
193 
31.1±0.9 
(24-40) 
26 
30.9±0.7 
(19-40) 
65 
31.1±2.0* 
(22-48) 
15 
26.6±0.7 
(16-44) 
67 
BMI 
(kg.m-2) 
23.4±1.2 
(21.1-
26.3) 
5 
25.5±0.4 
(14.7-
42.2) 
123 
28.0±1.1 
(18.2-46.5) 
34 
27.5±0.7 
(18.2-
49.7) 
70 
27.5±1.0 
(18.2-
46.5) 
38 
26.2±0.4 
(14.7-
49.7) 
193 
27.2±1.0 
(18.2-34.5) 
26 
28.6±0.8 
(18.2-
49.7) 
65 
28.9+1.9a 
(20.1-
42.5) 
11 
25.1±0.6a 
(17.4-41.6) 
56 
Previous history 
of PTB (n) 
NA NA 
 
23 
 
 
48 
 
23 48 21 47 5 10 
Cigarette 
Smokers 
n(%) 
2(40) 11(9) 8(23) 13(18) 10(25) 24(12) 5(19) 13(20) 1(7) 10(15) 
Cervical length 
(mm) 
36.2±1.6 
(32-40) 
1 
40.7±0.4 
(29-66) 
124 
29.4±1.9 
(13-53) 
30 
36.7±1.0* 
(18-52) 
65 
30.4±1.7 
(13-53) 
35 
39.3±0.5* 
(18-66) 
189 
24.8±2.3 
(7-44) 
26 
33.9±0.8* 
(15-50) 
37 
21.1±4.8a 
(7-45) 
8 
30.8±1.6*a 
(11-54) 
37 
Fetal fibronectin 
conc. 
(ng/ml) 
6.2±1.2 
(4-10) 
5 
16.0±2.6 
(1-187) 
121 
 
85.7±22.1* 
(2-453) 
29 
 
32.3±8.6 
(1-497) 
63 
74±19.5* 
(2-453) 
34 
21.6±3.4 
(1-497) 
184 
91.8±26.1* 
(1-442) 
24 
25.8±6.8 
(1-248) 
59 
188±85*a 
(5-501) 
6 
15.2±3 a 
(1-74) 
37 
Gestational age 
at presentation 
(days) 
143±2.1 
(139-151) 
1 
141±0.5 
(132-159) 
123 
146±1.5 
(115-165) 
35 
147±1.2 
(103-175) 
68 
146±1.4 
(115-165) 
40 
143±0.6 
(103-175) 
191 
190±1.1 
(182-205) 
26 
188±0.7 
(173-203) 
65 
 
206±5.4 
(177-237) 
15 
 
213±3.1 
(139-254) 
67 
Gestational age 
at delivery 
(days) 
225±13.1 
(189-254) 
5 
281±0.8 
(258-299) 
124 
225±5.2 
(146-258) 
34 
274±1.0 
(259-292) 
71 
225±4.8 
(146-258) 
39 
279±0.7 
(258-299) 
195 
233±4.1 
(187-258) 
25 
274±1.1 
(259-295) 
65 
221±5.7 
(187-257) 
15 
275±1.1 
(260-295) 
61 
Vagina pH 
4.2±0.2 
(3.6-4.8) 
5 
4.0±0.03 
(3.6-5) 
124 
4.2±0.1 
(3.6-5.3) 
30 
4.2±0.1 
(3.6-5.6) 
63 
4.2±0.1 
(3.6-5.3) 
35 
4.1±0.03 
(3.6-5.6) 
187 
4.3±0.1 
(3.6-6.1) 
26 
4.2±0.1 
(3.6-6) 
62 
4.4±0.3 a 
(3.6-6.1) 
7 
4.2±0.1 a 
(3.6-6.1) 
36 
Prevalence of 
PTB,% 
3.9 33.0 17.0 28.6 18.3 
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2.2. Introduction to 1H-Magnetic Resonance Spectroscopy 
 
With the observation of strong resonance signals from lactate, acetate, succinate, amino acids 
and glucose in CVF analysed with proton magnetic resonance (1H-MR) spectroscopy,65, 295, 439  it 
is plausible that the metabolic profile of these secretions, which is a reflection of the metabolic 
activities of the host interacting with the vaginal microbiota, can be elucidated both in pregnant 
and non-pregnant reproductive-age women using this technique. 1H-MR can also provide useful 
information regarding the functional capacity or chemical consequence of the prevailing vaginal 
microbial community composition at each instance. 1H-MR metabolite profile provides 
qualitative and quantitative data on the many different small molecules present in a sample at  
µM to mM concentration.440 Additionally, MR-based metabolomics gives direct data on the 
identity of the metabolites that are implicated in the disease under investigation, because 
information on the altered metabolite signatures is directly obtained through statistical analysis 
of the MR metabolite profiles.441, 442 These unique features of 1H-MR were recently explored to 
investigate the association between vaginal fluid microbial community composition and 
metabolic profiles in healthy and BV-infected non-pregnant reproductive-age women.189, 439  
Both human and bacterial metabolites involved in complex metabolic pathways as shown in Fig. 
2.1, were identified. As a result, determination of the changes and differences in CVF metabolite 
profiles which are direct reflections of biochemical events in the vaginal microenvironment 
could be of immense benefit in the diagnosis and prognostication of vaginal dysbiosis during 
gestation and PTB.  
We therefore sought to characterise the metabolite profile of CVF obtained from cohorts of 
pregnant women who eventually deliver prematurely compared to those who do not, classifying 
the participants according to their risk of PTB, and by presentation with symptoms of PTL. We 
hypothesised that the 1H-MR spectrum of CVF might predict pregnant women who ultimately 
deliver prematurely, as well as women with symptoms of PTL who deliver shortly after 
assessment. 
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Figure 2.1. Metabolic pathways involving metabolites identified in the vaginal microenvironment. (A) 
Glycolysis/Gluconeogenesis, (B) Tricarboxylic acid (TCA) cycle, (C) Carbon metabolism, (D) Biosynthesis of amino 
acids. 
Adapted from: KEGG pathway mapping tool (KEGG Mapper v2.5, Kanehisa Laboratories, JP). 
58 
 
2.3. Methods 
 
2.3.1. 1H-MR Sample preparation 
 
The end of the swab soaked with the vaginal fluid sample was cut off and placed in a 1.5 ml 
microfuge tube. Six hundred microlitres of Phosphate Buffered Saline at pH 7.4 was added to 
the tube as an extraction solvent. The vaginal fluid was washed off the swab by vortexing for 5 
min, after which the swab was removed and safely discarded. The solution was then centrifuged 
at 13,000 rpm for 3 min to separate swab and bacterial particles from the vaginal fluid solution. 
The supernatant was carefully aspirated into a separate clean 1.5 ml microfuge tube and stored 
at -80°C ready for analysis. Prior to 1H-MR analysis, a total of 400 µl of each sample comprising 
of 380 µl of vaginal fluid in solution and 20 µl of deuterium oxide (D2O) was immediately 
transferred into a 5 mm MR sample tube (Norell, Marion, NC) (Fig. 2.2). D2O was added to the 
samples to maintain the homogeneity of the static magnetic field and provide field-frequency 
lock via “shimming”. An unused (sterile) polystyrene Dacron swab was also prepared as above 
and analysed using the same protocol as a background signal control. This was repeated at 
regular intervals or change of swab batch to control for any swab manufacturing variations. 
2.3.2. 1H-MR Spectroscopy 
 
Pulse sequence is a series of timed rf pulse magnetic field gradients used to exploit nuclear spins 
in order to obtain the required data. For example, in our experiments the Watergate water 
(excitation sculpting) suppression pulse sequence427 was used to suppress net magnetisation of 
water in the samples, thereby eliminating the usually large water signal. This ensures that the 
metabolite peaks of interest are left unperturbed and easily analysed.420  
A 9.4T (400 MHz) Bruker Avance III MR spectrometer (Bruker BioSpin GmbH, Karlsruhe, 
Germany), with 5 mm broadband observe probe (Fig. 2.2), was used for the experiments. The 5 
mm broadband observe probe is designed for 5 mm MR sample tubes and located in the 
magnet. It contains rf coil that can be tuned over a wide frequency range (15N-31P, 1H) and as 
such used to detect most MR-active nuclei.420 Probes have the greatest impact on sensitivity in 
any given field strength.420  
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1H-MR spectra were acquired using the Watergate water suppression pulse sequence (number 
of scans, NS = 256, relaxation time, D1 = 5s, acquisition time, AQ = 1s, sweep width, SW = 
20.6 ppm, time domain, TD = 16446), for each of the CVF samples. All 1H-MR experiments 
were performed at approximately 21°C (294 K). Data was acquired and processed using the 
Bruker Topspin 2.1.6 software to produce a phase and baseline corrected spectrum. 
2.3.2.1. Assigning the 1H-MR spectral peaks 
 
The following 2-D MR spectra were acquired in order to confirm the structure of the 
metabolites and assign them to the 1H-MR spectral peaks presented in Fig. 2.3:65, 295 1H-13C 
presat-HSQC (Heteronuclear Single Quantum Correlation spectroscopy) – NS = 1024, D1 = 
1s, AQ = 0.078 x 0.006s, SW = 10.0 x 150 ppm, TD = 624 x 180; 1H-13C presat-HMBC 
(Heteronuclear Multiple Bond Correlation spectroscopy) - NS = 1024, D1 = 1s, AQ = 0.128 x 
0.005s, SW = 10.0 x 200 ppm, TD = 1024 x 200; 1H-1H watergate-DQFCOSY (Double 
Quantum Filtered Correlation spectroscopy) - NS = 256, D1 = 0.5s, AQ = 0.832 x 0.022s, SW 
= 9.0 x 9.0 ppm, TD = 6000 x 160; and  1H-1H presat-cleanTOCSY (Total Correlation 
spectroscopy) - NS = 16, D1 = 1.5s, AQ = 0.284 x 0.071s, SW = 9.0 x 9.0 ppm, TD = 2048 x 
512. A representative 2-D spectrum is shown in Fig. 2.4. All spectral peaks were referenced to 
the 1H lactate signal at δ = 1.30 ppm. This proved more consistent and reliable than 3-
(trimethylsilyl)-propionic-2,2,3,3-d4 acid sodium salt (TSP), which was discontinued due to 
variations in its peak intensities with each sample analysed. The metabolite peak intensities 
were then assigned by matching their chemical shifts and multiplicity with previous 
publications,431, 439, 443 the SDBS Spectral Database for Organic Compounds (AIST, JP) and 
Chenomx NMR Suite software (Chenomx Inc. CA, version 7.7). 
The 1H-13C HSQC correlates chemical shifts of proton-carbon nuclei connected by a single 
bond in molecules providing carbon and proton chemical shifts to aid molecular assignment. 
The 1H-13C HMBC is similar to the HSQC but detects correlations over 2 or 3 bonds indicating 
the location carbon-carbon or carbon-heteroatom bonds. Thereby defining the skeletal 
framework of the molecule.427 The 1H-1H watergate-DQFCOSY detects the single bond 
interactions (J-coupling) between protons, whilst the 1H-1H TOCSY identifies relationships 
between those protons that share the same coupled network over multiple bonds, but not the 
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same J-coupling e.g. amino acids and sugars.427 These 2-D MR techniques were employed for 
structural and conformational analysis of the metabolites in our samples. With these unique 
features MR has the ability to characterise the interactions between specific atomic nuclei 
within and between molecules.427 This is a significant advantage over other metabolomics 
techniques e.g. mass spectroscopy (MS), hence our choice of MR in this study.  Plausibly the 
greatest constraint of MRS is its sensitivity. Compared to MS, larger amounts of samples 
(nanograms) are required for MR analysis.420 However, the required amount of samples have 
been significantly reduced with development of stronger magnets e.g. 21 T (900 MHz), and 
advances in flow cell and probe design.420 
Identified metabolite signals in the 1H-MR spectra were integrated for peak area (which is 
proportional to metabolite concentration).65, 295 To correct for differences in CVF 
concentration (e.g. variation in the swab sampling), validate and optimise the sample preparation 
protocol, each metabolite integral was divided by the total spectrum integral (δ = 0.0-10.0 ppm, 
excluding the residual water signal between δ = 4.7-5.0 ppm) to provide a normalised integral 
(N.I.).65, 295 This procedure together with the background control signal obtained from sterile 
swabs further enhanced the optimization of our sample preparation protocol.  
2.3.3. Statistical analysis 
 
All Statistical and Receiver Operating Characteristics (ROC) curve analyses were performed 
using MATLAB (Mathworks, Natick, MA). The Wilcoxon’s rank-sum test was performed to 
compare differences in metabolite N.I. between and within the groups, while the relationships 
between clinical data and 1H-MR metabolite N.I. were determined by Pearson’s correlation 
coefficients. P values < 0.05 were considered statistically significant. The predictive capacity of 
the CVF metabolites for PTB was determined by ROC curves for the following comparisons: 
• Preterm (< 37 weeks) versus term births in all groups 
• < 32 versus > 32 weeks in symptomatic women 
• < 2 versus > 2 weeks from presentation to delivery in symptomatic women.  
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The ROC curve is derived by plotting sensitivity of a test against 1minus its specificity at each 
possible cut-off point . It is a graphical approach of evaluating the capacity of a diagnostic test to 
discriminate between the presence or absence of disease. The area under the ROC curve 
(AUC), provides an estimate of the overall performance of a diagnostic test, with an AUC of 
1.0 indicating a perfect test, > 0.9 (high accuracy), 0.7-0.9 (moderate accuracy), 0.5-0.7 (low 
accuracy), and 0.5 (chance result). The predictive accuracy of metabolite N.I. was also 
determined by the sensitivity, specificity, negative and positive predictive values, as well as 
likelihood ratio.444-447 
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Figure 2.2. A 9.4T (400 MHz) Bruker Avance III MR spectrometer and 5mm BBO broadband 
Observe probe (left), and MR 5 mm glass tube containing cervicovaginal fluid sample (right). 
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2.4. Results 
 
2.4.1. Integration 1H-MR metabolites 
 
Eight metabolite signals of interest were identified and analysed in the 1H-MR spectra (Fig. 2.3 
and 2.4). These were lactate, alanine, acetate, glutamine/glutamate, succinate, formate, glucose 
and branched chain amino acids (BCAA) (i.e. leucine, isoleucine and valine). Apart from 
identification of strong their signals in 1H-MR spectra, these metabolites were analysed as a 
result of their proven association with the vaginal microbiota and impact on vaginal pH from 
previous reports.38, 84 To avoid influence from other metabolite peaks in the glucose signal 
region 3.2-3.9 ppm, the glucose signal at δ = 5.2 ppm was integrated and used in subsequent 
analysis.  There were no differences in the 1H-MR total spectrum absolute integrals, indicating 
that total CVF metabolite concentration did not vary significantly between and within the study 
groups (Fig. 2.5). Comparison of 1H-MR metabolite N.I. from the different cohorts in relation to 
delivery outcomes is shown in Fig. 2.6.  
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Figure 2.3. 1-D 1H-MR spectrum of identified metabolites in cervicovaginal fluid (CVF) and sterile 
swab at 400 MHz and 294K. Due to the presence of other additional metabolite peaks at the δ = 3.2 ppm and 
3.9 ppm region, the glucose signal at δ = 5.2 ppm was integrated and used in subsequent analysis.  
BCAA, Branched chain amino acids (leucine, isoleucine, and valine) (δ = 0.9-1.2 ppm), ppm, parts per million. 
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Figure 2.4. 2-D 1H-13C HSQC MR spectrum of cervicovaginal fluid showing confirmed metabolites at 
400 MHz and 294K.  
BCAA, Branched chain amino acids (leucine, isoleucine, and valine); HSQC, heteronuclear single quantum correlation 
spectroscopy. 
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Figure 2.5. 1H-MR total spectrum absolute integrals of cervicovaginal fluid metabolites. Comparison of 
1H-MR total spectrum absolute integrals of cervicovaginal fluid in the various cohorts in relation to delivery 
outcomes indicated no significant difference. Box plots show the median line within the box, with the bottom and 
top edges of the box representing the 25% and 75% quartiles respectively. Whiskers extend to the furthermost 
value within 1.5 times the interquartile range from the 25% and 75% quartiles. Outlier values are also indicated 
(red pluses). 
ALR, asymptomatic low risk women; AHR, asymptomatic high risk women; ASYM, ALR and AHR 20-22w combined; 
SYM, symptomatic women; w, gestational weeks. 
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2.4.2. Differences in CVF 1H-MR metabolites in relation to delivery outcomes 
 
It is plausible that differences in CVF metabolites produced by vaginal microbiota in relation to 
the host could predispose the women to infection, inflammation and adverse pregnancy 
outcomes.38 84, 85 Therefore, comparing the medians of the 1H-MR metabolites identified, we 
observed that of all the metabolites analysed, only acetate N.I. and acetate/lactate ratio showed 
significant differences and these were observed in the SYM cohort alone (Fig. 2.6). The acetate 
N.I. (P = 0.002) and acetate/lactate ratio (P = 0.002) in the SYM women that delivered preterm 
were significantly higher than those of their term-delivered counterparts. There was over a 2-
fold (103%) increase in CVF acetate N.I. of women presenting with symptoms suggestive of PTL 
who ultimately delivered preterm, whilst the difference in acetate/lactate ratio was only 46%. 
Though not statistically significant, differences in acetate N.I. between preterm- and term-
delivered women were observed in the AHR26-28w (P = 0.17) group. 
In addition, the term-delivered women (n = 124), in the ALR group demonstrated non-
significant trends to higher lactate (P = 1.0), glutamine/glutamate (P = 0.36) and BCAA N.I.s (P = 
0.054), compared to their preterm counterparts (n = 5). 
Also, differences in all other metabolite N.I.s between preterm- and term-delivered women in 
the ALR, AHR20-22w and 26-28w, and SYM were not statistically significant (Fig. 2.6).  
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Figure 2.6. Comparison of mean 1H-MR metabolite normalised integrals from different cohorts of 
pregnant women in relation to delivery outcomes.  
Box plots show the median line within the box, with the bottom and top edges of the box representing the 25% 
and 75% quartiles respectively.  
ALR, asymptomatic low risk women; ACE/LAC, acetate/lactate ratio; AHR, asymptomatic high risk women; ASYM, 
ALR and AHR 20-22w combined; BCAA, Branched chain amino acids; SUC/LAC, succinate/lactate ratio; SYM, 
symptomatic women; w, gestation weeks.  
* P value < 0.05 considered statistically significant. 
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2.4.3. Relationship between vaginal pH and CVF 1H-MR metabolites 
 
The interactions between the various metabolites and vaginal pH could be indicative of the 
prevalent vaginal microbiota signature and the host-microbial interplay in the vaginal 
microecology.32, 448, 449 Our data showed vaginal pH correlated with lactate and acetate N.I. in 
the ALR20-22w, AHR20-22w, AHR26-28w, and SYM women, while it correlated with glucose, 
glutamine/glutamate, succinate N.I.s, and succinate/lactate ratio in the ASYM 20-22w and 
AHR26-28w women only  (Table 2.2 and Fig. 2.7A-F). Higher CVF lactate N.I. were associated 
with low vaginal pH, whilst higher acetate N.I. was associated with high vaginal pH in all the 
study participants irrespective of gestational age at sampling or the presence of symptoms of 
PTL (Fig. 2.8 and 2.9). Similar to the lactate N.I., higher glutamine/glutamate N.I. was associated 
with decreased vaginal pH in the ASYM 20-22w and AHR 26-28w women, whilst glucose N.I., 
succinate N.I. and succinate/lactate ratio were associated with increased pH in all the groups 
except the SYM women. 
Furthermore, across the groups, there were low (r = 0.3) to strong (r = 0.7-1.0) correlations 
between lactate vs. acetate N.I.s, lactate vs. glucose N.I.s, lactate vs. succinate N.I.s, lactate vs. 
glutamate/glutamine N.I.s, acetate vs. succinate N.I.s, alanine vs. glutamine/glutamate, alanine vs. 
BCAA N.I.s etc. (Fig. 2.7A-F). 
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Table 2.2: Correlation between vaginal pH and metabolites normalised integrals   
(r, P) 
 Asymptomatic 
Low risk 
women, 
20-22w 
Asymptomatic 
High risk 
women, 
20-22w 
Asymptomatic 
20-22w 
(Combined) 
Asymptomatic 
High risk 
women, 
26-28w 
Symptomatic 
women, 
24-36w 
Lactate -0.6, < 0.00001 -0.6, < 0.00001  -0.7, < 0.00001 -0.6, < 0.00001 
Acetate 0.4, < 0.00001 0.5, < 0.00001  0.5, < 0.00001 0.4, P < 0.01 
Glucose   0.2, < 0.0001 0.4, < 0.00001  
Glx   -0.3, 0.04 -0.5, < 0.00001  
Succinate   0.4, < 0.00001 0.2, 0.04  
Suc/Lac   0.4, < 0.00001 0.3, < 0.00001  
GLX, glutamine/glutamate; Suc/Lac, succinate/lactate ratio; r, Pearson’s correlation coefficient; P, significance level. 
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2.4.4. Relationship between CVF 1H-MR metabolites and gestational age at delivery 
 
In order to test for any relationships between 1H-MR metabolites and GAAD, we plotted the 
identified metabolites against the GAAD in days (Fig. 2.7A-F). Our results showed in the 
combined asymptomatic low and high risk women studied at 20-22w (ASYM 20-22w), lactate (r 
= 0.2, P = 0.02) and glutamine/glutamate N.I.s (r = 0.2, P = 0.04) correlate modestly with 
GAAD. However, when these women were subdivided based on their risk of PTB, only the low 
risk (ALR 20-22w) showed a correlation between glutamine/glutamate N.I. and GAAD (r = 0.2, 
P = 0.01). Higher lactate and glutamine/glutamate N.I.s were associated with increased GAAD 
especially in the ALR women. 
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Figure 2.7A. Association of 1H-MR cervicovaginal fluid metabolites and maternal clinical parameters 
in asymptomatic pregnant women (20-22 weeks gestation), with low risk of preterm birth.  
Pearson’s correlation coefficients (r, colour) range from -1 (dark blue) to +1 (dark red); and P, values (significance: 
bold black  < 0.05, bold purple < 0.01). GLX, glutamine/glutamate; BCAA, branched chain amino acid; ACE/LAC, 
acetate/lactate ratio; SUC/LAC, succinate/lactate ratio; Ace Conc, acetate concentration, CL, cervical length; BMI, 
Body mass Index; FFN, fetal fibronectin; G.A.A.D, gestational age at delivery; G.A.A.P, gestational age at presentation, 
Lobour, number of days between presentation and delivery; w, gestation weeks. 
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Figure 2.7B. Association of 1H-MR cervicovaginal fluid metabolites and maternal clinical parameters 
in asymptomatic pregnant women (20-22 weeks gestation), with high risk of preterm birth.  
Pearson’s correlation coefficients (r, colour) range from -1 (dark blue) to +1 (dark red); and P, values (significance: 
bold black  < 0.05, bold purple < 0.01). GLX, glutamine/glutamate; BCAA, branched chain amino acid; ACE/LAC, 
acetate/lactate ratio; SUC/LAC, succinate/lactate ratio; Ace Conc, acetate concentration, CL, cervical length; BMI, 
Body mass Index; FFN, fetal fibronectin; G.A.A.D, gestational age at delivery; G.A.A.P, gestational age at presentation, 
Lobour, number of days between presentation and delivery; w, gestation weeks. 
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Figure 2.7C. Association of 1H-MR cervicovaginal fluid metabolites and maternal clinical parameters 
in  asymptomatic pregnant women (20-22 weeks gestation), irrespective of risk of preterm birth. 
Pearson’s correlation coefficients (r, colour) range from -1 (dark blue) to +1 (dark red); and P, values (significance: 
bold black  < 0.05, bold purple < 0.01). GLX, glutamine/glutamate; BCAA, branched chain amino acid; ACE/LAC, 
acetate/lactate ratio; SUC/LAC, succinate/lactate ratio; Ace Conc, acetate concentration, CL, cervical length; BMI, 
Body mass Index; FFN, fetal fibronectin; G.A.A.D, gestational age at delivery; G.A.A.P, gestational age at presentation, 
Lobour, number of days between presentation and delivery; w, gestation weeks. 
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Figure 2.7D. Association of 1H-MR cervicovaginal fluid metabolites and maternal clinical parameters 
in  asymptomatic pregnant women (26-28 weeks gestation), with high risk of preterm birth. 
Pearson’s correlation coefficients (r, colour) range from -1 (dark blue) to +1 (dark red); and P, values (significance: 
bold black  < 0.05, bold purple < 0.01). GLX, glutamine/glutamate; BCAA, branched chain amino acid; ACE/LAC, 
acetate/lactate ratio; SUC/LAC, succinate/lactate ratio; Ace Conc, acetate concentration, CL, cervical length; BMI, 
Body mass Index; FFN, fetal fibronectin; G.A.A.D, gestational age at delivery; G.A.A.P, gestational age at presentation, 
Lobour, number of days between presentation and delivery; w, gestation weeks. 
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Figure 2.7E. Association of 1H-MR cervicovaginal fluid metabolites and maternal clinical parameters 
in symptomatic pregnant women (24-36 weeks gestation).  
Pearson’s correlation coefficients (r, colour) range from -1 (dark blue) to +1 (dark red); and P, values (significance: 
bold black  < 0.05, bold purple < 0.01). GLX, glutamine/glutamate; BCAA, branched chain amino acid; ACE/LAC, 
acetate/lactate ratio; SUC/LAC, succinate/lactate ratio; Ace Conc, acetate concentration, CL, cervical length; BMI, 
Body mass Index; FFN, fetal fibronectin; G.A.A.D, gestational age at delivery; G.A.A.P, gestational age at presentation, 
Lobour, number of days between presentation and delivery; w, gestation weeks. 
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Figure 2.7F. Association of 1H-MR cervicovaginal fluid metabolites and maternal clinical parameters 
in pregnant women (20-36 weeks gestation), irrespective of risk and symptoms of preterm birth. 
Pearson’s correlation coefficients (r, colour) range from -1 (dark blue) to +1 (dark red); and P, values (significance: 
bold black  < 0.05, bold purple < 0.01). GLX, glutamine/glutamate; BCAA, branched chain amino acid; ACE/LAC, 
acetate/lactate ratio; SUC/LAC, succinate/lactate ratio; Ace Conc, acetate concentration, CL, cervical length; BMI, 
Body mass Index; FFN, fetal fibronectin; G.A.A.D, gestational age at delivery; G.A.A.P, gestational age at presentation, 
Lobour, number of days between presentation and delivery; w, gestation weeks. 
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Figure 2.8. Association between vaginal pH and CVF lactate normalised integrals in pregnant 
women (A) Asymptomatic low risk women 20-22w, (B) Asymptomatic high risk women 20-22w, (C) 
Asymptomatic high risk women 26-28w, (D) Symptomatic women 24-36w. w, gestation weeks. 
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r = - 0.6, P < 0.00001 
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Figure 2.9. Association between vaginal pH and CVF acetate normalised integral in pregnant 
women (A) Asymptomatic low risk women 20-22w, (B) Asymptomatic high risk women 20-22w, (C) 
Asymptomatic high risk women 26-28w, (D) Symptomatic women 24-36w. w, gestation weeks. 
 
 
 
 
 
ALR 20-22 w 
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r = 0.4, P < 0.00001 
r = 0.5, P < 0.00001 
AHR 20-22 w 
AHR 26-28 w 
r = 0.5, P < 0.00001 
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2.4.5. Predictive capacity of CVF 1H-MR metabolites for preterm birth 
 
Analysis of the area under the ROC curves (calculated by plotting the sensitivity vs. 1 – 
specificity), for the 1H-MR metabolites showed the acetate N.I. and acetate/lactate ratio were 
highly predictive of women presenting with symptoms of PTL who delivered prematurely (< 
37w and < 32w), and within two weeks of the index assessment (Tables 2.2-2.3 and 2.11, Figs. 
2.10-2.11). Also, in the same women, glutamine/glutamate N.I. was predictive of premature 
delivery (< 32w), and within two weeks of the index assessment (Table 2.4 and Fig. 2.12). In 
addition, acetate and BCAA N.I. showed useful predictive capacities for PTB in the AHR 20-
22w and ALR women respectively (Tables 2.5-2.8 and Fig. 2.13-2.14). The other metabolites did 
not show significant predictive capacity for PTB in any of the study cohorts (Tables 2.7-2.11). 
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Table 2.3: Predictive performance of CVF acetate normalised integrals for preterm 
birth in symptomatic pregnant women 
Variables 
< 37  
weeks gestation 
< 32  
weeks gestation 
≤ 2 weeks of index 
assessment 
Area under the 
ROC curve (AUC) 
0.75 0.73 0.77 
Standard Error, SE 0.08 0.11 0.10 
95% Confidence 
Interval 
0.60-0.91 0.53-0.94 0.58-0.96 
Significance level, P 0.0005 0.01 0.003 
Youden index, J 0.85 0.59 0.49 
Sensitivity, % 60 88 100 
Specificity, % 85 59 49 
Positive predictive 
value (PPV), % 
47 21 21 
Negative predictive 
value (NPV), % 
91 97 100 
Positive likelihood 
ratio, LR+ 
4.0 2.1 2 
Negative likelihood 
ratio, LR- 
0.2 0.5 0.5 
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Table 2.4: Predictive performance of CVF acetate/lactate ratio for preterm birth in 
symptomatic pregnant women 
Variables 
< 37  
weeks gestation 
< 32  
weeks gestation 
≤ 2 weeks of index 
assessment 
Area under the 
ROC curve (AUC) 
0.76 0.79 0.78 
Standard Error, SE 0.08 0.10 0.09 
95% Confidence 
Interval 
0.61-0.91 0.60-0.98 0.60-0.97 
Significance level, P 0.0004 0.002 0.002 
Youden index, J 0.61 0.58 0.64 
Sensitivity, % 87 100 89 
Specificity, % 61 58 64 
Positive predictive 
value (PPV), % 
33 23 25 
Negative 
predictive value 
(NPV), % 
95 100 98 
Positive likelihood 
ratio, LR+ 
2.2 2.4 2.4 
Negative likelihood 
ratio, LR- 
0.5 0.4 0.4 
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Table 2.5: Predictive performance of CVF glutamine/glutamate normalised 
integrals for preterm birth in symptomatic pregnant women 
Variables 
< 32  
weeks gestation 
≤ 2 weeks of index 
assessment 
Area under the 
ROC curve (AUC) 
0.71 0.68 
Standard Error, SE 0.11 0.10 
95% Confidence 
Interval 
0.50-0.92 0.47-0.88 
Significance level, P 0.03 0.045 
Youden index, J 0.81 0.73 
Sensitivity, % 63 67 
Specificity, % 81 73 
Positive predictive 
value (PPV), % 
29 25 
Negative predictive 
value (NPV), % 
95 94 
Positive likelihood 
ratio, LR+ 
3.3 2.4 
Negative likelihood 
ratio, LR- 
0.3 0.4 
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Table 2.6: Predictive performance of CVF acetate normalised integrals for preterm 
birth in asymptomatic high risk (20-22w) pregnant women 
Variables 
< 37  
weeks gestation 
Area under the 
ROC curve (AUC) 
0.61 
Standard Error, SE 0.06 
95% Confidence 
Interval 
0.50-0.73 
Significance level, P 0.03 
Youden index, J 0.78 
Sensitivity, % 49 
Specificity, % 78 
Positive predictive 
value (PPV), % 
52 
Negative predictive 
value (NPV), % 
75 
Positive likelihood 
ratio, LR+ 
2.2 
Negative likelihood 
ratio, LR- 
0.5 
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Table 2.7: Predictive performance of CVF branched chain amino acids normalised 
integrals for preterm birth in asymptomatic low risk (20-22w) pregnant women 
Variables 
< 37  
weeks gestation 
Area under the 
ROC curve (AUC) 
0.75 
Standard Error, SE 0.13 
95% Confidence 
Interval 
0.50-1.00 
Significance level, P 0.03 
Youden index, J 0.65 
Sensitivity, % 100 
Specificity, % 65 
Positive predictive 
value (PPV), % 
10 
Negative predictive 
value (NPV), % 
100 
Positive likelihood 
ratio, LR+ 
2.9 
Negative likelihood 
ratio, LR- 
0.4 
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Table 2.8: Predictive performance of CVF metabolites normalised integrals for 
preterm birth (< 37w), in asymptomatic low risk pregnant women (20-22w) 
Metabolite AUC SE 
95% 
CI 
YI 
Sen 
(%) 
Spec 
(%) 
PPV 
(%) 
NPV 
(%) 
LR+ LR- 
P 
value 
Lactate 0.49 0.13 
0.24-
0.75 
0.80 40 80 7 97 2.0 0.5 0.5 
Acetate 0.56 0.14 
0.30-
0.83 
0.47 80 47 6 98 1.5 0.7 0.3 
Succinate 0.64 0.14 
0.37-
0.91 
0.61 80 61 7 99 2.0 0.5 0.1 
Formate 0.57 0.14 
0.30-
0.84 
0.51 80 51 6 98 1.6 0.6 0.3 
Glucose 0.62 0.14 
0.35-
0.89 
0.77 60 77 10 98 2.6 0.38 0.2 
Alanine 0.50 0.13 
0.25-
0.78 
0.68 60 68 7 98 1.8 0.5 0.5 
Glx 0.62 0.14 
0.36-
0.89 
0.63 80 63 8 99 2.2 0.5 0.2 
BCAA 0.75 0.13 
0.50-
1.0 
0.65 100 65 10 100 2.9 0.4 0.03* 
Suc/Lac 0.63 0.14 
0.36-
0.90 
0.63 80 63 8 99 2.2 0.5 0.2 
Ace/Lac 0.44 0.13 
0.19-
0.69 
0.43 80 43 5 98 1.4 0.7 0.7 
Ace/Lac, acetate-lactate ratio; BCAA, branched chain amino acids; Glx, glutamine/glutamate; Suc/Lac, succinate-lactate 
ratio; AUC, area under the ROC curve; SE, standard error; CI, 95% confidence interval; YI, Youden index (J); Sen, 
sensitivity; Spec, specificity; PPV, positive predictive value; NPV, negative predictive value; LR+, positive likelihood 
ratio; LR-, negative likelihood ratio; P, significance level.  
*Statistically significant 
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Table 2.9: Predictive performance of CVF metabolites normalised integrals for 
preterm birth (< 37w), in asymptomatic high risk pregnant women (20-22w) 
Metabolite AUC SE 
95% 
CI 
YI 
Sen 
(%) 
Spec 
(%) 
PPV 
(%) 
NPV 
(%) 
LR+ LR- 
P 
value 
Lactate 0.52 0.06 
0.40-
0.64 
0.85 29 85 48 71 1.8 0.5 0.4 
Acetate 0.61 0.06 
0.50-
0.73 
0.78 49 78 52 75 2.2 0.5 0.03* 
Succinate 0.56 0.06 
0.45-
0.68 
0.44 74 44 39 78 1.3 0.8 0.1 
Formate 0.42 0.06 
0.30-
0.53 
0.13 100 13 36 100 1.1 0.9 0.9 
Glucose 0.51 0.06 
0.39-
0.63 
0.23 88 23 36 79 1.1 0.9 0.43 
Alanine 0.55 0.06 
0.43-
0.67 
0.32 86 32 38 82 1.3 0.8 0.2 
Glx 0.54 0.06 
0.42-
0.66 
0.32 80 32 37 77 1.2 0.8 0.3 
BCAA 0.55 0.06 
0.43-
0.67 
0.51 69 51 41 77 1.4 0.7 0.2 
Suc/Lac 0.55 0.06 
0.43-
0.67 
0.38 80 38 39 79 1.3 0.8 0.2 
Ace/Lac 0.59 0.06 
0.47-
0.71 
0.51 69 51 41 77 1.4 0.7 0.06 
Ace/Lac, acetate-lactate ratio; BCAA, branched chain amino acids; Glx, glutamine/glutamate; Suc/Lac, succinate-lactate 
ratio; AUC, area under the ROC curve; SE, standard error; CI, 95% confidence interval; YI, Youden index (J); Sen, 
sensitivity; Spec, specificity; PPV, positive predictive value; NPV, negative predictive value; LR+, positive likelihood 
ratio; LR-, negative likelihood ratio; P, significance level.  
*Statistically significant 
 
 
 
 
89 
 
Table 2.10: Predictive performance of CVF metabolites normalised integrals for 
preterm birth (< 37w), in asymptomatic pregnant women (20-22w), irrespective of 
risk of preterm birth 
Metabolite AUC SE 
95% 
CI 
YI 
Sen 
(%) 
Spec 
(%) 
PPV 
(%) 
NPV 
(%) 
LR+ LR- 
P 
value 
Lactate 0.57 0.05 
0.47-
0.67 
0.58 60 58 23 88 1.4 0.7 0.07 
Acetate 0.57 0.05 
0.47-
0.67 
0.75 45 75 27 87 1.8 0.5 0.08 
Succinate 0.46 0.05 
0.37-
0.56 
0.11 95 11 18 92 1.1 0.9 0.8 
Formate 0.49 0.05 
0.39-
0.59 
0.20 92 20 19 93 1.2 0.9 0.6 
Glucose 0.48 0.05 
0.38-
0.58 
0.17 89 17 18 89 1.1 0.9 0.6 
Alanine 0.49 0.05 
0.40-
0.59 
0.21 88 21 18 89 1.1 0.9 0.6 
Glx 0.55 0.05 
0.45-
0.65 
0.59 55 59 21 86 1.3 0.8 0.2 
BCAA 0.57 0.05 
0.47-
0.67 
0.64 58 64 25 88 1.6 0.6 0.1 
Suc/Lac 0.49 0.05 
0.40-
0.59 
0.15 95 15 19 94 1.1 0.9 0.5 
Ace/Lac 0.45 0.05 
0.35-
0.55 
0.92 15 92 27 84 1.8 0.6 0.8 
Ace/Lac, acetate-lactate ratio; BCAA, branched chain amino acids; Glx, glutamine/glutamate; Suc/Lac, succinate-lactate 
ratio; AUC, area under the ROC curve; SE, standard error; CI, 95% confidence interval; YI, Youden index (J); Sen, 
sensitivity; Spec, specificity; PPV, positive predictive value; NPV, negative predictive value; LR+, positive likelihood 
ratio; LR-, negative likelihood ratio; P, significance level.  
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Table 2.11: Predictive performance of CVF metabolites normalised integrals for 
preterm birth (< 37w), in asymptomatic high risk pregnant women (26-28w) 
Metabolite AUC SE 
95% 
CI 
YI 
Sen 
(%) 
Spec 
(%) 
PPV 
(%) 
NPV 
(%) 
LR+ LR- 
P 
value 
Lactate 0.49 0.07 
0.36-
0.62 
0.59 54 59 34 76 1.3 0.8 0.6 
Acetate 0.39 0.06 
0.27-
0.52 
0.97 12 97 60 73 3.8 0.3 1.0 
Succinate 0.59 0.07 
0.46-
0.72 
0.65 58 65 39 79 1.6 0.6 0.09 
Formate 0.50 0.07 
0.37-
0.64 
0.12 100 12 31 100 1.1 0.9 0.5 
Glucose 0.53 0.07 
0.40-
0.67 
0.30 88 30 34 87 1.3 0.8 0.3 
Alanine 0.50 0.07 
0.37-
0.63 
0.86 27 86 44 75 1.9 0.5 0.5 
Glx 0.50 0.07 
0.37-
0.63 
0.48 65 48 33 76 1.3 0.8 0.5 
BCAA 0.50 0.07 
0.37-
0.64 
0.82 35 82 43 76 1.9 0.5 0.5 
Suc/Lac 0.38 0.06 
0.26-
0.51 
0.99 8 99 67 73 5.0 0.2 1.0 
Ace/Lac 0.41 0.06 
0.29-
0.54 
1.0 12 100 100 74 - - 0.9 
Ace/Lac, acetate-lactate ratio; BCAA, branched chain amino acids; Glx, glutamine/glutamate; Suc/Lac, succinate-lactate 
ratio; AUC, area under the ROC curve; SE, standard error; CI, 95% confidence interval; YI, Youden index (J); Sen, 
sensitivity; Spec, specificity; PPV, positive predictive value; NPV, negative predictive value; LR+, positive likelihood 
ratio; LR-, negative likelihood ratio; P, significance level.  
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Table 2.12: Predictive performance of CVF metabolites normalised integrals for 
preterm birth (< 37w), in symptomatic pregnant women (24-36w) 
Metabolite AUC SE 
95% 
CI 
YI 
Sen 
(%) 
Spec 
(%) 
NPV 
(%) 
PPV 
(%) 
LR+ LR- 
P 
value 
Lactate 0.56 0.08 
0.39-
0.72 
0.65 67 65 30 90 1.9 0.5 0.2 
Acetate 0.75 0.08 
0.60-
0.91 
0.85 60 85 47 90 4.0 0.2 0.0005* 
Succinate 0.55 0.08 
0.39-
0.72 
0.64 53 64 25 86 1.5 0.7 0.3 
Formate 0.50 0.08 
0.35-
0.68 
0.38 80 38 23 90 1.3 0.8 0.4 
Glucose 0.52 0.08 
0.35-
0.68 
0.46 80 46 25 91 1.5 0.7 0.4 
Alanine 0.59 0.09 
0.42-
0.75 
0.83 47 83 38 87 2.8 0.4 0.2 
Glx 0.46 0.08 
0.30-
0.62 
0.83 33 83 31 85 2.0 0.5 0.7 
BCAA 0.56 0.08 
0.39-
0.72 
0.99 27 99 80 86 17.3 0.1 0.3 
Suc/Lac 0.40 0.08 
0.25-
0.56 
0.08 100 8 20 100 1.1 0.9 0.9 
Ace/Lac 0.76 0.08 
0.61-
0.91 
0.61 87 61 33 95 2.2 0.5 0.0004* 
Ace/Lac, acetate-lactate ratio; BCAA, branched chain amino acids; Glx, glutamine/glutamate; Suc/Lac, succinate-lactate 
ratio; AUC, area under the ROC curve; SE, standard error; CI, 95% confidence interval; YI, Youden index (J); Sen, 
sensitivity; Spec, specificity; PPV, positive predictive value; NPV, negative predictive value; LR+, positive likelihood 
ratio; LR-, negative likelihood ratio; P, significance level.  
*Statistically significant 
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Figure 2.10. Performance of CVF acetate normalised integrals in predicting preterm delivery in 
symptomatic pregnant women (A) < 37 weeks, (B) < 32 weeks, (C) within 2 weeks of index assessment.  
AUC, area under the ROC curve. 
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Figure 2.11. Performance of CVF acetate/lactate ratio in predicting preterm delivery in 
symptomatic pregnant women (A) < 37 weeks, (B) < 32 weeks, (C) within 2 weeks of index assessment.  
AUC, area under the ROC curve. 
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Figure 2.12. Performance of CVF glutamine/glutamate normalised integrals in predicting preterm 
delivery in symptomatic pregnant women (A) < 32weeks, (B) within 2 weeks of index assessment.  
AUC, area under the ROC curve 
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Figure 2.13. Performance of CVF acetate normalised integrals in predicting preterm delivery (<37 
weeks) in asymptomatic high risk pregnant women studied at mid second trimester (20-22w).  
AUC, area under the ROC curve 
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Figure 2.14. Performance of CVF branched chain amino acids normalised integrals in predicting 
preterm delivery (<37 weeks) in asymptomatic low risk pregnant women studied at mid second 
trimester (20-22w).  
AUC, area under the ROC curve 
 
 
 
 
 
 
 
 
 
 
97 
 
2.5. Discussion 
 
In this chapter, we sought to characterise the CVF metabolite profile of a unique study cohort 
of pregnant women who delivered prematurely compared to those who do not, based on their 
risk of PTB, and by presentation with symptoms of PTL. We speculated that the CVF 1H-MR 
spectrum may reliably predict pregnant women who deliver prematurely, as well as women 
with symptoms of PTL who deliver shortly after assessment. With our study cohort adequately 
designed and stratified, and the commonly used assessment markers of PTB applied (Chapter 
5), CVFs obtained by high-vaginal swabs from both asymptomatic and symptomatic pregnant 
women (n = 408) across the mid trimester, with intact membranes and no evidence of genital 
infection, were analysed with a 9.4T MR spectrometer. Metabolites (acetate, succinate, formate, 
lactate, glucose, glutamine/glutamate, alanine and branched chain amino acids) were identified in 
the 1H-MR spectrum, integrated for peak area and normalised to the total spectrum integral 
(excluding residual water peak). This was in order to validate and optimise the sample 
preparation procedure and fairly compare the CVF samples from our study cohorts and 
prevent errors due to variations in the total sample concentration which can eclipse specific 
changes in individual metabolites. Normalisation counteracts the influence of variations in total 
sample concentration.450 The large residual water signal was omitted as it has intensity in 
approximately 2 orders of magnitude greater than the other metabolites present and this can 
immensely obscure the intensities of other metabolite signals if not excluded. Other metabolite 
peaks associated with infection and PTB that were not identified in the 1H-MR spectra, but still 
undergoing investigation include propionate, butyrate, isobutyrate, cadaverine, putrescine, 
trimethylamine etc. 
In comparison to other metabolomics techniques, 1H-MR is non-invasive and non-destructive, 
and has a relatively higher resolution and sensitivity. Samples can be recovered after the 
experiment and stored for future analyses. Furthermore, it is a highly flexible technique as MR 
spectroscopy and imaging can be employed in a single experiment, thus making it possible to 
obtain metabolic, physiological, and anatomical data. Another advantage of MRS over other 
techniques is the absence of ionizing radiation.419 However, due to its ability to detect large 
water signals at significantly greater intensity than other metabolites, some metabolites 
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especially those around the vicinity of the water signal may not be identified on the spectrum. 
This greatly affects the sensitivity of the technique compared to other analytical methods 
including gas and liquid chromatography mass spectroscopy (GC/LC-MS). Fortunately, it can be 
used to analyse the structural properties of molecules including non-volatile compounds, as 
opposed to GC/LC-MS which is usually challenging with non-volatile compounds. Recent 
investigations employing mass spectroscopy have been unable to identify vaginal fluid acetate (a 
volatile metabolic acid),65, 84, 358, 451 which is readily detected by 1H-MR.65, 189, 295, 439 Also, working 
in a high magnetic-field environment such as that of an MR lab could be dangerous if adequate 
safety precautions are not observed. More so, MRS systems are usually not readily available and 
accessible owing to their very huge cost.419 
Normalisation of the identified metabolite peaks to the total spectrum integral was to correct 
for any concentration differences in the obtained CVF due to sampling.65, 295 This was verified by 
the absence of any statistically significant differences in the 1H-MR total spectrum absolute 
integrals, indicating that CVF concentration did not vary significantly between and within the 
study groups (Fig. 2.5). An alternative approach is the probabilistic quotient normalisation 
method.189, 439 This method involves determination of the most probable quotient or 
normalisation factor by dividing the signals of interest in a test spectrum by corresponding 
signals of a reference spectrum. The median of the resultant quotients has been recommended 
as the best approach for normalising all variables (metabolite signals) of the test spectrum.450 
This has been argued to be a more robust and accurate method of normalisation in quantitative 
metabolite analysis compared to the integral normalisation method. This is because integral 
normalisation is susceptible to alterations due to extreme concentrations of particular 
metabolites in a given sample. However, the probability quotient still requires normalisation to 
total spectrum integral as its initial step.450 
The CVF metabolite fingerprint is reflective of changes in the vaginal microecology that may 
impact the initiation of PTB.1 Our metabolite data showed that pregnant women presenting 
with symptoms of threatened preterm labour who eventually delivered preterm had 
significantly higher acetate N.I. (> 2 fold, 103%) and acetate/lactate ratio (46%) (P = 0.002), than 
their term counterparts (Fig. 2.6). In all study groups i.e. both symptomatic and asymptomatic 
pregnant women, acetate and lactate N.I.s correlated with vaginal pH, whilst glucose N.I., 
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glutamine/glutamate N.I., succinate N.I. and succinate/lactate ratio only correlated with vaginal 
pH in the asymptomatic low and high risk women studied at 20-22w (ASYM 20-22w), and 
asymptomatic high risk women studied at 26-28w. Consistent with their relationship with the 
vaginal pH, the metabolites also correlated among themselves across the groups (Fig. 2.7A-F). 
For instance, lactate N.I. was inversely related to acetate, succinate and glucose N.I.s, but was 
directly related to glutamine/glutamate N.I. Acetate and succinate N.I.s, alanine, 
glutamine/glutamate and BCAA N.I.s were also directly related.  
All these metabolites are part of a complex metabolic interaction that occurs between the host 
vaginal epithelial cells and microbial population as illustrated in Fig. 2.1. The direction of these 
metabolic pathways in the vaginal microenvironment is also influenced by hormonal factors such 
as the sex hormones and the menstrual cycle. For instance, high oestrogen levels as seen in 
premenopausal and pregnant women enhance the maturation and deposition of large amounts 
of glycogen in the vaginal epithelium. Glycogen is further metabolised via the glycolytic pathway 
to glucose and then lactate predominantly by Lactobacillus sp. Consistent with our data, elevated 
lactate is related to low pH and decreased risk of PTB, whilst elevated acetate, a SCFA 
produced by anaerobes associated with BV, is related to higher pH and increased risk of PTB.37, 
38  
The vaginal pH in women whose vaginal microflora is dominated by Lactobacillus is strongly 
related with elevated CVF lactic acid levels,37 and is protective against infection 38, 160, 452, 453 and 
PTB.1, 207, 454  On the other hand, acetate and other SCFAs are related to abnormal vaginal flora, 
BV and PTB.100, 207, 210, 452, 455 Also, there were correlations between lactate and succinate N.I.s in 
all the groups, as well as between elevated vaginal succinate/lactate ratio, a marker of dysbiosis 
(e.g. BV)38,84 and high pH in the asymptomatic women. Though these were modest relationships, 
they indicate the importance of succinate/lactate ratio as a predictor of abnormal vaginal flora 
and consequently adverse delivery outcome. However, with the recent report that vaginal 
succinate is not associated with high vaginal microbial diversity and clinical BV,85 and whether 
such metabolite marker can be applied irrespective of symptoms or identified risk,451 the data 
indicate that the predictive utility of these markers should be elucidated by further investigation 
with larger and well stratified study population. 
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The positive association between acetate and succinate N.I.s across the groups, and their 
negative correlation with lactate N.I. observed was not unexpected. Acetate and succinate are 
produced by anaerobic BVAB and have been reported to exhibit immune modulatory activities 
inhibiting optimal host immune response against pathogens, contributing to a dysbiotic vaginal 
microflora and subsequently leading to increased risk of poor sexual and reproductive 
outcomes.38, 100, 144, 210, 455, 456 Like acetate, elevated succinate N.I. was associated with high vaginal 
pH in all the groups except the symptomatic women. Combined together, elevated CVF acetate 
and succinate N.I.s are associated with low lactate N.I., high vaginal pH and hence, altered 
vaginal microbial environment and poor delivery outcome. 
The relationship between vaginal pH and glutamate levels in relation to abnormal vaginal flora 
has been highlighted in recent studies.84, 439 It was reported that elevated vaginal glutamate level 
(like lactic acid) is associated with low vaginal pH but inversely related to an L. iners and BVAB-
dominated microbiota.84 In line with the above observation, our data showed an inverse 
association between glutamine/glutamate N.I. and vaginal pH in the asymptomatic women 
studied at 20-22w and 26-28w (Fig. 2.7C-D); and a direct correlation between 
glutamine/glutamate and lactate N.I.s in both symptomatic and asymptomatic women (Fig. 2.7A- 
F). This is exciting as glutamine/glutamate could be another metabolite that influences vaginal 
pH and by extension vaginal microenvironment with conceivable prognostic value. In depth 
analysis of the vaginal microbiota community compositions of these study groups using broad-
range PCR and pyrosequencing in relation to glutamine/glutamate and other identified 
metabolites may improve our understanding of the diagnostic implications of these associations. 
Although the amino acids identified in this study did not differ significantly between term- and 
preterm-delivered women, there were modest associations and trends between them. Alanine 
correlated positively with both glutamine/glutamate and BCAA N.I.s. The implications of these 
associations are unclear. Nonetheless, it is known that BVAB utilise amino acids as carbon and 
nitrogen sources as opposed to Lactobacillus species which preferentially metabolise 
carbohydrates, such as glycogen.84, 457 Accordingly, a high level of intact amino acids in the 
vaginal ecosystem is associated with Lactobacillus sp. dominance and/or low amount of anaerobic 
BVAB. This is supportive of our data as we observed firstly, positive associations between 
lactate and the amino acids especially glutamine/glutamate and BCAA; and secondly, positive 
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associations between the amino acids themselves (Fig. 2.7A-F). Furthermore, Srinivasan et al.84 
demonstrated a positive association between the BCAAs (valine, leucine, and isoleucine) and 
glutamate with Lactobacillus sp. particularly L. crispatus and L. jensenii; and a negative association 
between these amino acids and BVAB (e.g. G. vaginalis, A. vaginae, Eggerthella, Megasphaera etc.).  
This was recently validated by Vitali et al.439 who by employing the same technique as ours (i.e. 
1H-MR), demonstrated decreased levels of glutamate, leucine and isoleucine in BV-infected 
women compared to their healthy counterparts. This is another identifiable source of future 
experiments as the potential diagnostic utility of these specific amino acids remains unresolved.  
We also examined the relationship between the identified 1H-MR metabolite N.I.s and the 
gestational age at delivery. There were no significant associations except in the asymptomatic 
women studied at 20-22w combined regardless of their risk statuses. In this combined group, 
only lactate and glutamine/glutamate N.I.s correlated with gestational age at delivery (Fig. 2.7C). 
When they were reclassified into low and high risk group, only the low risk women showed a 
positive association between glutamine/glutamate N.I. and gestational age at delivery (Fig. 2.7A). 
These observations buttress the negative relationship between lactate, glutamine/glutamate 
N.I.s and vaginal pH on one hand, and the negative relationship between vaginal pH and 
gestational age at delivery on the other hand (Fig. 2.7C). Taken together, elevated CVF lactate 
and glutamine/glutamate N.I.s in asymptomatic women sampled at mid second trimester 
regardless of a prior PTB and/or short cervix, are associated with lower vaginal pH and normal 
gestational age at delivery. 
Another metabolite identified in the CVF 1H-MR spectra of our study participants was formate, 
a SCFA also produced by BVAB. Though there were no significant differences in this metabolite 
in relation to delivery outcomes, we observed certain associations with other SCFAs, organic 
acid and amino acid metabolites across the groups (Fig. 2.7A-F). The implications of these 
associations are unclear but like acetate and succinate, high levels of formate are associated 
with BV and poor reproductive outcomes.38, 439 
With the identification of metabolite differences and associations with other maternal clinical 
parameters currently used as assessment markers for PTB, we investigated the predictive 
potential of the CVF metabolites identified by MRS for risk of PTB in our unique study 
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population. Acetate N.I. and acetate/lactate ratio were predictive of < 37 weeks and < 32 
weeks premature deliveries, as well as delivery within 2 weeks of presentation and 
measurement in women presenting with symptoms of threatened preterm labour (Tables 2.2-
2.3 and Figs. 2.10-2.11). Similar predictive potential for delivery before 32 weeks gestation and 
within 2 weeks of presentation was observed for glutamine/glutamate N.I. in the same women 
(Table 2.4 and Fig. 2.12). These metabolites showed high sensitivities, specificities and NPVs but 
low PPVs for PTB comparable to those of FFN309, 310, 458 and ultrasound CL.354, 459-461 The high 
NPVs achieved in our series also indicate that low acetate N.I., just like low FFN and high CL,303, 
459 may demonstrate a good “exclusion” test for imminent premature birth, referring women to 
outpatient care, providing maternal reassurance and thus minimizing waste of scarce resources. 
Combining measurements of FFN, CL and acetate could enhance the diagnostic performance of 
these markers in both asymptomatic and symptomatic women. This is discussed later in this 
report (Chapter 5). We also observed that women with increased acetate N.I.  and 
acetate/lactate ratio had 4-fold and 2-fold chances of delivering preterm (< 37 weeks) 
respectively. A 2-fold increase in CVF acetate N.I. produced a 4-fold likelihood of delivery 
before 37 weeks gestation, and a 2-fold likelihood of delivery before 32 weeks gestation and 
within 2 weeks of presentation. This is intriguing as all the PTBs recorded in the symptomatic 
women in this study occurred approximately within 2 weeks of presentation. Also, in women 
presenting with symptoms of threatened PTL, the prediction of the likelihood of spontaneous 
preterm delivery occurring within 2 weeks of testing is of utmost interest as this determines 
the level of management.313 In other words it ensures adequate “diagnostic evidence in 
therapeutic decision making”.313 Glutamine/glutamate N.I. also showed 3-fold and 2-fold 
probability for delivery before 32 weeks gestation and within 2 weeks of presentation 
respectively (Table 2.2-2.4). These observations suggest probable clinical utility of these 
metabolites for predicting PTB. Whether this is achievable independently or in combination 
with FFN and CL remains undetermined. A multivariate analysis of these markers could 
enhance predictive performance compared to CL or FFN alone. This was attempted by our 
group and will be seen later in this report (Chapter 5). 
In addition to its predictive value in symptomatic pregnant women, acetate N.I. also showed 
considerable discriminative capacity for premature delivery (< 37 weeks) in the asymptomatic 
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high risk women studied at mid second trimester (20-22w), with high sensitivity, specificity, 
PPV, NPV, and a LR+ of 2.2 (Table 2.5 and Fig. 2.13). Again, this can be compared to the 
predictive capacities of FFN and ultrasound CL in this specific cohort of pregnant women.311, 312, 
320, 321  
Also, in the asymptomatic low risk cohort, apart from showing a trend to higher branched 
chain amino acids (BCAA), in the women who delivered at term compared to those that 
delivered preterm, the BCAAs were predictive of preterm birth (< 37w), with high sensitivity, 
specificity, NPV, but low PPV, and LR+ of 2.9 (Table 2.6 and Fig. 2.14). This is not only 
comparable to the data obtained from FFN and ultrasound CL in other studies with 
asymptomatic women,303 but was even a better predictor of spontaneous preterm birth than 
FFN (AUC: 0.75 vs. 0.65313), with a significantly higher sensitivity (BCAA:100% vs. FFN: 20-29% 
vs. CL: 33-54%303). Women with high BCAA had about 3-fold likelihood of delivering at term. 
This is corroborated by the observation of decreased vaginal protein/amino acid catabolism in 
normal healthy women,84 such as the term-delivered low risk women in our study. High 
amounts of BCAA (as seen in the term-delivered women) are associated with L. crispatus and L. 
jensenii dominance characteristic of a healthy vaginal ecosystem with good reproductive 
prognosis.84, 439 CVF amino acids, including the BCAA (leucine, isoleucine and valine) are 
catabolised and used up as energy sources by BVAB. Therefore, high amounts of intact BCAA, 
could be suggestive of absence of BVAB and/or dominance of Lactobacillus sp.84 To our 
knowledge this is the first of its kind in the quest for identification of CVF metabolite markers 
with prognostic utility for spontaneous preterm delivery in a low risk population. More so, as 
will be seen subsequently in this report, FFN and ultrasound CL were not predictive of preterm 
birth in this group of women in our study (Chapter 5).  
The associations between CVF FFN and metabolites especially acetate in the asymptomatic 
women (20-22w) (Fig. 2.7C), and the comparable predictive capacity of acetate in the high risk 
women of this group, suggests that combining these analytes may offer additional predictive 
potential for preterm delivery. A more robust approach using MR spectrometers with stronger 
magnetic field (e.g. 600 MHz (14.1T), 700 MHz (16.4T) and 900 MHz (21.1T)), that allow more 
sensitive analysis of metabolites; and a larger study population with more stringent inclusion and 
exclusion criteria is necessary. 
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One limitation to the current study which is a critical subject for future investigation is the 
identification of the chiral forms of lactate in CVF of our cohorts in relation to reproductive 
health. Lactate has 2 optical isomers (D- and L-lactate). D-lactate is almost exclusively produced 
by bacterial cells, while L-lactate can be synthesised by both human and bacterial cells.1, 114 The 
vaginal epithelial cells, like other human cells produce L-lactate only because they lack the 
enzyme D-lactate dehydrogenase.1, 114 As could be the case in our study, the vaginal epithelium 
secretes L-lactate into the vaginal environment irrespective of the composition of the vaginal 
bacterial community. L-lactate is less potent in protecting the host against microbial invasion of 
the upper genital tract compared to D-lactate which is produced by Lactobacillus sp. including L. 
crispatus, L. gasseri and L. jensenii but not L. iners. L. iners, like human cells, lacks D-lactate 
dehydrogenase and so does not synthesise D-lactate.1, 114, 196 Because of its significant protective 
capacity against ascending intrauterine infection in relation to L-lactate, via the inhibition of 
extracellular matrix metalloproteinase inducer (EMMPRIN) and MMPs, D-lactate has been 
recommended as a prebiotic in the treatment of BV and prevention of preterm birth.1, 114, 196 
Determination of CVF L-/D-lactate ratio in pregnant women at risk of preterm birth will 
provide insight into the source(s) of lactate identified, the composition of the vaginal microbial 
population as well as the predominant Lactobacillus sp. at any given gestational time point. 
Fortunately, CVF D- and L-lactate optical isomers can be measured colourimetrically by 
commercially available assay kits.1, 114,196 This warrants further study.  
Lastly, in these experiments we were unable to identify significant differences or predictive 
utility of any of the metabolites in the asymptomatic women who were studied again at 26-28 
weeks. For example, the AUC for acetate was 0.39, significantly lower than those of the other 
groups. These observations could be attributed to the administration of several therapeutic 
interventions including antibiotics to women in this group due to their high risk status (Chapter 
5). Antibiotics were administered in cases of suspected subclinical genital bacterial infection 
acquired in later gestation (after sampling at 20-22 w). This may have altered the vaginal 
microbiome towards normal403, 462 and by extension metabolite profile, hence, an alteration in 
certain metabolite levels. Such interventions could not be prevented as it will be unethical to 
abstain from treating such cases when identified. Nevertheless, some of these women ultimately 
delivered preterm. An in-depth investigation of the influence of antibiotic treatment and other 
105 
 
interventions such as cervical cerclage and progesterone on the vaginal microenvironment at 
mid-trimester is required. 
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Chapter 3 
 
Quantification of cervicovaginal fluid acetate in pregnant women by 
biochemical assay 
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3.1. Introduction 
 
Magnetic resonance spectroscopy is a powerful tool to establish the metabolite profiles of 
tissues and biofluids, and in identifying potentially useful biomarkers in relation to health and 
disease conditions. It is highly analytical, sensitive and capable of detecting volatile compounds 
such as acetate.65, 295, 430, 432, 439 However, one setback of this approach is that additional steps are 
required to determine absolute concentrations of metabolites, e.g. concentration standards 
added to the sample, and this poses a challenge when cut-off values of a metabolite marker are 
required for diagnosis in the clinical setting. Also constraints due to its relatively low sensitivity 
compared to other techniques (e.g. MS), and cost effectiveness are prevalent. With these 
limitations, application of MRS in the clinical setting where rapid and accurate tests are needed 
to inform diagnosis and treatment may not be feasible. Hence there is the need to provide 
more rapid, cost-effective and easily assessable techniques of quantifying these CVF metabolites 
in clinical settings.  
A relatively cost-effective and readily assessable technique capable of measuring the absolute 
concentrations of metabolites in biofluids is spectrophotometry. Vaginal fluid acetate and lactate 
have been measured spectrophotometrically with great success.37 Spectrophotometry is a 
quantitative analytical technique that measures the concentrations of analytes in samples by 
their ability to absorb or transmit light in form of electromagnetic radiation, over certain range 
of wavelengths. With the use of a spectrophotometer, the intensity of light (amount of 
photons) absorbed by a sample solution can be measured, and the concentration of the analytes 
can be determined from the intensity of light detected. There are 2 types of 
spectrophotometers based on the range of wavelength of the light source. 
The first is the Ultraviolet-Visible (UV/Visible) spectrophotometer, which utilises 
electromagnetic radiations between wavelengths of 190-400 nm (ultraviolet), and 400-900 nm 
(visible).420 The other is the Infrared (IR) spectrophotometer, which utilises electromagnetic 
radiations between wavelengths of 700-1500 nm (infrared). 
The mechanism of spectrophotometry as depicted in Fig. 3.1 involves 2 components: a 
spectrometer that provides the desired light in a range of colours (wavelengths), and a 
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photometer that detects the intensity of light that is absorbed which can be read on digital 
monitor or electric meter. 
The spectrometer comprise of a lens (collimator) that transmits photons (beam of light). The 
beam of light is refracted (dispersed) as it passes through a prism (monochromator), into a 
spectrum of a range of wavelengths. Only light rays with the required wavelengths are 
transmitted with the aid of a wavelength selector (aperture). When the required wavelength of 
light traverses the sample contained in the cuvette, the intensity of light beam absorbed is 
detected by the photometer, with the aid of a light detector (photoelectric transducer). The 
signals are then amplified and recorded by an absorbance meter. 
The concentration of a metabolite in a sample can be determined from the absorbance of the 
sample using the Beer-Lambert Law.463 The Beer-Lambert Law states that absorbance of a given 
sample is directly proportional to its concentration i.e. 
                                    
where A is the measured absorbance with no unit, Ɛ is a constant called molar absorbtivity 
coefficient (M-1cm-1). It is unique for each molecule and is wavelength-dependent. l is the path 
length i.e. the length of sample solution the light passes through and it is dependent on the 
width of the cuvette (usually 1 cm), c is the concentration of the analyte (M or molL-1), I0 is the 
initial (incident) light intensity, I1 is the transmitted light intensity (i.e. after it passes through the 
sample), while T is the Transmittance (i.e. the fraction of light that is not absorbed). 
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Figure 3.1. Schematic representation of the components and mechanism of a spectrophotometer 
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Analysis of CVF from pregnant women at risk of PTB across mid gestation using 1H-MR, 
revealed significantly different acetate N.I. between term- and preterm-delivered SYM women.  
Also, acetate N.I. showed significant prognostic utility for PTB (< 37w, < 32w), and delivery 
within 2 weeks of presentation with symptoms suggestive of PTL (Chapter 2). With these 
fascinating findings, we sought to further validate the data obtained by 1H-MR and attempt to 
provide a biochemical assay to assess the concentrations of acetate and other metabolites in 
CVF of pregnant and even non-pregnant women in relation to reproductive health.  As a result 
we measured the concentrations of acetate in the same CVF samples of the symptomatic 
women (as in the 1H-MR experiments) by enzyme-based spectrophotometric technique.    
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3.2. Methods 
 
Acetate concentrations were determined from a randomly selected subset of CVF samples 
from pregnant women presenting with symptoms of threatened PTL (n = 57), by 
spectrophotometric absorption of NADH using an acetic acid assay kit (ADP-Glucokinase 
format, K-ACETGK 08/14, Megazyme, IE). The assay principle is based on the determination of 
acetate concentration by the generation of NADH from NAD+, which is then quantified by the 
increase in absorbance at 340 nm.464 The enzymes involved in the 4-step reaction and supplied 
with the assay kit include (1) acetate kinase (AK), (2) phosphotransacetylase (PTA), (3) ADP-
glucokinase (ADP-GK), and (4) glucose-6-phosphate dehydrogenase (G6P-DH). Acetate is 
converted through the following reaction which is positively related to the eventual formation 
of NADH:  
 
The reaction is a positive reaction indicated by the increase in absorbance as demonstrated by 
the calibration curve (R2 = 0.975, detection limit: 1.8 g/l) (Fig. 3.2). The acetic acid GK assay kit 
is an endpoint type assay specific for acetate with its lowest sensitivity limit ~0.1 g/l. All 
reagents were prepared, mixed, and stored according to manufacturer’s instruction. A single 
reaction mixture containing 3 µl CVF sample in PBS, 200 µl of reagent 1 (distilled water, buffer 
and AK/PTA/ADP-GK/G6P-DH), and 20 µl of reagent 2 (NAD+/ATP/D-glucose/CoA/PVP), was 
assayed for each sample. The reaction time was ~ 5 mins at 37°C after which the absorbance of 
the end product NADH, was read at 340 nm. A calibration curve indicating the linearity of K-
ACETGK 08/14 was produced by plotting absorbance at 340 nm against concentrations of the 
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acetic acid standards (g/l) (Fig. 3.2). Different concentrations (calibrators) of the acetic acid 
standard (1.8 g/l), were made be serial dilution (i.e. 1.8, 1.2, 0.9, 0.6, 0.45, 0.36, 0.3, 0.225, 0.2, 
and 0.15 g/l). From the calibration curve concentrations of acetate in the samples were 
ascertained after measurement of their absorbance at 340 nm. All assays were performed using 
optical grade 96 well plates on a computer controlled Infinite M200 microplate reader 
(TECAN, CH), capable of detecting UV/Visible light, fluorescence, and luminescence. 
3.2.1. Statistical analysis 
 
All Statistical analyses were performed using MATLAB (Mathworks, Natick, MA). Values are 
presented as median ± quartile range and the Wilcoxon’s rank-sum test was performed to 
compare differences in acetate concentration within the groups. The relationship between 
acetate concentration and 1H-MR acetate N.I. was determined by Pearson’s correlation 
coefficient and P values < 0.05 were considered statistically significant. The predictive capacity 
of the CVF acetate concentrations for PTB was determined by ROC curves for the following 
comparisons: 
• Preterm (< 37 weeks) versus term births, 
• < 32 versus > 32 weeks and 
• < 2 versus > 2 weeks from presentation to delivery in symptomatic women. 
A cut-off value of acetate concentration for predicting  PTB < 37 weeks was also calculated 
from the ROC curve. 
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3.3. Results 
 
By exploring the spectrophotometric absorption of NADH produced by a 4-step 
phosphorylation reaction involving acetic acid and D-glucose, we were able to measure the 
concentration of acetate in the CVF obtained from 57 women presenting with symptoms 
suggestive of threatened PTL in whom we hitherto observed significant difference in 1H-MR 
acetate N.I. in relation to term and PTB (Chapter 2). Acetate concentration was determined by 
the generation of NADH from NAD+ and quantified by the increase in absorbance at 340 nm.464  
Similar to our observation with acetate N.I., acetate concentrations measured by 
spectrophotometric technique was significantly higher in the preterm-delivered vs. term- 
delivered women in the symptomatic cohort (P = 0.006), and correlated strongly with the 1H-
MR acetate N.I. (r = 0.69, P < 0.00001) (Fig. 3.3A-B). Though there were significant differences 
in both acetate concentration and 1H-MR acetate N.I. between preterm- and term-delivered 
women in the symptomatic cohorts, the difference observed in relation to 1H-MR acetate N.I. 
was significantly greater (> 2-fold, 103%), compared to ~17% difference in acetate 
concentration (Fig. 2.6 and Fig. 3.3A). Compared to the 1H-MR acetate N.I., the difference in 
acetate concentration was marginal. However, acetate concentrations in concordance with the 
acetate N.I. were predictive of PTB (< 37 w) and delivery within 2 weeks of index assessment 
with an optimal cut-off value for delivery < 37 w of > 0.53 g/l (0.009 mol/L).  Its predictive 
ability for PTB < 32w did not attain statistical significance (AUC = 0.63, P = 0.13) (Table 3.1 and 
Fig. 3.4). 
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Figure 3.2. Calibration curve indicating the linearity of K-ACETGK. The reactions from which this 
calibration curve was generated were performed at 37°C for 5 mins using a TECAN Infinite M200 microplate 
reader (detection limit = 1.8 g/l or 0.03 mol/l). 
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Figure 3.3. Validation of the differences in CVF acetate levels in pregnant women presenting with 
symptoms of preterm labour between 24 and 36 weeks gestation (A) Comparison of acetate 
concentration between preterm- and term-delivered women, (B) Association between acetate normalised integrals 
(N.I.) measured by 1H-Magnetic Resonance Spectroscopy and acetate concentrations measured by 
spectrophotometry. 
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Table 3.1: Predictive performance of CVF acetate concentration for preterm birth 
in symptomatic pregnant women 
Variables 
< 37 
weeks gestation 
< 32 
weeks gestation 
≤ 2 weeks of index 
assessment 
Area under the 
ROC curve (AUC) 
0.74 0.63 0.68 
Standard Error, SE 0.08 0.12 0.11 
95% Confidence 
Interval 
0.57-0.90 0.40-0.87 0.47-0.89 
Significance level, P 0.002 0.13 0.045 
Youden index, J 0.71 0.63 0.79 
Sensitivity, % 71 71 67 
Specificity, % 71 63 79 
Positive predictive 
value (PPV), % 
36 19 29 
Negative predictive 
value (NPV), % 
92 95 95 
Positive likelihood 
ratio, LR+ 
2.5 2.0 3.1 
Negative likelihood 
ratio, LR- 
0.4 0.5 0.3 
Optimal cut-off, g/l 0.53   
Acetate concentration was not predictive of preterm birth < 32 weeks gestation (P = 0.13). 
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Table 3.2: Predictive accuracy of CVF acetate 1H-MR normalised integral and 
concentration for preterm birth 
 AUC 95% CI 
Sens 
(%) 
Spec 
(%) 
PPV 
(%) 
NPV 
(%) 
LR+ LR- P value 
Delivery < 37 weeks gestation 
Acetate N.I. 0.75 0.60-0.91 60 85 47 91 4.0 0.2 0.001 
AceConc 0.74 0.57-0.90 71 71 36 92 2.5 0.4 0.002 
Delivery < 32 weeks gestation 
Acetate N.I. 0.73 0.53-0.94 88 59 21 97 2.1 0.5 0.01 
AceConc 0.63 0.40-0.87 72 63 19 95 2.0 0.5 0.13 
Delivery within 2 weeks of assay 
Acetate N.I. 0.77 0.58-0.96 100 49 21 100 2.0 0.5 0.003 
AceConc 0.68 0.47-0.89 67 79 29 95 3.1 0.3 0.045 
N.I., 1H-MR normalised integral;  AceConc, acetate concentration; AUC, area under the ROC curve; CI, 95% 
confidence interval; Sens, sensitivity; Spec, specificity; PPV, positive predictive value; NPV, negative predictive value; 
LR+, positive likelihood ratio; LR-, negative likelihood ratio; P, significance level. 
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3.4. Discussion 
 
In this chapter we validated our data obtained by MRS and attempted to identify a possible 
clinical assay to assess concentrations of CVF acetate in pregnant women in relation to 
premature delivery.  A subset of randomly selected CVF samples from the women presenting 
with symptoms of threatened preterm labour were analysed for acetate by spectrophotometric 
absorption using cheaper, but sensitive commercially available assay kit. To our knowledge, this 
comparative analysis is the first of its kind. 
It can be recalled that of all the metabolites identified in our 1H-MR experiments (Chapter 2), 
only acetate N.I. was significantly different between term- and preterm-delivered women and 
this difference was only observed to attain significance in the symptomatic cohort. Similar to 
this observation, acetate concentration measured by a spectrophotometric technique also 
differed significantly between term- and preterm-delivered women in the symptomatic group. In 
other words, the symptomatic women that delivered preterm had higher vaginal acetate 
concentrations compared to their term counterparts. Furthermore, acetate concentrations 
measured correlated with acetate N.I. measured by 1H-MR (Fig. 3.3A-B), and was likewise 
predictive of preterm birth (< 37 weeks) and delivery within 2 weeks of presentation with 
comparable sensitivities, specificities, PPVs, NPVs and likelihood ratios. An optimal cut-off value 
of > 0.53 g/l for predicting deliveries before 37 weeks was obtained from the ROC curve (Table 
3.1 and Fig. 3.4).  In other words, at a concentration greater than 0.53 g/l, acetate is 
considerably capable of discriminating symptomatic pregnant women at a greater risk of PTL 
and delivery before 37 weeks of gestation. 
Though acetate concentration measured by spectrophotometric technique produced similar 
results as and correlated with acetate N.I. measured by 1H-MR in this study, it was not as 
sensitive and powerful as acetate N.I. measured by 1H-MR. This is clearly depicted by the 
marginal difference (17%) in acetate concentration between term- and preterm-delivered 
women as opposed to the over 2-fold (103%) difference observed with acetate N.I. 
Additionally, the acetate N.I. was a better predictor of delivery within 2 weeks of presentation 
(AUC: 0.77 vs. 0.68), and < 32 weeks (AUC: 0.73 vs. nil), compared to acetate concentration. 
These disparities could be due to the higher sensitivity of 1H-MR over spectrophotometry. 
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However, the lower sample population analysed by spectrophotometric technique (n = 57) vs. 
1H-MR (n = 82) may partly account for the differences noted. Fewer samples were analysed 
when the cut-off for preterm birth was restricted to less than 32 weeks of gestation (n = 8). 
This may account for the poorer performance of acetate concentration in predicting preterm 
birth less than 32 weeks. Also, the use of microplate reader instead of an auto-analyser as 
indicated by the manufacturer may have impacted the current data.  
Some investigators, using the same assay kit as that employed in our study, analysed arterial 
blood acetate levels in patients after cardiopulmonary bypass with great success.464  Another 
group, applying the same principle, but with a different commercially available assay kit validated 
the measurement of CVF lactate and acetate concentrations by spectrophotometric technique 
which was comparable to High Performance Liquid Chromatography (HPLC) analysis.37 Despite 
its relatively weaker sensitivity and difficulty in discovering unknown metabolites, 
spectrophotometric measurement of acetate concentrations in CVF of pregnant women with 
symptoms suggestive of threatened PTL as shown by our data could provide a cheaper, rapid 
and more accessible tool for predicting PTL and premature delivery in the clinical setting. This 
is in contrast to 1H-MR which is a great technique for discovery of metabolites, but with less 
affordability and accessibility requiring a great deal of expertise, sophistication and safety 
precautions as a high magnetic field environment is required.  Furthermore, apart from 1H-MR, 
other techniques with relatively higher sensitivity and affordability particularly GC/LC-MS have 
been unable to detect reasonable amounts of acetate in CVF probably due to its high volatility 
and as such were unable to make useful inferences in relation to this metabolite and vaginal 
health.84, 85, 358, 451 
Going forward, a more robust analysis using an auto-analyser (e.g. ChemWell® 2910 Auto-
Analyser), in place of a microplate reader as used in this study, will enhance the accuracy and 
output of these assays. The ChemWell® 2910 is an automated (robotic) bench top open system 
auto-analyser supplied with optimised programming protocols (for Megazyme assay kits), with 
the capacity to perform biochemical assays. It is equipped with a 96 well plate layout where the 
assays are performed, 27 reagents and 96 sample racks, as well as a flush system that washes 
the 96 well plate ready for re-use at the end of the experiment. It employs continuous flow 
analysis to perform repetitive stages of sample analysis. It can simply be described as an 
120 
 
“automatic spectrophotometer” capable of mixing precise quantities of reagents and samples 
incubated at the right temperature and duration, reading the absorbance at the appropriate 
wavelength (e.g. UV-Vis light range), and washing up the micro-wells at the end of the assay. 
Though the sensitivities of the microplate reader and auto-analyser are similar, increasing the 
volume of sample used during the reaction can enhance the sensitivities of both methods. 
However, for improved precision, repeatability and simultaneous analysis of multiple 
metabolites in CVF sample from different study populations, the auto-analyser is preferred. 
Depending on the duration of the reaction, the auto-analyser can perform up to 200 endpoint 
assays per hour (https://secure.megazyme.com/ChemWell-2910-Chemistry-Analyser). 
Meanwhile, not only does this spectrophotometric assay validate our data obtained by 1H-MR, it 
also kindles the possibility of a specific, rapid and affordable clinical assay for the assessment of 
risk of preterm birth at least in symptomatic women. Also, we are currently unaware of any 
impediments to its utility by health care systems involved in maternal and child care, and the 
UK’s National Health Service (NHS) could benefit tremendously from the application of such 
technique.  There is also the possibility that by using spectrophotometry, interesting data could 
emerge from other metabolites in which we were unable to demonstrate any statistically 
significant difference by 1H-MR in relation to delivery outcomes in this study. 
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Chapter 4 
Investigation of the vaginal microbiome in the second trimester of 
pregnancy in relation to delivery outcomes 
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4.1. Introduction 
 
The vaginal bacterial community comprises a mixed population of diverse species, and the 
relative abundance of these organisms impact the woman’s urogenital health and disease.465 A 
normal and healthy vaginal microbiome is characterised by the predominance of Lactobacillus sp., 
while the dominance by genera other than Lactobacillus is termed abnormal and unhealthy.24, 25  
Loss of vaginal Lactobacillus dominance and the subsequent proliferation of facultative and 
strictly anaerobic bacteria (e.g. Gardnerella, Prevotella Atopobium, Fusobacterium, Mycoplasmas, 
Mobiluncus etc.), describes a common syndrome among reproductive-age women known as 
BV.21, 64, 66, 466 BV is an established risk factor of PTB and other adverse pregnancy outcomes.94, 160, 
196 A considerable amount of these anaerobes are unculturable and of low abundance,465, 466 
hence the need for high throughput cultivation-independent characterisation of the vaginal 
microecology in health and disease conditions.  
Characterisation of vaginal microbial composition has been enhanced recently by cultivation-
independent broad-range and species-specific PCR techniques.64, 465-467 The initial crucial 
procedure employed for vaginal microbiome study is the extraction of 16S rDNA from the 
crude samples (See section 4.2.1. of this chapter for a general description). Contaminants such 
as molecules and artefacts capable of hindering the efficiency of the PCR and sequencing 
processes in producing adequate quantities of useable reads, need to be eliminated. This is then 
followed by PCR amplification of the isolated DNA with primers specific for the hypervariable 
regions of the 16S rRNA genes, and purification of amplicons generated. These processes will 
produce pure amplicon libraries that can be sequenced using the 454 - Next Generation 
sequencing platforms. Sequencing produces Operational Taxonomy Units (OTUs) which can be 
classified by BLAST, SILVA, Greengenes, EzTaxon-e and RDP classifiers.21, 66 
In this chapter, PCR assays to determine the prevalence and relative abundance of 10 vaginal 
bacterial species (Lactobacillus sp., L. crispatus, L. jensenii, Bacteroides-Prevotella, Gardnerella, Group 
B Streptococcus, Fusobacterium sp., Mycoplasma, Mobiluncus curtisii, and Mobiluncus mulieris) were 
performed. These bacterial species were amplified because they are commensal endogenous 
vaginal microorganisms detected both in healthy and deranged vaginal microbiota. Some of 
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them have been implicated in infection and pathogenesis of adverse delivery outcome.12, 21, 74, 84, 
85, 168  
Furthermore, the presence of these bacterial species has been linked to various metabolites we 
have already identified in the previous chapters of this report (Chapter 2 and 3). For instance, 
Lactobacillus sp. dominance is associated with elevated lactate and low levels of acetate, 
succinate, formate etc., while decreased amounts of Lactobacillus sp. is associated with 
proliferation of BVAB, elevated acetate, succinate and other SCFAs.38 In other words 
alterations in the vaginal microbial population are also reflected in the metabolite profile. 
Whether either of these markers could be used as a proxy for the other necessitated our 
analyses of the bacterial species by PCR. Collectively, investigation of the composition of the 
vaginal bacterial population and their metabolic by-products could provide a holistic approach 
to the predictive value of these potential markers for PTB.  
These experiments were applied on vaginal fluid samples from both asymptomatic and 
symptomatic pregnant women presenting at the antenatal clinics and Triage Delivery Suites of 
the Jessop Wing Hospital, Sheffield, UK, with intact membranes and no clinically defined genital 
infection. These women were studied at 20-22 and 26-28w (asymptomatic women), and 24-
36w (symptomatic women). The symptomatic women were those presenting with regular 
uterine contractions but < 3 cm dilated cervical os. Knowledge of the prevalence and relative 
abundance of vaginal bacteria is required to ascertain their impact on pregnancy outcomes and 
identify women at risk of PTB in relation to the metabolites identified. PCR is capable of 
identifying and quantifying both culturable and unculturable bacteria at the species level and has 
gained immense usefulness in the determination of the vaginal bacterial community composition 
in relation to infection and adverse pregnancy outcome.465, 468-470 
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4.2. Methods 
4.2.1. DNA Extraction 
The sample DNA was extracted using a standard operating procedure for DNA extraction 
from vaginal swabs with QIAamp DNA mini kit (Qiagen, 51304, UK) performed according to 
amended manufacturer’s instructions as described below.  
The cut off swab tips were placed in 1.5 ml microfuge tubes with 400 µl Phosphate Buffered 
Saline (PBS) (Sigma-Aldrich, D8537, UK) and vortexed thoroughly for 5 minutes. To each tube 
of 250 µl sample, 75 µl lysozyme (10 mg/ml; Sigma-Aldrich, L1667-1G, UK), and 10.5 µl Tris-
EDTA buffer at pH 8.0 (Fisher, BP2473-100, CA) were added and incubated at 37°C for 1 hour 
to degrade the bacterial cell wall and preserve the genomic DNA from degradation. Proteins 
and RNA were digested by adding 20 µl proteinase K (Qiagen, 19131, UK) and 4 µl RNase A 
(100 mg/ml; Qiagen, 19101, UK) and 250 µl of buffer AL (lysis buffer i.e. 1:1 ratio) to each tube, 
mixed by inverting tube 2–3 times and incubated for 10 minutes at 56°C. 400 µl of absolute 
ethanol was then added to each tube and vortexed for 15s to precipitate the DNA out of 
solution. DNA was further precipitated by adding each sample to a spin column in 2 ml 
collection tube and centrifuged at 6,000 x g for 1 minute. The filtrate was discarded and the 
column was transferred into a clean collection tube and recentrifuged briefly. We then added 
500 µl buffer AW2 (wash buffer) to each column and centrifuged at 20,000 x g for 3 minutes. 
This was followed by another centrifugation for 1 minute at full speed. Each column was 
transferred to a clean 1.5 ml microfuge tube, 100 µl of nuclease free water added and incubated 
at room temperature. After a minute, the samples were centrifuged at 6,000 x g for 1 minute 
and the DNA sample was obtained. The quantity and purity of the isolated DNA was assessed 
by spectrophotometry using the Thermo Scientific NanoDrop (ND1000) spectrophotometer 
(Labtech International LTD, UK). The extracted DNA samples were then preserved at -20°C 
until required for further analysis. 
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4.2.2. Targeted PCR amplification of vaginal bacterial species 
 
Bacterial genus-specific primers (Sigma-Aldrich, UK), targeted at the bacterial 16S rDNA were 
used to examine for a range of commensal and potentially pathogenic bacterial species which 
included Lactobacillus, Bacteroides (Prevotella), Gardnerella, Group B Streptococcus, Fusobacterium, 
Mycoplasma and Mobiluncus. The names of the primers, their sequences and targets, annealing 
temperatures, amplicon product size and sources are represented in Table 4.1. A pair of 
primers specific for Lactobacillus sp. was designed by first identifying the Lactobacillus 16S rRNA 
gene and then identifying base sequences complementary to the gene of interest. The primer 
sequences were confirmed with the National Centre for Biotechnology Information Basic Local 
Alignment Search Tool (BLAST). PCR amplification experiments were performed using 12.5 µl 
AmpliTaq Gold DNA polymerase (Applied Biosystems, UK ), 5 ng genomic DNA template, 1 µl 
each of forward and reverse primers (10 µM),  in a total reaction volume of 25 µl. Reactions 
were run in an Applied Biosystems 2720 Thermal cycler (Life Technologies, UK) with the 
following cycling criteria: 95°C (5 mins) – denaturation, followed by 35 cycles of 95°C (1 min) - 
denaturing, 50 - 62°C depending on the primer sets (1 min) – annealing, 72°C (1 min) – 
elongation, with a final extension at 72°C (7 mins). The results were visualised on a UV-
transilluminator by 1% agarose gel electrophoresis and ethidium bromide staining.  Positive 
results were assigned according to the presence of bands of the appropriate size. The chi-
square test alongside a benchmark of ≥10% was then applied to determine any differences in 
prevalence of vaginal bacterial species based on delivery outcome.  
4.2.3. Quantitative (Real-time) PCR analysis of vaginal bacterial species 
Real-time PCR (qPCR) amplification and detection was performed using 16S rDNA specific 
primers for Gardnerella and Mobiluncus curtisii only. This was not only because of the availability 
of a suitable calibrant DNA for these bacterial species used to produce accurate standard 
calibration curves (absolute quantification), but due to the high prevalence of Gardnerella in all 
women among the groups and its association along with M. curtisii to BV and PTB. A relatively 
lower number of women across the groups had positive results for Bacteroides compared with 
Gardnerella and Mobiluncus curtisii, thus it was not a priority due to finite resources. The PCR 
reactions were performed using Power SYBR green master mix (Applied biosystems, 1503489, 
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UK), on a 7900HT Fast Real-Time PCR system (Applied Biosystems, UK) using optical grade 96 
well plates. The total reaction mixture (20 µl) contained 10 µl SYBR green master mix, 1 µl 
genomic DNA template (1 ng), 1 µl each of forward and reverse primers (10 µM), and 7 µl of 
DNAse free water. The temperature cycling conditions for all experiments was 50°C for 2 
mins, 95°C for 10 mins, and 40 cycles of 95°C for 15 s, and 65°C (Gardnerella) or 57°C (M. 
curtisii) for 1 min. For each experiment vaginal samples and calibrant bacterial DNA were run in 
triplicates. Fluorescence was measured at the final stage of each cycle and the threshold cycle 
(Ct) obtained. Data obtained were analysed by Sequence Detection Software (version 1.2.2) 
supplied by Applied Biosystems. Final DNA concentration in the samples was extrapolated from 
the equation of the fit line of the standard curve (Fig. 4.2), and compared in relation to delivery 
outcomes. The equation is as follows:  
 
 
 
 
 
 
4.2.4. Bacterial strains and culture conditions 
 
Bacterial strains were grown in different selective media for use as PCR standards/calibrant 
DNA (controls) confirming the quality of bacterial 16S rDNA primers used for amplification. 
The bacteria and their respective culture media are shown in Table 4.2. The organisms were 
cultured in an anaerobic chamber containing a gas mix of 10% CO2, 80% N2 and 10% H2, at 
37ºC for 24-72 h (Gardnerella and Mobiluncus) and 16 hours (Bacteroides and Fusobacterium), 
followed by gram staining to confirm their growth. With confirmation of growth, bacterial DNA 
was isolated using QIAamp DNA mini kit (Qiagen, 51304, UK) and the same procedure as 
applied to the vaginal bacterial DNA. 
 
        y = M log X + B 
Where:  
y = Ct value 
M = Slope 
X = Concentration of bacterial genomic DNA 
B = Y-intercept 
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Table 4.1: Bacterial genus-specific primers, targets, and annealing temperatures  
Primera Sequence (5’-3’) Target Annealing  
temp (ºC) 
Amplicon 
size 
(bp) 
Reference 
LABF 
LABR 
AGAGTTTGATYMTGGCTCAG 
CACCGCTACACATGGAG 
Lactobacillus 62 667 467 
LJ2F 
LJ2R 
GCACGTAGTTAGCCGTGACT 
GAAACAGATGCTAATACCGG 
Lactobacillus 61 ~350 This study 
LBF 
LBR 
ATGGAAGAACACCAGTGGCG 
CAGCACTGAGAGGCGGAAAC 
L. jensenii 
L. crispatus 
50 ~150 471 
FBF 
FBR 
ACTCCTACGGGAGGCAGCAGT 
CGAATTTCACCTCTACACTTGT 
Fusobacterium 60 341 472 
GV1F 
GV3R 
GGAAACGGGTGGTAATGCTGG 
CGAAGCCTAGGTGGGCCATT 
G. vaginalis 65 125 465 
BAC32F 
BAC708R 
AACGCTAGCTACAGGCTT 
CAATCGGAGTTCTTCGTG 
Bacteroides-
Prevotella 
53 676 473 
Sag59 
Sag190 
TTTCACCAGCTGTATTAGAAGTA 
GTTCCCTGAACATTATCTTTGAT 
GBS 55 153 474 
M. curt-440F 
M. curt-
1026R 
TTCTCGCGAAAAAGGCACAG 
CTGGCCCATCTCTGGAACCA 
M. curtisii 57 586 466 
Mobil-577F 
M.mulie-
1026R 
GCTCGTAGGTGGTTCGTCGC 
CCACACCATCTCTGGCATG 
M. mulieris 62 449 466 
Mh1-F 
Mh2-R 
CAATGGCTAATGCCGGATACGC 
GGTACCGTCAGTCTGCAAT 
M. hominis 62 334 471 
GBS, group B Streptococcus. 
a Primers designed to detect the species-specific regions of the 16S rRNA gene. 
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Table 4.2: Bacterial strains and media 
Bacteria species Culture medium DNA conc. 
(ng/µl) 
Bacteroides fragilis 
(NCTC 9343) 
FAA 112 
Fusobacterium nucleatum 
(ATCC 25586) 
FAA 5.3 
Fusobacterium polymorphum 
(ATCC 10953) 
FAA - 
Gardnerella vaginalis 
(NCTC 11292) 
CA and CBA 6.7 
Mobiluncus curtisii 
(NCTC 11656) 
CA, CBA and BHI 3.2 
Streptococcus agalactiaea 
(clinical isolate) 
CBA 3.8 
BHI, Brain heart infusion broth (Oxoid, CM1135, UK) containing 5% horse serum (Oxoid, SR0035C, UK); CA, 
Casman agar (Becton, Dickson and Company, 211106, UK) containing 5% defibrinated sheep blood (Oxoid, 
SR0051B, UK); CBA, Columbia blood agar (Oxoid, CM0331, UK) containing 5% defibrinated sheep blood (Oxoid, 
SR0051B, UK); FAA, Fastidious anaerobe agar (Lab M, LAB090, UK) supplemented with 5% oxalated horse blood 
(Oxoid, SR0049C, UK). 
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4.2.5. Vaginal cytology 
 
To detect the cells present in the vaginal eluate obtained, various staining procedures were also 
performed. This was necessary to provide an insight into the predominant bacterial sp., 
morphology of vaginal epithelial cells and consequently the possible source(s) of the metabolites 
identified in the cervicovaginal fluid. The staining techniques performed include Hematoxylin 
and Eosin (H & E), Papanicolaou (Pap) stains, which stain human cells e.g. vaginal and cervical 
epithelial cells; and Gram stain which stains bacterial cells. 
Gram stain is the gold standard in the diagnosis of BV. It is used to identify vaginal bacteria 
based on morphology.475 The vaginal flora can then be categorised as normal, intermediate, or 
BV.173 It has a sensitivity of 62-100% and a specificity of 79-100%.475 
Pap stain is commonly used in screening women for cervical dysplasia.83 It can also be used for 
detecting clue cells and BV microflora with significantly high sensitivity and specificity.476, 477 
175However, Pap test is not a routine test for the diagnosis of BV.83 
4.2.5.1. Smear preparation 
For Hematoxylin and Eosin (H & E) and Papanicolaou (Pap) stains, a smear of vaginal swab was 
prepared on a clean glass slide and allowed to air dry for 0.5–1 min. The slide was then placed 
in a coplin jar containing 90% alcohol for 1 hr. This was done in order to dehydrate the cells, 
denature the proteins, and dissolve and remove lipids (Fixation). 
4.2.5.2. Hematoxylin and Eosin (H & E) stain 
Hematoxylin is a dark blue basic (positive) stain, that binds to basophilic substances (such 
DNA/RNA - which are acidic and negatively charged), hence staining the nuclei blue/violet. 
Eosin is a red or pink acidic (negative) stain that binds to acidophilic substances (such as 
proteins - which are basic and positively charged) staining them pink. 
The H & E stain was performed on an automatic Leica ST4040 linear staining system (Leica 
biosystems, UK). 
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4.2.5.3. Papanicolaou stain (Pap stain) 
The solutions used for this method include: Harris haematoxylin (stains the nuclei blue), 
Orange G-6 (stains keratin yellow or orange red), Eosin Azure (EA50) (stains the cytoplasm of 
non-keratinized cells blue-green), 0.1% hydrochloric acid in 70% alcohol and Scott’s tap water 
substitute. 
The first part of the procedure was done on the automatic Leica ST4040 linear staining 
machine, from 70% industrial methylated spirit (IMS) to the running tap water bath before the 
eosin. The slide was then removed from the staining machine and rinsed with 95% IMS. This 
was followed by staining with Orange G-6 for 2 mins on the rails across the special stain sink. 
The slides were then rinsed in 95% IMS and stained with EA 50 for 2 mins. The slides were 
then returned to the first dehydrating 99% IMS bath on the staining machine after being rinsed 
in 95% IMS and allowed to proceed to xylene. Finally the slides were mounted and viewed 
under light microscope. 
4.2.5.4. Gram stain 
This staining technique differentiates bacteria by detecting the peptidoglycan (PGN) layer of the 
cell wall. Gram-positive bacteria retain the primary dye (crystal violet) and stain purple (bluish) 
due to their thick PGN layer. While Gram-negative bacteria with thinner PGN layer take up 
the counter stain (carbol fuschin) and appear pinkish. 
10 µl of vaginal fluid sample dissolved in PBS was placed on a glass slide and allowed to air dry 
for 10 mins and then heat fixed. This was to stick the bacterial cells to the glass slide to prevent 
them from being washed away during the following staining process. The staining process 
involved application of a primary stain (crystal violet) for 2 mins after which the slide was rinsed 
with running water. Then the slide was fixed with a mordant (Gram’s iodine) for 2 mins and 
rinsed again with running water. This binds to the primary stain and increases the affinity of the 
bacterial cell wall for the stain. Iodine-acetone (decolourizer) was then added to the slide for 30 
s after which the slide was rinsed again. Finally, a counter stain (Carbol fuschin) was applied for 
2 mins and then rinsed off. The slides were ready for viewing after allowed to dry. 
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4.2.6. Statistical analysis 
All Statistical analyses were performed using GraphPad Prism 6.0c (GraphPad Software, Inc. 
CA). The Wilcoxon’s rank-sum test was performed to compare differences in bacterial DNA 
concentration within the groups. For the qualitative PCR, The chi-square test alongside a 
benchmark of ≥10% was then applied to determine any differences in prevalence of vaginal 
bacterial species based on delivery outcome. P values < 0.05 were considered statistically 
significant. 
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4.3. Results 
4.3.1. PCR confirmation of vaginal bacterial species 
Two hundred and eighteen vaginal fluid samples from 181 pregnant women across the second 
and third trimesters classified into 4 groups were analysed: SYM (n = 80, preterm = 14, term = 
66); AHR(20-22w) (n = 50, preterm = 19, term = 31); AHR(26-28w) (n = 37, preterm = 17, 
term = 20); and ALR (n = 51, preterm = 5, term = 46). PCR amplification of vaginal bacterial 
16S rRNA genes from these participants revealed the presence of both commensal (e.g. 
Lactobacillus sp.) and potentially pathogenic anaerobic bacterial organisms (Table 4.3). These 
bacterial organisms were chosen for analysis because they are normal endogenous vaginal 
organisms only becoming virulent when there is a distortion in the vaginal ecosystem. A 
representative picture of bacterial DNA bands observed on agarose gel is shown in Fig. 4.1. As 
presented in Table 4.4., qualitative assessment of vaginal microbial composition in the SYM 
group indicated higher prevalence of Fusobacterium sp., M. mulieris and M hominis in the 
preterm-delivered women, except for M. curtisii (P < 0.0001).  
Similar trends were observed in the AHR (26-28w) group, where the preterm-delivered 
women showed a higher prevalence of Fusobacterium sp., Bacteroides sp., M. curtisii, M. mulieris 
and M. hominis (P < 0.0001).  
There were no significant differences observed in the AHR (20-22w) group except for M. 
mulieris and M. hominis (P = 0.006). However, in the ALR group, the term-delivered women 
showed higher prevalence of Fusobacterium sp., Gardnerella, M. curtisii, M. mulieris and M hominis 
compared to the preterm-delivered women, except for Bacteroides sp. (P < 0.001). Only 
1.5%(1/66) and 5%(1/20) of the term-delivered women in the SYM and AHR(26-28w) groups 
respectively, had positive results of group B Streptococcus. Group B Streptococcus was not 
observed in any preterm-delivered woman across the groups. At least one specie of 
Lactobacillus which is commensal to the host was identified in all vaginal samples analysed. 
Comparing the prevalence of the different bacteria species in the vaginal microbiome of 
asymptomatic women studied at 20-22w, i.e. ALR vs. AHR (20-22w), we observed that there 
were significant differences between the preterm-delivered women in these groups. The 
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preterm-delivered women in the AHR(20-22w) group had higher prevalence (P < 0.0001) of 
Gardnerella (100%(19/19) vs. 60%(3/5)), Fusobacterium sp. (16%(3/19) vs. 0%(0/5)); and M hominis 
(11%(2/19) vs. 0%(0/5)), but lower prevalence of Bacteroides sp. (16%(3/19) vs. 40%(2/5); 
compared to the preterm-delivered women in the ALR group.  The term-delivered women did 
not show any significant differences (Table 4.3 and 4.4). In the women that delivered preterm, 
the prevalence of Gardnerella, Fusobacterium sp., and M hominis was higher in the AHR (20-22w), 
than the ALR group.  
A similar comparison was made for the asymptomatic high risk women studied at two 
gestations i.e. AHR (20-22w) vs. AHR (26-28w). Again, the term-delivered women in these 
groups did not show any significant differences. However, the preterm-delivered women in the 
AHR (26-28w) group had higher prevalence (P = 0.007) of Fusobacterium sp. (41%(7/17) vs. 
16%(3/19); Bacteroides sp. (71%(12/17) vs. 16%(3/19)); and M. mulieris (29%(5/17) vs. 0%(0/19). 
The prevalence of Fusobacterium sp., Bacteroides sp., and M. mulieris increased with gestation in 
the preterm-delivered asymptomatic high risk women (Table 4.3). 
Also, we observed that compared to preterm-delivered women in other groups, the preterm-
delivered women in the SYM cohort had the greatest prevalence of M. hominis (SYM: 29% vs. 
AHR (26-28w): 6% vs. AHR (20-22w): 11% vs. ALR: 0%). 
When the groups were analysed as a whole (preterm vs. term), we observed a higher 
prevalence of Fusobacterium sp. (25%(14/55) vs. 11%(18/163)); Bacteroides sp. (45%(25/55) vs. 
34%(56/163)); M. mulieris (15%(8/55) vs. 6%(9/163)); and M hominis (13%(7/55) vs. 5%(8/163)) (P 
< 0.01), although the differences in the prevalence of M. mulieris and M. hominis were less than 
10% but ≥8%. The prevalence of Lactobacillus sp. and Gardnerella were similar in both groups, 
while only 1%(2/163) of the term women had group B Streptococcus positive vaginal fluid 
samples. 
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Figure 4.1. Presence of bacterial species in vaginal fluid of pregnant women. Bacterial genomic DNA 
bands visualized on a UV-transilluminator by agarose gel electrophoresis :  1) Lactobacillus sp., 2) L. jensenii, 3) L. 
jensenii and/or L. crispatus, 4) Fusobacterium sp., 5) G. vaginalis, 6) Bacteroides-Prevotella sp., 7) Mobiluncus cutisii, 8) 
Mycoplasma hominis. Bacterial DNA standards used as positive controls: a) Fusobacterium nucleatum (ATCC 25586), 
b) Gardnerella vaginalis (NCTC 11292), c) Bacteroides fragilis (NCTC 9343), d) Streptococcus agalactiaea (clinical 
isolate), e) Mobiluncus curtisii (NCTC 11656).  
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     Table 4.3: Prevalence of endogenous vaginal bacterial species identified by PCR 
       a Commensal bacterial sp. 
       b Potentially pathogenic bacterial sp. associated with abnormal vaginal microflora, infection and PTB. 
      * Differences in the prevalence of bacterial sp.  between term and preterm-delivered women ≥10%. 
    GBS, group B Streptococcus. 
 
 
 
 
 
 
 
 
 
 
 
Bacterial 
sp., % 
Asymptomatic 
Low risk women, 
20-22w 
Asymptomatic 
High risk 
women, 
20-22w 
Asymptomatic 
High risk 
women, 
26-28w 
Symptomatic 
women 
24-36w 
Preterm 
N=5 
Term 
N=46 
Preterm 
N=19 
Term 
N=31 
Preterm 
N=17 
Term 
N=20 
Preterm 
N=14 
Term 
N=66 
Lactobacillus 
sp.a 
100 100 100 100 100 100 100 100 
L. crispatusa 
L. jensenii 
100 100 95 97 100* 90 100 99 
Fusobacterium 
sp.b 
0 13* 16 16 41* 10 29* 8 
Gardnerella 
vaginalisb 
60 96* 100 94 77 82 86 82 
Bacteroides-
Prevotellab 
40* 26 16 23 71* 25 57 49 
GBSb 0 0 0 0 0 5 0 2 
Mobiluncus 
curtisiib 
0 30* 26 29 29* 20 21 33* 
Mobiluncus 
mulierisb 
0 9 0 3 29* 10 21* 3 
Mycoplasma 
hominisb 
0 2 11 3 6 0 29* 9 
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Table 4.4: Differences in prevalence of vaginal bacterial species 
Symptomatic women 24-36w 
 
Fusobacterium 
sp., %(n) 
Mobiluncus 
curtisii, %(n) 
Mobiluncus 
mulieris, %(n) 
Mycoplasma hominis, 
%(n) 
P value 
Preterm, 
N=14 
29(4) 21(3) 29(4) 21(3) 
<0.0001 
Term, N=66 8(5) 8(2) 9(6) 33(22) 
Asymptomatic High risk women, 26-28w 
 
Fusobacterium 
sp., %(n) 
Bacteroides-
Prevotella, 
%(n) 
Mobiluncus 
curtisii, 
%(n) 
Mobiluncus 
mulieris, %(n) 
Mycoplasma 
hominis, %(n) 
P value 
Preterm, 
N=17 
41(7) 71(12) 29(5) 29(5) 6(1) 
<0.0001 
Term, 
N=20 
10(2) 25(5) 20(4) 10(2) 0(20) 
Asymptomatic High risk women, 20-22w 
 
 
Mobiluncus mulieris, 
%(n) 
 
Mycoplasma hominis, %(n) 
 
P value 
Preterm, 
N=19 
0(0) 11(2) 
<0.006 
Term, N=31 3(1) 3(1) 
Asymptomatic Low risk women, 20-22w 
 
Fusobacterium 
sp. 
%(n) 
Gardnerella 
vaginalis 
%(n) 
Mobiluncus 
curtisii 
%(n) 
Mobiluncus 
mulieris 
%(n) 
Mycoplasma 
hominis 
%(n) 
Bacteroides-
Prevotella 
%(n) 
P value 
Preterm, 
N=5 
0(5) 60(3) 0(5) 0(5) 0(5) 40(2) 
<0.001 
Term, 
N=46 
13(6) 96(44) 30(14) 9(4) 26(12) 26(12) 
N, total number of term- or preterm-delivered women in each cohort; n, subset of women habouring the bacterial 
sp. in either the term- or preterm-delivered women. P, significance level. 
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4.3.2. Relationship between bacterial DNA quantity and delivery outcome 
In addition to determining the prevalence of identified commensal and potentially pathogenic 
vaginal bacteria in the vaginal fluid samples in each cohort, there was the need to ascertain any 
differences in the relative abundance of these bacterial species in relation to delivery outcome. 
This is more advantageous than the standard PCR as it does not only detect the presence of 
bacterial species but also provides an idea of the predominant specie(s) in the vagina microflora 
in relation to others at a particular time which can be used to ascertain the health status of the 
vaginal milieu and by extension the host. It indicates the relative quantity and not just the 
presence of the organisms. It can also be used to calculate the number of bacterial cells in a 
given sample.82 This can also influence the type of treatment or intervention (if any) required. 
For example, the particular species of BVAB can be identified and its susceptibility to the 
antibiotic agent of choice is ascertained before administration.82 However resolution to the 
species level is challenging as more than one specie in a genus can share similar genetic 
sequence in the amplified region.82 To this end, a subset of randomly selected CVF samples 
across the groups: SYM (term = 11, preterm = 11); AHR(20-22w) (term = 12, preterm = 12); 
AHR(26-28w) (term = 12, preterm = 12), were analysed for the DNA quantity of 2 known BV- 
and PTB-associated bacterial species (Gardnerella and M. curtisii). This was due to the relatively 
low numbers of women with preterm deliveries across the groups and the finite resources 
available. After a quality control process i.e. removal of sample replicates with differences in Ct 
values > 1, the sample size reduced to as follows: SYM (G. vaginalis: term = 11, preterm = 9; M. 
curtisii: term = 7, preterm = 8); AHR(20-22w) (G. vaginalis: term = 7, preterm = 6; M. curtisii: 
term = 10, preterm = 10); AHR(26-28w) (G. vaginalis: term = 9, preterm = 6; M. curtisii: term = 
9, preterm = 7). Samples from participants in the ALR were not included in these experiments 
because of the very few numbers of preterm deliveries (n = 5), recorded in this group which 
occurred after the analysis were concluded. 
Comparison of DNA quantity between term- and preterm-delivered women within the various 
cohorts did not indicate any statistically significant difference in relation to either Gardnerella or 
M. curtisii except in the AHR(20-22w) group. In this group, the term-delivered women had 
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significantly higher (4-fold) amounts of M. curtisii DNA compared to their preterm counterparts 
(P = 0.0001) (Fig. 4.3). 
Also, a comparison of the abundance of Gardnerella and M. curtisii DNA in the vaginal samples of 
term- and preterm-delivered women in all groups considered together indicated a significant 
difference in the amount of M. curtisii DNA, but not for G. vaginalis (Fig. 4.3). This is somewhat 
consistent with data obtained using the standard PCR. From our data, it is noteworthy that G. 
vaginalis DNA constituted about a quarter of total quantity of DNA in the samples and was 
about 100 – 1500 times more than M. curtisii DNA. Gardnerella also showed a non-significant 
trend to higher amounts in the term-delivered women across the groups (Fig 4.3).  
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A. 
 
B. 
 
Figure 4.2. Real-time PCR standard calibration curve for (A) G. vaginalis and (B) M. curtisii. The Log 
[DNA] (quantity of bacterial 16S rDNA) is plotted against the number of cycles at which the fluorescence (positive 
signal) exceeds the threshold (threshold cycle or Ct). Both vaginal samples and calibrant bacterial 16S rDNA were 
run in triplicates. Similar results were obtained for each cohort and a total of 12 independent thermocycler runs 
were performed. 
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Figure 4.3. Comparison of the relative abundance of 16S rDNA of G. vaginalis and M. curtisii in 
vaginal fluid samples of different cohorts of pregnant women sampled at various gestational time 
points. Data are presented as median ± quartile range. 
AHR, Asymptomatic high risk pregnant women 
SYM, Symptomatic pregnant women 
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4.3.3. Cellular composition of vaginal fluid samples 
In order to identify the cellular composition of the vaginal milieu of the study cohorts various 
staining procedures were also performed. This was necessary to provide an insight to the 
predominant bacterial sp., morphology of cervicovaginal epithelial cells and consequently the 
potential source(s) of the metabolites identified in the CVF. The metabolite profile of the CVF 
is a function of both host and microbial activities.38 Representative vaginal smear micrographs 
obtained from randomly selected samples (n = 14) are shown in Fig. 4.4-4.6. Both host vaginal 
epithelial and bacterial cells were identified in the vaginal fluid samples across the various 
gestational time points studied. No abnormal cells (e.g. clue cells, cancerous cells etc.) were 
identified giving credence to the strict exclusion criteria applied during participants’ 
recruitment. This provides insight to the source(s) of the metabolites observed. For instance 
gram-positive rods indicative of Lactobacillus morphotypes, as well as Gram-negative and Gram-
variable organisms representative of Gardnerella, Bacteroides and Mobiluncus morphotypes were 
identified (Fig. 4.6). Furthermore, H&E and Pap staining revealed the presence of normal vaginal 
squamous epithelial cells and some bacterial cells particularly of Lactobacillus morphology (Fig. 
4.4-4.5). 
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Figure 4.4. Vaginal fluid smears (x100) of pregnant women stained by Hematoxylin and Eosin (H & 
E) at 20-22 weeks (A-D), 26-28 weeks (E-F). L, Lactobacillus morphotype; sq, vaginal squamous epithelial cells. 
Scale bar = 20 μm for all pictures. 
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Figure 4.5. Vaginal fluid smears (x100) of pregnant women stained by Papanicolaou stain (Pap   
stain) at 20-22 weeks (A-B), and 33 weeks (C-F). L, Lactobacillus morphotype; sq, vaginal squamous epithelial 
cells. Scale bar = 20 μm for all pictures. 
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Figure 4.6. Vaginal fluid smears (x100) of pregnant women stained by Gram stain at 20-22 weeks (A-
C), and 26-28 weeks (D-E). L, Lactobacillus morphotype (large Gram-positive rods); g, Gardnerella morphotype 
(small Gram-variable cocci); n, Gram-negative rods (Bacteroides morphotype). Scale bar = 20 μm for all pictures. 
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4.4. Discussion 
 
In this chapter we present PCR and vaginal cytology data of different cohorts of pregnant 
women studied at different gestational time points and classified into 2 broad categories i.e. 
asymptomatic women and women presenting with symptoms of preterm labour. The former 
who were studied at 20-22w, were further subdivided into low and high risk group based on a 
previous history of preterm birth. A subset of the high risk women were studied again at 26-
28w. In all, the vaginal fluid samples of 4 groups of pregnant women were analysed. All women 
presented with intact membranes and no clinical signs of genital infection. We then analysed the 
prevalence and relative abundance of specific vaginal endogenous bacterial species in these 
participants using standard and real-time PCR techniques and also detected various cell types 
present in the vaginal specimens obtained. This was in order to identify the potential source(s) 
of the metabolites observed in the vaginal fluid of these women (Chapters 2 and 3). 
The composition of vaginal microbiota in both pregnant and non-pregnant women at any given 
time is indicative of the health status of the host and is critical to the prevention of several 
urogenital diseases and adverse delivery outcome.6, 21, 65, 74, 118, 212, 295 The vaginal microbiota has 
been classified into 5 major CSTs based on the dominant bacterial species. Four of the CSTs 
are dominated by Lactobacillus sp. while the fifth is comprised of higher proportions of mixed 
anaerobes and lower amounts of Lactobacillus sp. and other lactate producers.21 The vaginal 
microbiota in health is said to be predominated by commensal Lactobacillus sp. and more stable 
in pregnant compared with non-pregnant women.74 While some researchers have identified a 
strong association between vaginal bacterial community dominated by mixed anaerobes (CST 
IV) and preterm birth,75 others argue that the vaginal microbiota of women who deliver 
preterm does not differ from those that deliver at term,6 and that the presence of little or no 
Lactobacillus sp. is not associated with preterm birth.266 This is perhaps because preterm birth is 
regarded as a syndrome with many causative factors.212 In addition to 16S rRNA gene 
quantification and sequencing as employed in most of these investigations, evaluation of the risk 
of preterm birth may require assessment of the host-microbial interactions as well as metabolic 
or biochemical activities of both the host cells and microbial population.6, 478 In line with these 
assertions, we have employed a more comprehensive approach involving metabolomics, PCR, 
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and cytology to elucidate probable differences in vaginal microbiota composition between term- 
and preterm-delivered pregnant women. In addition, other members of our group have 
characterised the vaginal microbiome by bacterial 16S gene sequencing. Although the data are 
not presented in this report, 5 Community state types (CSTs), similar to those of previous 
studies21, 65, 75, 277, 295 were identified and related to delivery outcomes. 
In relation to PCR analysis, several studies have detected the presence of both commensal and 
potentially pathogenic bacterial organisms in vaginal specimens.118, 465, 479 The presence in high 
amounts of anaerobic bacterial species has been associated with unhealthy vaginal microflora, 
infection and adverse pregnancy outcomes.465, 469, 480-482 This in conjunction with clinical diagnosis 
is highly reproducible480 and has been advocated to be more sensitive and advantageous than 
Gram staining.471, 483 Both cultivated and culture-insensitive bacteria have been detected using 
this method ultimately determining their relationship with preterm birth.469 It is also a useful 
technique in elucidating the structure and composition of the vaginal microecosystem in health 
and disease.465, 471, 484 The above reasons necessitated our application of targeted PCR 
amplification of specific bacterial species as well as quantitative PCR to elucidate the microbial 
structure and composition of the vagina in pregnant women to identify those at higher risk of 
preterm delivery. The targeted PCR showed a higher prevalence of mixed anaerobes in 
preterm-delivered women compared to their term counterparts, whilst quantification of the 
DNA revealed a higher amount of M. curtisii in the term-delivered women, but no significant 
differences in G. vaginalis in relation to delivery outcome. The association between the 
prevalence of mixed anaerobes in the vagina during gestation and eventual preterm delivery 
supportive of our data has been reported.5, 7, 111, 160 Some have even implicated uncultured 
bacteria species.266 However, there have been contrasting views arguing that the vaginal 
microbiome between term- and preterm-delivered women does not differ.6 
In the asymptomatic low risk pregnant women, we observed that Fusobacterium, Gardnerella, M. 
curtisii and to a lesser degree M. mulieris were more prevalent in the women who delivered at 
term compared to the women with preterm deliveries. In fact none of the 5 preterm-delivered 
women in this group had positive results of Fusobacterium, M. curtisii, M. mulieris and M. hominis. 
These findings in asymptomatic women at low risk of preterm birth differ from the established 
link between the prevalence of vaginal mixed anaerobic bacteria and preterm delivery.82, 469, 485 
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The relatively few preterm deliveries recorded in this cohort could account for this disparity. 
However, in spite of the convincing link between BV and preterm birth, a considerable number 
of women with high amounts of BV-associated organisms still deliver at term.469 Some studies 
were even unable to establish any difference in vaginal microbiome between women who 
deliver preterm and term.6 Interestingly, consistent with the association of BV-related 
organisms and preterm birth, Bacteroides sp. another obligate anaerobe was detected in higher 
proportions in the preterm-delivered women compared to their term counterparts. 
Unfortunately, due to finite resources, duration of this research and the relatively lower 
number of women with positive results across the groups, it could not be further quantified and 
the more prevalent G. vaginalis and M. curtisii were chosen instead. With the contrasting data 
obtained from this cohort, it is plausible that the link between the prevalence of mixed 
anaerobes in the vagina during pregnancy and preterm delivery in women at low or undefined 
risk of preterm birth is contestable. This warrants further investigation 
Consistent with our data in the asymptomatic high risk participants studied at 20-22w, the 
presence of M. hominis (a facultative anaerobe) is associated with increased risk of preterm 
birth.82 However, racial/ethnic modifications suggest that the association between Mycoplasma 
and preterm birth may not be causal, but an indication of the presence of cofactors that can 
cause preterm birth.160, 193 Though our study population involved predominantly Caucasians, our 
observations in the subset of these women studied at later gestation (26-28w) were consistent 
with the established association of higher prevalence of facultative and obligate anaerobic 
bacterial species with preterm birth. The preterm-delivered women in this group showed 
significantly higher prevalence of Fusobacterium, Bacteroides, Mobiluncus and Mycoplasma species 
compared to their term counterparts. Whether the prevalence of these organisms change with 
gestation warrants further investigation. Pro tem, this is thought-provoking as these differences 
are seen despite the influence of the treatment interventions administered to a considerable 
number of these women (Chapter 5). This challenge the therapeutic accuracy of current 
treatments (especially antibiotics) routinely employed in the prevention of preterm births. 
Similar to the data observed in the asymptomatic high risk women studied at 26-28w, the 
women presenting at the labour ward with symptoms of preterm labour who eventually 
delivered preterm showed significantly higher prevalence of Fusobacterium, M. mulieris and M. 
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hominis, compared to their term counterparts. In contrast, M. curtisii was more prevalent in the 
term-delivered women, similar to the observations in the asymptomatic low risk women 
sampled at 20-22w. A similar trend was seen in the asymptomatic high risk women (20-22w), 
though not statistically significant. When compared to women in the other groups who also 
delivered preterm, the women who presented with symptoms of threatened PTL and 
eventually delivered preterm had a higher prevalence of M. hominis. Significant prevalence of M. 
hominis and subsequent reduction in preterm birth rate after treatment with antibiotics has 
been recorded in symptomatic pregnant women.486 Its impact alongside U. urealyticum has been 
associated with adverse delivery outcomes.153, 486 Independently, these organisms may not be 
able to cause sufficient pathology. However, acting synergistically with other BVAB or 
incompetent cervix, they can initiate significant inflammatory process leading to preterm labour 
and delivery.153 This may be responsible for the high incidence of preterm birth observed in the 
symptomatic women in our study.  
In the asymptomatic women, we observed an increase in the prevalence of anaerobic bacteria 
species in relation to risk of preterm birth and gestational age at sampling in those women who 
eventually delivered preterm. The prevalence of Gardnerella, Fusobacterium and M. homins was 
low in the low-risk women compared to the high-risk women. In the high-risk preterm-
delivered women, the prevalence of Fusobacterium, Bacteroides and M. mulieris increased 
between 20-22w (mid second trimester), and 26-28w (late second trimester). The low 
prevalence of mixed anaerobes in the low risk women is not surprising and could be a reason 
for the relatively low incidence of preterm birth (10%) recorded in this group. Though the 
normal vaginal microbiome is increasingly stable as pregnancy progresses with Lactobacillus sp. 
being predominant,74 the increased prevalence of some anaerobes associated with adverse 
pregnancy outcome between the mid and late second trimester, and the associated increase in 
the preterm birth rate (AHR 20-22w: 38% vs. AHR 26-28w: 46%), observed in our study is 
interesting. Even with the vaginal microbiome stability observed during pregnancy, transitions 
between community state types dominated by different species of Lactobacillus have been 
recorded.74 More so, L. iners have been reported to confer lesser protection/stability compared 
to L. crispatus and L. jensenii, hence, its association with the presence of BVAB.111 In the event of 
a transition from an L. crispatus or L. jensenii-dominated CST to that dominated by L. iners, an 
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environment suitable for the growth and proliferation of mixed anaerobes may be 
established.111 This could be the case in the asymptomatic high risk women in our study. 
Determination of the relative abundance of these species in these women by amplifying and 
sequencing the 16S rRNA gene could further delineate any differences in relation to delivery 
outcome.   
With the observed inconsistencies in our data, we further analysed our study population as a 
whole classifying them into 2 groups in relation to delivery outcome (i.e. preterm vs. term). The 
results indicated that only Fusobacterium sp., Bacteroides sp., M. mulieris and M. hominis were 
significantly associated with preterm birth, while M. curtisii was seen in more term-delivered 
women, although this did not reach statistical significance. High prevalence of Lactobacillus sp. 
and Gardnerella were observed and were similar irrespective of delivery outcome, while only 
1%(2/163) of the participants had group B Streptococcus. The insignificant levels of group B 
Streptococcus in our cohorts was not unexpected as only 25% of women in the general 
population harbour this bacteria vaginally.487 
With the plethora of evidence that it is not just the presence or absence of, but the relative 
quantities (abundance) of bacteria that is related to the risk of preterm birth,168 we conducted 
further analysis of the relative abundance of Gardnerella and M. curtisii using real-time PCR. 
There was no statistically significant difference in the abundance of G. vaginalis in the CVF 
specimens of both term- and preterm-delivered women in all the cohorts when analysed 
individually and as a whole, despite the non-significant trend to greater abundance in the term-
delivered women.  This is in accordance with our previous observation and could be attributed 
to the very low incidence of BV in our study cohort (due to exclusion) and the narrow racial 
mix - mainly Caucasian, but it is a shift from the widely reported association of G. vaginalis with 
BV and adverse pregnancy outcome.481, 482, 488-490 Nevertheless, using the same method as applied 
in our study, Vitali et al. reported that the amount of G. vaginalis does not vary significantly in 
healthy and BV-infected women.439 More so, others have opined that G. vaginalis does not differ 
in relation to delivery outcome as it is commonly isolated from women with normal vaginal 
microflora.81, 475 274, 491 G. vaginalis has also been detected in more healthy samples compared to 
any other non-Lactobacillus sp.465 It is often cultured from women regardless of infection (e.g. 
BV) status.492 In fact, it is found in almost 100% of healthy women.465 In addition, Fredricks et 
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al.466 demonstrated that G. vaginalis amidst other organisms, was one of the most frequently 
identified bacteria in subjects without BV. Besides, no single bacterium has been implicated as 
the sole cause of BV,467 hence it has been regarded as a microbiological and immunological 
conundrum.36, 38, 493, 494Whether Gardnerella alone in the absence of other BVAB can initiate PTL 
and PTB is still a subject of controversy. The heterogeneity of this infection, synergistic effects 
of diverse Gram-negative and Gram-variable anaerobes and host immune response in relation 
to infection and consequent sequelae is still of great value.12, 36, 97, 103, 104, 495 
Using primers with high sensitivity (56%) and specificity (93%),466 we were able to quantify M. 
curtisii genomic DNA from CVF samples of both asymptomatic and symptomatic pregnant 
women. Though M. curtisii has been exclusively recovered from women who deliver preterm,496 
our data revealed otherwise especially in the asymptomatic high risk pregnant women studied 
at 20-22w. The presence and persistence of this organism has also been shown in recurrent 
BV,479 and attributed to its resistance to metronidazole treatment.497 In contrast, its presence in 
the vagina was earlier described to be highly specific but not sensitive for the diagnosis of BV.498, 
499 Again, although it is usually isolated from women with BV, it is more common in healthy 
women than previously suspected.500 This may explain the higher abundance of M. curtisii in the 
asymptomatic high risk women who delivered at term in particular and the term-delivered 
women on the whole compared to the preterm-delivered women in this study.  
Another possible reason for this variation could be the low incidence of BV and other genital 
infection in our study cohorts as women with proven genital infection were excluded from the 
study. Besides, this supports the inability of some investigators to identify a link between the 
presence of noxious vaginal bacterial species and premature birth.266 Also, the effect of the 
antibiotics treatment administered in those women who were diagnosed with BV or other 
infection in later gestation (after inclusion), alongside other routine preterm birth prevention 
therapies is suspected. Additionally, variations in host immune response to female genital tract 
colonisation by bacterial organisms in relation to adverse delivery outcome, and not just the 
presence of these organisms have been documented.82, 256 Risk of preterm birth is modified by 
maternal genetic composition, epigenetics and immune response to altered vaginal microflora 
during gestation.166, 167, 243, 245, 501, 502 Also, the relatively small sample size analysed, differences in 
the concentration of extracted DNA (range = 1-617 ng/µl), could be co-factors capable of 
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influencing our observations. Though the amount of genomic DNA per PCR mix (5 ng/µl), was 
normalised to correct for any inter-individual variations, our unique observations may be due to 
the disparity in quantity of extracted DNA from each participants. Molecular characterisation 
using high fidelity specie-specific primers and 16S gene sequencing is required to holistically 
describe and quantify the vaginal bacterial species associated with health and disease. A 
multiplex PCR approach which involves the amplification of multiple different DNA 
simultaneously can be applied in the assessment of the vaginal microbiome in relation to disease 
burden.468 It uses multiple optimised primers and a temperature-mediated DNA polymerase to 
amplify several DNA of interest in a single experiment and has being employed in the diagnosis 
of common genital infections with great success.468 Applying this technique, we could 
simultaneously amplify more bacterial DNA associated with dysbiosis and adverse pregnancy 
outcome including Bacteroides, which we were unable to analyse further despite its higher 
prevalence in the preterm-delivered women in this study.  Also, because specie level 
differentiation of microorganisms is usually difficult using qPCR, 16S gene sequencing and 
classification of vaginal bacterial species in to CSTs could provide a more lucid picture of the 
microbiota with greater diagnostic utility.  
Our study of the vaginal fluid of pregnant women also permitted us to examine the vaginal 
cytology of the study participants. This was done because Gram staining alone or in 
combination with Nugent criteria identifies women with BV infection.38 In all the samples 
analysed, we observed the presence of squamous epithelial cells characteristic of the normal 
vaginal epithelium. Gram-staining demonstrated the presence of numerous long Gram-positive 
rods characteristic of Lactobacilli morphotypes as wells as Gram-negative and Gram-variable 
short rods and cocci characteristic of Gardnerella, Bacteroides and Mobiluncus morphotypes as 
amplified earlier using PCR techniques (Fig. 4.6). No abnormal human cells (e.g. clue cells, 
cancerous cells etc.), or differences in cytology between and within the groups were identified 
giving credence to the strict exclusion criteria applied during participants’ recruitment i.e. 
women with clinically proven genital infection (e.g. BV) and/or abnormal cervical cytology were 
excluded from the study. This observation provides an insight to the potential source(s) of the 
metabolites observed. The presence of host epithelial cells in the samples is suggestive that 
some of the metabolites identified (Chapters 2 and 3), could originate from these cells. This is 
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because; the metabolite profile of the CVF is a representation of both host and microbial 
factors.38 Also, it is not just the presence of these cells but their relative abundance and level of 
metabolic by-products that are capable of influencing delivery outcome.1 The metabolic profile 
of the vaginal environment at any given instance could be a manifestation of the metabolic 
activities of both the host epithelium and microbial cells. For instance, D-lactate is almost 
exclusively of bacterial origin, while the vaginal epithelial cells like other human cells, L. iners and 
other lactic acid-producing bacteria produce L-lactate.449 D-lactate produced by L. crispatus, L. 
jensenii and L. gasseri enhances protection against microbial invasion of the upper genital tract, 
reduce MMP-8 levels via its inducer (EMMPRIN), and prevents the degradation of the cervix and 
fetal membrane rupture.114, 196 In this study we were unable to differentiate D/L optical isomers 
of lactic acid. An in-depth study of the prevailing vaginal host-microbial cellular composition in 
relation to L/D-lactate ratios and other metabolites in pregnant women sampled at various 
gestational time points could further improve our understanding of the pathogenesis of preterm 
birth. In addition, the microscopic examination of vaginal specimen by the Gram staining 
method is based on the relative abundance of bacterial morphotypes, but it does not distinguish 
the different bacterial species. However, the proportion of different bacterial species in a 
vaginal specimen can be predictive of normal or abnormal microflora. For instance, L. crispatus is 
observed mainly in females with healthy vaginal microflora, while L. iners is found both in healthy 
and abnormal vaginal microflora.97, 465, 470 Using qPCR, these organisms can be quantified and 
compared in relation to the amount of their metabolic by-products. Furthermore, because 
certain fastidious or unculturable bacterial cells may have been omitted by the methods applied 
in this study, analysis with high throughput cytogenetic techniques such as Fluorescence in situ 
hybridization (FISH) may better resolve the structural composition of the vaginal ecology in 
health and disease e.g. FISH can determine the localisation or distribution of specific bacterial 
species in the vaginal microbial ecology.  
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Chapter 5 
 
Association of Cervicovaginal fluid metabolites with fetal fibronectin, cervical 
length, and gestational age at delivery 
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5.1. Introduction 
 
Putatively the most widely used clinical test in prognosticating PTB within 7–14 days especially 
in symptomatic women is FFN. This is due largely to its high NPV.313, 315, 316 Its predictive utility 
has also been investigated in asymptomatic women, although not as effective as in the 
symptomatic women.313 FFN is a glycoprotein produced by cells of the fetal membrane located 
in the feto-maternal interface, binding the fetal membranes to the decidua.201, 304 In normal 
pregnancies, FFN is present in insignificant amounts in CVF in early mid trimester (16–22 
weeks). Between 22-34 weeks gestation, detection of FFN at levels ≥50 ng/ml is suggestive of 
membrane activation and premature separation of the fetal membranes from the uterine lining 
and associated with an increased risk of spontaneous PTB.201, 304,309 
Although, the detection of FFN in the CVF is currently the most effective marker of PTB 
especially in women with threatened PTL, and one of the best risk assessment markers for PTB 
in all populations,303, 305 it has low sensitivity and PPV especially in asymptomatic women. Its 
applicability is also affected by common factors such as unprotected vaginal intercourse before 
testing, recent vaginal digital examination, vaginal bleeding and contamination with amniotic fluid 
from ruptured membranes leading to a false positive result.303 
Another widely used clinical assessment tool for the prediction of PTB is ultrasonographic 
measurement of cervical length (CL).303, 367 It is a simple and reliable method of objectively 
evaluating the integrity of the cervix and dilation of the internal cervical os with minimal patient 
discomfort.407 The length of the cervix during pregnancy is inversely correlated with the risk of 
spontaneous PTB, though there is no consensus as to the threshold CL at which such risk 
becomes significant.303, 367 In asymptomatic women, a CL <25 mm at <24 weeks is associated 
with PTB (< 35 weeks), with LR+ of 2.8-6.3. Various CL threshold values (25-35 mm) predicted 
PTB with 33-55% sensitivity and 73-100% specificity.303 However, in asymptomatic women at 
low risk for PTB, its low sensitivity has posed some constraints to its utility as a 
routine/universal screening tool.303, 398  
In symptomatic women, CL <25 mm (24-36 weeks) had PPV, NPV and specificity of 24%, 97% 
and 71% respectively.329 Also, in high risk symptomatic women, a CL threshold value of 30 mm 
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(26-34 weeks) produced 72% sensitivity, 100% specificity, 100% PPV and 70% NPV.354 Despite 
its predictive potential in symptomatic women, evaluation of CL did not significantly reduce the 
incidence of PTB (< 37 weeks), and as a result routine screening was not recommended.395 
An association between a short cervix and intrauterine infection i.e. microbial invasion of the 
amniotic cavity, and intra-amniotic inflammation have been identified. This is due to 
chorioamnionitis-stimulated cervical shortening or an already shortened cervix permitting 
ascending genital tract infection,407 ultimately leading to PTL and spontaneous PTB. Intrauterine 
infection and the subsequent inflammatory processes that ensue can also disrupt the fetal 
membranes with a concomitant leakage of FFN into the cervicovaginal space.199 
Ultrasound CL, like FFN, has enhanced the prediction of PTB, nonetheless, there is a 
considerable high rate of false positive results as most women with short cervix (< 25 mm), still 
go on to deliver at term.503 More recently, combining CL and FFN screening in asymptomatic320, 
321 and symptomatic women302, 322-324 compared to either of these tests alone, results in an 
improved discriminative and predictive ability for risk of PTB.  This aids the decision making 
process during management and reduces unnecessary interventions particularly in low risk or 
unknown risk population.302  
Considering the obvious deficiencies of FFN and ultrasound CL, and the awareness that these 2 
biomarkers of PTB, as well as changes in vaginal pH are associated with ascending intrauterine 
infection which can be detected by CVF metabolite profiling, in this chapter we sought to: 1) 
examine the relationship between FFN, CL, vaginal pH and 1H-MR CVF metabolites, and 2) 
Combine the predictive abilities of these biomarkers to determine whether the prediction of 
PTB could be improved.  
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5.2. Methods 
5.2.1. Study participants 
As enumerated in chapter 2 of this report, the study participants comprised of the same clinical 
cohorts of pregnant women (N = 458), recruited via the antenatal clinics and Triage Delivery 
Suites of the Jessop Wing Hospital, Sheffield, UK: those that had no symptoms of PTL 
(asymptomatic group) and those presenting to the delivery suite with symptoms of, but not 
established, PTL. The asymptomatic pregnant women were further classified into 2 
gestationally-matched groups based on a prior PTB: a low-risk group (ALR, n = 183), who had 
no prior PTB (assessed at 20-22 gestational weeks, w), and a high-risk group (AHR, n =186), 
who had at least 1 prior PTB and/or short cervix (< 25 mm) on transvaginal ultrasonography 
(assessed at 20-22w and repeated at 26-28w). The third study group (SYM, n = 89) comprised 
women presenting with uterine contractions, cervix < 3cm dilated, and intact fetal membranes 
(24-36w). The clinical characteristics of the study participants are represented in Table 2.1 
(Chapter 2). 
5.2.2. Measurement of CVF fetal fibronectin and cervical length 
 
Also at presentation, commonly employed clinical assessment methods of PTL and PTB 
including CVF FFN level and ultrasound cervical length were examined. Quantitative CVF FFN 
levels were analysed using the 10Q Rapid FFN analyser (Hologic, MA), according to 
manufacturer’s instruction, and cervical length (CL) by transvaginal ultrasonography. Both 
measurements were performed by the same clinical research staff at the Jessop Wing Maternity 
Hospital. The qualitative FFN cut-off value (50 ng/ml) has the capacity to determine the risk of 
spontaneous PTB in women with symptoms suggestive of threatened PTL with a considerably 
high negative predictive value. In addition, we measured quantitative FFN because it is reliable 
and provides thresholds (e.g. 10 and 200 ng/ml), thereby improving the predictive utility of the 
test.301 
5.2.3. Vaginal fluid pH measurement  
 
During vaginal fluid sample collection, the vaginal pH was also determined by obtaining a sample 
of vaginal discharge from the lateral vaginal wall with the aid of a dry swab and smeared on a 
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hiqh quality narrow range pH paper (pH-Fix 3.6-6.1, #92130, Macherey-Nagel, Düren, 
Germany).504, 505 This pH indicator paper has the advantage of measuring pH values of 
unbuffered or weakly buffered solutions or samples and the dye does not bleed even in strongly 
basic solutions. Vaginal pH-determination by this method is highly accurate (reading accuracy: ± 
0.1 pH), rapid and reliable as the reference colour chart to which the test strips are compared 
matches both colour and position of the 4 indicator pads on the strips. The product is certified 
according to ISO 13485 and CE-marked for in-vitro diagnostic applications (98/79/EG) 
ftp://ftp.mn-net.com/english/Flyer_Catalogs/Test_Sticks_Test_Papers/Fl.%20pH-
FixTest_StripsEN.pdf.    
ftp://ftp.mn-net.com/english/Instruction_leaflets/Testpapers/pHFix/92130en.pdf 
5.2.4. Treatment Interventions to reduce preterm birth 
 
In order to prevent the occurrence and reduce the complications associated with PTB, as well 
as improve delivery outcomes, a subset of the study cohort received a range of therapeutic 
interventions between the 1st study at 22 weeks and the second at 26-28 weeks depending on 
the particular needs of the patient. The interventions include the administration of antibiotics 
for asymptomatic bacteriuria or subclinical genital bacterial infection,188, 402, 403, 462 progesterone 
for women with previous PTB and short cervix,506, 507 history and/or ultrasound-indicated 
cervical cerclage for incompetent cervix,408, 410, 506 anticontraction medication (tocolytics),414, 416 
and corticosteroids (e.g. betamathasone) effective against respiratory distress syndrome, 
intraventricular haemorrhage and fetal mortality.412, 413, 508 The treatment options and the 
number of participants that were administered such treatments in relation to the eventual 
delivery outcomes are presented in Table 5.1. 
5.2.5. Statistical analysis 
 
All Statistical analyses were performed using MATLAB (Mathworks, Natick, MA). The 
Wilcoxon’s rank-sum with Bonferroni PostHoc tests was performed to compare differences in 
clinical data between and within the groups. The relationships between clinical data were 
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determined by Pearson’s correlation coefficients and P values < 0.05 were considered 
statistically significant. 
Also, the predictive capacities of CVF FFN, CL and vaginal pH for PTB (< 37 weeks), were 
determined by ROC curves and combined with CVF metabolite N.I. by binary logistic 
regression. 
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5.3. Results 
5.3.1. Fetal fibronectin concentration and cervical length 
 
In all study cohorts except the ALR group, the preterm-delivered women had significantly 
higher CVF FFN levels compared to the term delivered women (Table 2.1 and Fig. 5.1). This 
difference was more pronounced in the SYM cohort (> 12 times). Similarly, the CL of the 
preterm-delivered women was significantly shorter than that of the term-delivered women in 
all study cohorts except the ALR group (Table 2.1 and Fig. 5.1). Both FFN and CL correlated 
with gestational age at delivery (GAAD) (an indication of term or preterm birth), in all groups 
except the ALR group (Fig. 5.2 and Fig. 5.3).  
Analysing all asymptomatic low and high risk women studied at 20-22w irrespective of their risk 
of delivering preterm (ASYM 20-22w), we observed that the preterm-delivered women had 
greater than 3-fold higher (> 200%) CVF FFN levels and 29% shorter CL compared to the 
term-delivered women (P < 0.00001) (Table 2.1 and Fig. 5.1). Also, the ALR women generally 
had a 3-fold (> 200%) lower CVF FFN concentration (P = 0.0001) and about 18% longer CL (P 
< 0.0001) compared to their high risk counterparts (i.e. AHR 20-22w).  
In addition, modest correlations were observed between CVF FFN and CL in all groups: ALR (r 
= -0.2, P = 0.02); AHR 20-22w (r = -0.5, P < 0.00001); ASYM 20-22w (r = -0.4, P < 0.00001); 
AHR 26-28w (r = -0.4, P < 0.005); and SYM (r = -0.5, P = 0.007) (Fig. 5.4). 
5.3.2. Vaginal pH  
 
Sampling the vaginal pH values of participants whose consents were obtained in this study, we 
observed a pH range of 3.6-6.1 and there were no significant differences between term- and 
preterm-delivered women within the groups (Table 2.1). However, the ALR women in general 
had lower vaginal pH (4.0±0.03 vs. 4.2±0.05, P = 0.0004), and correspondingly higher lactate 
N.I. (0.21±0.006 vs. 0.18±0.006 a.u., P = 0.0005), than their high risk counterparts studied at the 
same gestation i.e. AHR20-22w. Vaginal pH was modestly associated with GAAD in the 
combined asymptomatic low and high risk women studied at 20-22w (ASYM 20-22w) (r = -0.2, 
P = 0.009), and AHR (26-28w) (r = -0.3, P = 0.008) women only (Fig. 2.7C-D). There was no 
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correlation between vaginal pH and GAAD when the participants studied at 20-22w were 
subdivided into high (AHR) and low risk (ALR) groups. Additionally, there were modest 
correlations between vaginal pH and CVF FFN in the AHR 20-22w (r = 0.3, P = 0.03), ASYM 
20-22w (r = 0.2, P < 0.00001), and AHR 26-28w (r = 0.2, P = 0.01) (Fig. 2.7B-D); and CL in the 
SYM women only (r = -0.4, P = 0.03) (Fig. 2.7E). 
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Table 5.1: Therapeutic interventions administered to prevent preterm birth 
N, total number of term- or preterm-delivered women. 
 
 
 
 
 
                      
 
 
 
 
 
 
 
 
Treatment 
Option 
Asymptomatic 
Low risk women 
20-22w 
Asymptomatic 
High risk 
women 
20-22w 
Asymptomatic 
20-22w 
(Combined) 
Asymptomatic 
High risk 
women 
26-28w 
Symptomatic 
women 
24-36w 
Preterm 
(N=5) 
Term 
(N=124) 
Preterm 
(N=35) 
Term 
(N=71) 
Preterm 
(N=40) 
Term 
(N=195) 
Preterm 
(N=26) 
Term 
(N=65) 
Preterm 
(N=15) 
Term 
(N=67) 
Antibiotics 
     
Yes 1 30 15      31      16   61   18        41      5     25 
No 4 91 15      34      19   125   5       18      1     12 
Progesterone      
Yes 0 0 5    7      5  7   10      10      2    2 
No 5 121 25     58      30   179   13      49      4    35 
Cervical 
cerclage 
     
Yes 0 0 7    6     7  6   7      6      0    0 
No 5 121 23     59      28  180   16      53      6    37 
Tocolytics      
Yes 0 0 1     0    1 0   1      1     2   7 
No 5 120 29      65      34  185  22      58     4   30 
Steroids      
Yes 0 0 1     0    1 0  6      3     5   27 
No 5 121 29      65      34  186  17      56     1   10 
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Figure 5.1. Clinical assessment methods for preterm birth (A) quantitative cervicovaginal fluid fetal 
fibronectin level and (B) cervical length in different cohorts of pregnant women in relation to delivery outcomes. 
Box plots show the median line within the box, with the bottom and top edges of the box representing the 25% 
and 75% quartiles respectively.  
ALR, asymptomatic low risk women; AHR, asymptomatic high risk women; ASYM, ALR and AHR 20-22w combined; 
SYM, symptomatic women; w, gestation weeks.  
* P value < 0.05, ** P value < 0.01, *** P value < 0.001. 
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Figure 5.2. Association between cervicovaginal fluid fetal fibronectin (FFN) level and gestational age 
at delivery (G.A.A.D) (A) Asymptomatic high risk women 20-22w, (B) Asymptomatic high risk women 26-28w, 
(C) Symptomatic women 24-36w. w, gestation weeks.  
 
 
 
SYM 24-36 w 
r = -0.5, P = 0.0007 
C. 
B. A. 
r = -0.3, P = 0.001 
r = -0.4, P = 0.00007 
AHR 20-22 w AHR 26-28 w 
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Figure 5.3. Association between ultrasound cervical length (CL) and gestational age at delivery 
(G.A.A.D) (A) Asymptomatic high risk women 20-22w, (B) Asymptomatic high risk women 26-28w, (C) 
Symptomatic women 24-36w. w, gestation weeks.  
 
 
B. 
r = 0.5, P = 0.0008 
SYM 24-36 w C. 
A. AHR 26-28 w 
r = 0.5, P < 0.00001 
AHR 20-22 
w 
r = 0.6, P < 0.00001 
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Figure 5.4. Association between CVF Fetal fibronectin (FFN) and ultrasound cervical length (CL)  
(A) Asymptomatic low risk women 20-22w, (B) Asymptomatic high risk women 20-22w, (C) Asymptomatic high 
risk women 26-28w, (D) Symptomatic women 24-36w. w, gestation weeks.  
 
Correlations between clinical parameters and metabolites are also depicted in Chapter 2 (Fig. 
2.7A-F). 
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5.3.3. Predictive capacity of CVF fetal fibronectin, cervical length and vaginal pH 
for preterm birth 
 
Analysis of the area under the ROC curves for the measured CVF FFN, CL and vaginal pH 
showed significant discriminative abilities of CVF FFN and CL in all groups except the ALR 
women. Vaginal pH was not predictive of PTB in any of the study groups (Table 5.2). 
In the asymptomatic women studied at 20-22w irrespective of their risk of PTB, CL had the 
best predictive utility (AUC = 0.79, P < 0.0001), while the combination of CL, FFN, vaginal pH, 
and 1H-MR N.I.s of acetate, lactate and succinate, produced a slightly better predictive capacity 
than either of these markers alone (AUC = 0.81, P < 0.001) (Fig. 5.5). 
Also, in the AHR (26-28w) women, combination of CVF 1H-MR N.I.s of acetate and succinate, 
and succinate/lactate ratio, FFN and CL, only modestly improved the predictive values of FFN, 
and CL (Fig. 5.6).  
However, in the SYM group, a combination of acetate N.I., FFN and CL improved the 
predictive value for PTB, compared to either of FFN and CL alone (AUC = 0.85, P = 0.02). 
Addition of 1H-MR N.I.s of lactate and succinate did not change this predictive ability (AUC = 
0.85, P = 0.003) (Fig. 5.7).  
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Table 5.2: Predictive performance of Fetal fibronectin and ultrasound cervical 
length for preterm birth (< 37w), in pregnant women 
Metabolite AUC SE 
95% 
CI 
YI 
Sen 
(%) 
Spec 
(%) 
NPV 
(%) 
PPV 
(%) 
LR+ LR- P value 
Asymptomatic Low risk women 
(20-22w) 
FFN 0.50 0.13 
0.24-
0.76 
0.32 100 32 7 100 1.5 0.7 0.5 
CL 0.70 0.13 
0.44-
0.97 
0.49 100 49 7 100 2.0 0.5 0.06 
Vaginal pH 0.60 0.14 
0.33-
0.87 
0.44 80 44 5 98 1.4 0.7 0.2 
Asymptomatic High risk women 
(20-22w) 
FFN 0.61 0.07 
0.48-
0.73 
0.86 48 86 62 77 3.4 0.3 0.0499* 
CL 0.72 0.06 
0.60-
0.84 
0.52 87 52 47 89 1.8 0.6 0.0001* 
Vaginal pH 0.49 0.06 
0.36-
0.62 
0.86 23 86 45 69 1.6 0.6 0.6 
Asymptomatic High and Low risk women (combined) 
(20-22w) 
FFN 0.61 0.06 
0.50-
0.72 
0.89 41 89 43 88 3.6 0.3 0.03* 
CL 0.79 0.05 
0.68-
0.87 
0.60 83 60 30 94 2.1 0.5 <0.00001* 
Vaginal pH 0.57 0.05 
0.47-
0.68 
0.73 46 73 26 87 1.7 0.6 0.09 
Asymptomatic High risk women 
(26-28w) 
FFN 0.70 0.07 
0.57-
0.83 
0.81 58 81 56 83 3.1 0.3 0.001* 
CL 0.72 0.06 
0.59-
0.84 
0.84 58 84 59 83 3.6 0.3 0.0004* 
Vaginal pH 0.49 0.07 
0.35-
0.62 
0.97 15 97 66 74 4.8 0.2 0.6 
Symptomatic women 
(24-36w) 
FFN 0.76 0.1 
0.53-
1.0 
0.92 67 92 65 92 8.2 0.1 0.01* 
CL 0.73 0.1 
0.52-
0.94 
0.73 75 73 38 93 2.8 0.4 0.02* 
Vaginal pH 0.50 0.1 
0.26-
0.74 
0.89 29 89 37 85 2.6 0.4 0.5 
CL, ultrasound cervical length; FFN, fetal fibronectin; AUC, area under the ROC curve; SE, standard error; CI, 95% 
confidence interval; YI, Youden index (J); Sen, sensitivity; Spec, specificity; PPV, positive predictive value; NPV, 
negative predictive value; LR+, positive likelihood ratio; LR-, negative likelihood ratio; P, significance level.  
*Statistically significant 
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Figure 5.5. Combined ROC curves of cervical length, fetal fibronectin, and 1H-MR normalised 
integrals of acetate, lactate and succinate for the prediction of preterm birth (< 37 weeks), in 
asymptomatic high and low risk women (20-22w).   
CL + FFN + pH + ACE + LAC + SUC 
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Figure 5.6. Combined ROC curves for the prediction of preterm birth (< 37 weeks), in 
asymptomatic high risk women (26-28w), (A) cervical length and fetal fibronectin, (B) cervical 
length, fetal fibronectin, and 1H-MR normalised integrals of acetate, (C) cervical length, fetal 
fibronectin, and succinate/lactate ratio. 
 
 
 
 
 
 
 
C. 
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Figure 5.7. Combined ROC curves for the prediction of preterm birth (< 37 weeks) in symptomatic 
women (24-36w), (A) cervical length, fetal fibronectin, and 1H-MR integrals of acetate, (B) fetal 
fibronectin, and 1H-MR normalised integrals of lactate, acetate and succinate.  
A. 
B. 
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5.4. Discussion 
 
In this study we present a unique cohort of both asymptomatic and symptomatic pregnant 
women studied across the mid trimester. The asymptomatic women were further subdivided 
into low and high risk groups based on a previous history of PTB and/or mid trimester 
ultrasound cervical length < 25 mm.  None of the asymptomatic low risk women had a previous 
history of PTB or short cervix at second trimester, and only 5(3.9%) of these women delivered 
preterm compared to 35(33%) of their high-risk counterparts studied at similar gestation (20-
22w) (Table 2.1). Also, their mean CL was about 18% higher than that of their high-risk 
counterparts. The prevalence of preterm birth in the low risk asymptomatic women in this 
study was significantly lower than the average recorded in the general population (3.9% vs. 
12%), while that of the high-risk women was above 2.5 times greater than the general 
population average (33% vs. 12%).2, 3, 266 This justifies the classification of the asymptomatic 
pregnant women into low and high-risk groups based on previous PTB and length of cervix at 
mid second trimester (20-22w). Due to their “high risk” status, a subset of the asymptomatic 
high risk women who attended for routine antenatal care at 26-28 weeks gestation were 
assessed again after their first study visit at mid second trimester (20-22w). The strict exclusion 
criteria employed were in order to prevent contamination of the CVF with microbes and/or 
fluid from the external environment or any other body compartment particularly the amniotic 
cavity. 
With our study population well defined and stratified, we determined the risk of PTL and PTB 
using currently available clinical assessment methods i.e. quantitative CVF FFN level, ultrasound 
CL and vaginal pH.  As anticipated, the lowest prevalence of PTB (~4%) was observed in the 
asymptomatic low risk group (Table 2.1). But more interestingly, all preterm-delivered women 
in the symptomatic group delivered approximately within 2 weeks of presentation with 
symptoms suggestive of PTL. This could be a critical window period in which a biomarker with 
accurate predictive capacity will be clinically useful. Elevated CVF FFN and short cervix were 
associated with preterm delivery, whilst low CVF FFN and normal/longer cervix were 
associated with term delivery. Both CVF FFN and second trimester ultrasound CL correlated 
strongly with gestational age at delivery. These observations were recorded in all the groups 
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except the asymptomatic low risk women (Table 2.1 and Figs. 5.1-5.3). Our data corroborates 
the already established relationship between FFN, ultrasound CL and PTB.332, 459, 509-515 FFN is an 
extracellular matrix glycoprotein binding the gestational tissues at the feto-maternal interface. It 
is released after an abruption or cytokine-mediated damage to the membranes or placenta 
before delivery.300 FFN is predictive of delivery within 2 weeks with a high negative predictive 
value and is a useful biomarker of PTB in women with symptoms of PTL.301, 313 This was obvious 
in our data especially in the symptomatic group where the FFN concentration in the preterm-
delivered women was more than 12 times higher compared to the term-delivered women. FFN 
was also predictive of preterm delivery in these women as well as the asymptomatic high risk 
women, but not in the low risk group.  
Compared to FFN, the differences in CL observed in the cohorts in relation to delivery 
outcome was significantly less. However CL had a better discriminative utility for preterm 
delivery compared to FFN in the asymptomatic high risk women, whilst the reverse was 
observed in the symptomatic women. Hence, FFN level could be a better assessment tool for 
risk of preterm birth in women presenting with symptoms suggestive of PTL.303 However, just 
like we have observed in our study, other researchers have reported high sensitivities, 
specificities, PPVs and NPVs for CL in the prediction of preterm birth in asymptomatic high risk 
and symptomatic pregnant women.354, 459 A combined measurement of FFN and CL improved 
the prognostication of preterm birth.459   Again, both FFN and CL were not predictive of 
preterm birth in the asymptomatic low risk women. Perhaps, these differences, correlations and 
predictive utility were not seen in the asymptomatic low risk women in this study because of 
the low number of preterm delivery in this group. The trend can be seen and at least other 
studies suggest that FFN is equally useful in this group.516 It is just not cost-effective as a 
reasonable number of women are needed to identify one at risk of preterm birth. Also, FFN 
and CL could be useful in distinguishing between high and low risk women, and then applied to 
those women at significantly higher risk of PTB. This was obvious in our study population as the 
asymptomatic women sampled at mid second trimester (20-22w), were clearly differentiated in 
terms of their level of CVF FFN and ultrasound CL. The asymptomatic low risk women had 
over 200% lower FFN and about 18% increase in CL compared to their high risk counterparts. 
Though, in the low risk women FFN and ultrasound CL were not predictive of preterm birth in 
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this study, the prognostic potential of these two markers were observed in high risk women 
and those presenting with symptoms of threatened preterm labour. This is in accordance with 
the views that women with prior term deliveries tend to have lower incidence of short 
cervix,398 and FFN levels and ultrasound CL measurements have proven capacity to identify 
women that are at significant risk for PTB.304, 458, 459, 506, 517, 518 Although from our data it is obvious 
that in asymptomatic pregnant women at mid second trimester, ultrasound CL could be a more 
powerful biomarker in identifying women with higher risk of PTB compared with quantitative 
FFN. This is strengthened by the absence of significant improvement in the predictive ability of 
CL when FFN and metabolite markers were added. 
Again, for the asymptomatic women studied at 26-28w, combination of the metabolites 
markers and FFN/CL did not seem to enhance the prediction of preterm birth significantly. FFN 
and CL remained the most powerful predictors of preterm birth in this group of women. 
Because FFN and ultrasound CL are the most widely employed predictors of PTBs clinically, it 
was not surprising that there were modest inverse relationships between these 2 clinical 
assessment methods for PTB in all our study groups. Chorioamnionitis due to a perturbed 
vaginal microbiota signature and the associated ascending intrauterine infection can lead to 
cervical weakening (remodeling), disruption of fetal membranes and leakage of FFN.199, 211 
Therefore, an elevated CVF FFN level could be indicative of concomitant shortened cervix. 
Besides, fibronectin has been reported to stimulate the release of MMPs (e.g. MMP-2 and MMP-
9) at least in human cancer and inflammatory cells via several signaling pathways.519-523 MMPs 
degrade the collagen matrix of the cervix leading to cervical remodeling/shortening and PTB.524-
526  
The normal healthy vaginal pH in reproductive-age women ranges from 3.8-4.5, above which an 
imbalance in the vaginal microbial environment is suspected.36, 449 Our data showed a pH range 
of 3.6-6.1 and no differences in relation to delivery outcome was observed within the groups 
(Table 2.1). Also, there was a modest relationship between vaginal pH and gestational age at 
delivery in all asymptomatic women studied at 20-22w irrespective of risk status, and the 
asymptomatic high-risk women studied at 26-28w. This correlation was not seen when the 
asymptomatic low and high-risk women were separated according to their risk statuses (Fig. 
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2.7A-D). Again, although this to an extent confirms the well documented relationship between 
vaginal pH and PTB,509, 527-531 whether it can be conveniently applied singly in a low or undefined 
risk population warrants further investigation.  Consistent with other reports,509, 527 a modest 
inverse correlation between vaginal pH and ultrasound CL was observed but in the 
symptomatic women only. This relationship is noteworthy as an increase in vaginal pH could be 
suggestive of an altered vaginal microbiota and/or an ascending genital infection capable of 
triggering the release of MMPs via proinflammatory cytokine-mediated neutrophil and 
macrophage degranulation. MMPs catalyse the degradation of the cervical extracellular matrix 
and mucus plug leading to shortening, softening and dilation of the cervix and thus, promoting 
the establishment of an ascending genital infection and consequently PTL and PTB.1, 114, 196 213  
In addition to the above observations, as gestation progressed and depending on the indication, 
a subset of our study participants in each group received a range of treatments aimed at 
reducing or preventing the risk of PTL and PTB as well as the attendant complications (Table 
5.1). Nevertheless, some of these women still went on to deliver preterm. Though unethical 
and beyond the scope of this investigation, an ideal experimental situation would be allowing 
normal pregnancy progression without any therapeutic intervention. The effects of these 
treatment measures independently or as a whole on the vaginal microbiota and metabolite 
signatures at various gestational time points in asymptomatic and symptomatic high and low risk 
pregnant women is a subject for future investigation. In the meantime, we acknowledge that 
these measures may have influenced the eventual delivery outcome, although our study cohorts 
were recruited and sampled at presentation prior to the administration of any treatment. 
Despite the possible impact of these treatments on the ultimate delivery outcomes, the 
incidence of PTB in our study cohorts is comparable to that of the general population which 
ranges from 5-18% of all live births annually.2, 3, 5, 304, 305, 532, 533 Albeit, evidence supporting routine 
transvaginal ultrasound screening of all pregnant women regardless of symptoms or a prior 
term delivery was meager,395, 398 recent reports have recommended universal screening for both 
asymptomatic and symptomatic women with or without previous preterm birth, but was not 
indicated for those with multiple gestation.506, 534, 535 
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Chapter 6 
 
General Discussion 
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It is conceivable that vaginal microorganisms and their biochemical activities are traceable from 
the metabolic by-products produced. There is an established association between the vaginal 
microbial composition and preterm birth.160, 193, 536 By extension the vaginal microbiota 
metabolites, which are an indication of not just the presence but the functional activities of the 
bacterial species, should be associated with preterm birth. Also, adequate analyses of these 
metabolites can elucidate the microbiology of the female genital tract in pregnant and non-
pregnant states.34, 210 These observations, as well as the requirement of an accurate marker for 
the prognostication of preterm birth, formed the rationale for investigating CVF metabolites in 
different cohorts of pregnant women in relation to preterm birth. Specifically, this study was 
designed; firstly, to determine if the 1H-MR spectrum of CVF can diagnose women who 
ultimately deliver prematurely from cohorts of women at high or low risk of preterm birth, and 
in pregnant women presenting with symptoms suggestive of threatened preterm labour. 
Secondly, this study aimed to characterise and verify the CVF metabolite signature of a cohort 
of pregnant women by 1H-MRS and spectrophotometry, and determine their predictive utility 
for preterm birth. Thirdly, we examined the relationship between current clinical assessment 
methods for preterm birth such as CVF fetal fibronectin and ultrasound cervical length; and 
vaginal microbiota metabolites of pregnant women in relation to gestational age at delivery. 
Lastly, to identify the cellular composition of the CVF sample and determine the vaginal 
bacterial specie composition by PCR during pregnancy. Overall, these were performed in order 
to provide a comprehensive analysis of the cervicovaginal environment during gestation for the 
purpose of predicting the likelihood of preterm delivery. 
A unique cohort of pregnant women comprising of asymptomatic pregnant women and women 
presenting with symptoms of threatened preterm labour were studied. The asymptomatic 
women were sub-classified into low and high risk depending on a prior preterm delivery as well 
as the presence of a short cervix. These women were studied at mid second trimester (20-22 
weeks gestation), but the high risk women had a second study visit at late second trimester (26-
28 weeks gestation), due to their high-risk status. The primary endpoint for these women was 
delivery before 37 weeks gestation (preterm), while the secondary endpoint was delivery 
before 32 weeks. The women who presented with symptoms reminiscent of threatened 
preterm labour (symptomatic women), were studied between 24 and 36 weeks gestation. The 
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predictive endpoint for these women was delivery within 2 weeks of index assessment while 
secondary endpoints were delivery before 32 and 37 weeks of gestation. 
Our choice of this unique cohort was to take into consideration the controversy regarding the 
usefulness of the predictive potential of CVF metabolite markers obtained from a high risk 
population when applied in a population of low or undefined risk.451 Also, it was hoped that 
potential CVF metabolite markers from this study independently or in conjunction with current 
clinical assessment makers (i.e. FFN and CL), could be applied effectively and accordingly 
depending on the risk and symptom statuses of the patients. To our mind, this is somewhat a 
holistic approach to the investigation of CVF metabolite markers of preterm birth. 
Notably, our results revealed that in the asymptomatic women studied at 20-22 weeks 
gestation, acetate and BCAA normalised integrals measured by 1H-MRS were predictive of 
preterm birth before 37 weeks gestation in the high and low risk groups respectively. In the 
symptomatic women, acetate normalised integrals and acetate/lactate ratio were predictive of 
preterm birth before 32 and 37 weeks gestation as well as within 2 weeks of index assessment. 
Also, the glutamine/glutamate normalised integral in these women was predictive of preterm 
birth before 32 weeks gestation and within 2 weeks of index assessment. Furthermore, just like 
acetate normalised integrals, CVF acetate concentration measured by spectrophotometric assay 
technique in the symptomatic women was predictive of preterm birth before 37 weeks 
gestation and within 2 weeks of index assessment, but not at 32 weeks gestation (possibly due 
to smaller sample population). The predictive abilities of the above metabolites in the different 
cohorts were comparable to those of FFN and CL, but not in the asymptomatic low risk 
women where both FFN and CL did not show significant predictive utility for preterm birth. 
Similar to both FFN and CL, the metabolites showed high sensitivities (49-100%), specificities 
(61-85%), NPVs (75-100%), but low PPVs (10-52%). No metabolite was predictive of preterm 
birth in the asymptomatic high risk women studied at 26-28 weeks gestation. 
We also observed that in the symptomatic women, apart from being correlated, both acetate 
normalised integral and acetate concentration were higher in the women who delivered 
preterm than those that delivered at term. In addition, acetate normalised integral enhanced 
the predictive abilities of both FFN and CL for preterm birth before 37 weeks gestation.  
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Although vaginal pH did not differ between term- and preterm-delivered women, and was not 
predictive of preterm birth in any of the groups in this study, it was associated with acetate and 
lactate normalised integrals across the groups similar to other reports.38 Increase in CVF 
acetate and decrease in lactate as seen during anaerobic bacterial colonisation due to 
diminished Lactobacillus dominance is associated with a corresponding increase in vaginal pH. 
This provides a favourable environment for mixed anaerobes to thrive leading to 
infection/inflammation and adverse reproductive outcomes.38 
In an attempt to determine the cells responsible for the metabolites identified, we observed 
that the CVF samples comprised of both vaginal squamous epithelial cells and Gram positive 
and Gram negative bacterial cells. Generally, there was a higher prevalence of mixed anaerobes 
in preterm-delivered women compared to their term counterparts, whilst quantification of the 
bacterial 16S rDNA using qPCR revealed a higher amount of M. curtisii in the term-delivered 
women particularly in the asymptomatic high risk women studied at 20-22 weeks gestation, but 
no significant differences in G. vaginalis was observed in relation to delivery outcome. In 
contrast to this trend, the asymptomatic low risk women showed an unexpected higher 
prevalence of mixed anaerobes in the term-delivered women compared to their preterm 
counterparts. This is somewhat consistent with the qPCR-identified higher abundance of M. 
curtisii in the term-delivered asymptomatic high risk women. This warrants further investigation 
as our observations in the asymptomatic group, and especially the low risk women are 
inconsistent with the established relationship between the prevalence of mixed anaerobes 
including M. curtisii with preterm delivery.75, 111, 118, 160, 469 However, there are evidences that M. 
curtisii is not sensitive for the diagnosis of vaginal dysbiosis such as BV, and is even more 
frequently isolated from healthy women.500  
Taken together, the CVF metabolite profile, microbiota signature, vaginal pH, FFN, and CL can 
be linked in a common pathological pathway. Bacterial colonisation of the female genital tract 
during gestation and the subsequent ascending genital infection, which could be subclinical in 
some cases, triggers both maternal and fetal immune responses. This induces cytokine-mediated 
synthesis and release of prostaglandins and MMPs. The prostaglandins stimulate uterine smooth 
muscle contraction and cervical remodeling (softened, shortened and dilated cervix), and 
release of MMPs, whilst the MMPs triggers membrane rupture in addition to cervical ripening. 
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Ruptured membranes, compromised cervix and degraded cervical plug allow leakage of FFN 
into the vaginal compartment on one hand and ascension of more potentially virulent bacterial 
organisms into the upper genital tract on the other hand. An infection-triggered inflammatory 
positive feed-forward cycle is then established and if allowed uncontrolled could lead to 
preterm labour and ultimately preterm birth.1, 7, 114, 214 Therefore, during pregnancy, the 
detection of CVF microbiota composition, microbiota metabolic by-products and/or the 
products of the inflammatory processes initiated by these microorganisms could be useful singly 
or in combination with other clinical diagnostic techniques for the prognostication of adverse 
reproductive outcomes.  
To our knowledge this is the first report of CVF metabolic profiling in such a unique 
classification of pregnant women. It is also the first report of the prognostic utility of branched 
chain amino acids i.e. leucine, isoleucine and valine, in asymptomatic pregnant women at low 
risk of preterm birth against even the widely employed clinical assessment methods. In addition, 
an intriguing diagnostic capacity of CVF acetate for preterm birth less than 32 and 37 weeks of 
gestation and within 2 week of presentation in women presenting with symptoms suggestive of 
preterm labour, and less than 37 weeks only in asymptomatic women at high risk of preterm 
birth was observed. This further enhanced the predictive abilities of FFN and CL particularly in 
the symptomatic women. However, it should be noted that these observations were obtained 
from relatively smaller samples and require confirmation in larger study populations. These 
metabolites offer potentially cheaper, more accurate and less invasive clinical assays for the 
prediction of preterm deliveries that can be applied even in primary health care facilities in 
which other clinical assessment methods may be inadequate. 
Future investigations will benefit from acknowledging the interrelations of vaginal microbiome, 
CVF metabolites profiles, pH, fetal fibronectin, ultrasound cervical length as well as pro- and 
anti-inflammatory cytokines in the prediction of preterm delivery. 
6.1. Conclusion 
 
In conclusion, we have reported that apart from FFN and CL, there are differences in CVF 
metabolite signatures in asymptomatic and symptomatic pregnant women that can be exploited 
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for the identification of women at risk and the prognostication of preterm delivery. Elevated 
CVF acetate showed clinically useful discriminative propensity for preterm delivery and delivery 
within 2 weeks of presentation in symptomatic women, and for only preterm delivery in 
asymptomatic high risk women. A ratio of acetate to lactate showed similar discriminatory 
capacity in symptomatic women, whilst branched chain amino acids appeared predictive of 
preterm delivery in asymptomatic women at low risk of preterm birth. These metabolite 
differences were supported with the identification of an association of higher prevalence of 
mixed anaerobes in the vaginal melieu and preterm birth. 
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6.2. Future work 
 
Though the data presented in this report is promising, we have identified the limitations and 
prospective improvements: 
Participants: 
- Continuous recruitment of pregnant women especially women presenting with 
symptoms suggestive of preterm labour. 
- Reclassification and analysis of CVF metabolites and microbiome data of currently 
available study cohorts. 
- Recruitment of non-pregnant women at the proliferative and secretory phases of 
menstrual cycle attending the gynaecological clinics. 
- Recruitment of pregnant women from other ethnic/racial inclination e.g. African and 
Hispanic women and determination of racial differences in CVF metabolite and 
microbiota signatures in relation to preterm birth. 
Metabolite study: 
- Identification of more metabolites from the 1H-MR spectra and the possible use of MR 
spectrometer with stronger magnetic field strength e.g. 900 MHz (21T).  
- Normalisation of identified 1H-MR signals using the probabilistic quotient normalisation 
method in comparison to the integral normalisation approach. 
- Analyses of CVF metabolite concentrations of both asymptomatic and symptomatic 
pregnant women using spectrophotometric technique e.g. the ChemWell® 2910 auto-
analyser and determination of their predictive utility for preterm birth.  
- Evaluation of the relationship between CVF total lactic acid, D-lactic acid, L-lactic acid, 
L/D-lactic acid ratio and preterm birth in our cohort.  
- Investigation of the predictive capacity of branched chain amino acids in asymptomatic 
low risk women for preterm birth and in comparison to their high risk counterparts. 
- Comparison and combination of the predictive abilities of metabolite concentrations and 
those of FFN and CL as well as pro- and anti-inflammatory cytokines associated with 
preterm birth. 
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Microbiome study: 
- Molecular characterisation of CVF bacterial gene using high fidelity specie-specific 
primers and 16S gene sequencing. 
- Application of multiplex PCR technique which involves the amplification of multiple 
different DNA simultaneously in the assessment of the vaginal microbiome in relation to 
delivery outcomes. 
- Detection of fastidious and unculturable vaginal bacterial species by Fluorescence in situ 
hybridization (FISH). FISH can determine the localisation or distribution of specific 
bacterial species in the vaginal microbial ecology.  
- Evaluation of the relationship between CVF total lactic acid, D-lactic acid, L-lactic acid, 
L/D-lactic acid ratio and Lactobacillus sp. dominance in relation to preterm birth.  
- Determination of the relationship between branched chain amino acids and vaginal 
microbiome in asymptomatic low risk women.  
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